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English summary  
 
Stenotrophomonas maltophilia is an emerging multidrug resistant nosocomial pathogen, mostly 
associated with chronic pulmonary infections and medical device-associated infections. 
Treatment of S. maltophilia infections is compromised due to its many mechanisms of resistance 
against different families of antibiotics such as β-lactams, aminoglycosides, quinolones, 
tetracyclines, macrolides and sulfonamides. 
 
Former proteomic studies on the cellular response of the clinical S. maltophilia strain 44/98 
showed an increase in expression of two outer membrane Ax21 homologues after treatment with 
the β-lactam imipenem. Ax21 was previously shown to be involved in virulence and biofilm 
formation, and to be secreted in association with outer membrane vesicles (OMVs). Therefore, 
we characterized the imipenem-induced OMVs to assess their role in β-lactam resistance. OMV 
proteomics revealed a diverse protein cargo, with mainly outer membrane and periplasmic 
proteins, but also inner membrane and cytoplasmic proteins. Interestingly, the L1-metallo-β-
lactamase and the L2-serine-β-lactamase were also identified as part of the OMV proteome. Next 
to imipenem, we investigated the effect of diffusible signal factor (DSF) quorum sensing 
molecules on OMV production. In the closely related plant pathogen Xylella fastidiosa, a DSF 
synthase knock out strain produced more OMVs, pointing to an inhibitory role of the DSF system. 
In contrast, a stimulatory effect was observed in S. maltophilia after exposure to its own DSF, cis-
Δ2-11-methyl-dodecenoic acid. Moreover, exposure to the Burkholderia cenocepacia DSF cis-Δ2-
dodecenoic acid also induces an increase in OMV production. Imipenem, cis-Δ2-11-methyl-
dodecenoic acid and cis-Δ2-dodecenoic acid all lead to abundant OMV-associated secretion of 
the two Ax21 homologues, but the expression of both homologues seems to be differentially 
regulated. Unfortunately, the actual role of Ax21 is still unknown and presents an interesting topic 
for further research. 
 
Both chromosomal encoded β-lactamases were identified as part of the OMV cargo. Next, the 
intra- and interspecies impact of OMVs was examined on β-lactam tolerance. A nitrocefin β-
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lactamase assay on intact OMVs indicated an equal distribution between L1 and L2 activity, while 
the cellular activity is predominantly achieved by L1. The clinically relevant β-lactams imipenem, 
amoxicillin and ticarcillin were also shown to be degraded by intact β-lactamase-carrying OMVs, 
but all with different efficiency. S. maltophilia often thrives in polymicrobial biofilm communities 
with species like Pseudomonas aeruginosa and Burkholderia cenocepacia, especially in cystic 
fibrosis-associated chronic lung disease. Therefore, the ability of S. maltophilia β-lactamase-
packed OMVs to confer intra- and interspecies protection against β-lactams was investigated. The 
OMVs not only increase the β-lactam tolerance of S. maltophilia cultures, but also have drastic 
effects on the tolerance of the less resistant P. aeruginosa and B. cenocepacia cultures. These 
findings suggest the possibility of S. maltophilia OMVs to aid in intra- and interspecies protection 
against β-lactam antibiotics. Furthermore, biofilm mode of growth also aids in antibiotic 
protection. In several species, OMVs were shown to be important for biofilm initiation and 
maintenance. Here, β-lactam-induced vesicles from S. maltophilia were proven to inhibit its 
transition to biofilm, most likely through blocking of available surfaces. Strikingly, the opposite 
effect was observed when these OMVs were administered to P. aeruginosa and B. cenocepacia 
cultures. 
 
Besides β-lactams, we also studied the effect of the fluoroquinolone ciprofloxacin on vesicle 
secretion in S. maltophilia. Ciprofloxacin is believed to induce vesiculation through the SOS 
response and increased oxidative stress. Increased vesicle secretion was demonstrated in S. 
maltophilia after ciprofloxacin stimulation, but both vesicle morphology and protein cargo 
showed significant differences to those secreted after β-lactam stress. Two morphologically 
different populations of ciprofloxacin-induced vesicles were observed: small vesicles (± 50 nm) 
comparable to β-lactam-induced vesicles and large vesicles (± 100-200 nm) with surface-attached 
filaments. The protein cargo of ciprofloxacin-induced vesicles includes different stress-related 
proteins typically induced by DNA damage, protein misfolding and oxidative stress, as well as the 
ciprofloxacin target DNA gyrase. Remarkably, far more cytoplasmic and inner membrane proteins 
were identified, indicating the presence of outer-inner membrane vesicles (OIMVs). The presence 
of both inner and outer membrane was confirmed in the large vesicles with cryo-electron 
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microscopy. Another interesting observation, was the identification of a cluster of phage tail-
related proteins, solely present in ciprofloxacin-induced vesicles. The production of bactericidal 
phage tails (or tailocins) was already demonstrated in S. maltophilia P28, described as maltocin 
P28. The filaments observed at the vesicle surface are most likely such phage tails. The 
bactericidal effect of the ciprofloxacin-induced vesicles ratifies this premise. However, among the 
used strains the bactericidal effect was only observed against P. aeruginosa PAO1, not against S. 
maltophilia 44/98 itself or the B. cenocepacia type strain. 
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Dutch summary 
 
Stenotrophomonas maltophilia is een multi-drug resistente nosocomiale pathogeen, die steeds 
vaker geassocieerd wordt met chronische luchtweginfecties en infecties opgelopen na contact 
met medische toestellen. De behandeling van S. maltophilia infecties wordt bemoeilijkt door zijn 
diversiteit aan resistentiemechanismen tegen de verschillende antibiotica families zoals β-
lactams, aminoglycosiden, quinolones, tetracyclines, macroliden en sulfonamiden. 
 
Voorgaande proteoomstudies aangaande de cellulaire respons van de klinische S. maltophilia 
stam 44/98 toonden een verhoging aan van de expressie van twee buitenste membraan Ax21 
homologen na behandeling met het β-lactam imipenem. Ax21 werd eerder al gelinkt aan 
virulentie en biofilmvorming, en wordt gesecreteerd via buitenste membraan vesikels (outer 
membrane vesicles; OMVs). Wij hebben de cargo van imipenem-geïnduceerde OMVs 
gekarakteriseerd om inzicht te krijgen in hun mogelijke rol na te gaan in de resistentie tegen β-
lactam antibiotica. Proteoomanalyse van de OMVs onthulde de aanwezigheid van een waaier aan 
eiwitten, voornamelijk buitenste membraan- en periplasmatische eiwitten, maar ook binnenste 
membraan- en cytoplasmatische eiwitten. Interessant is de identificatie van L1-metallo-β-
lactamase en L2-serine-β-lactamase als onderdeel van het OMV proteoom. Wij hebben eveneens 
het effect nagegaan van diffusible signal factor (DSF) quorum sensors op de OMV productie. Een 
DSF synthase knock-out stam van de nauw verwante plantenpathogeen Xylella fastidiosa 
produceert minder OMVs, wijzend op een inhiberende rol van het DSF systeem. Wij namen 
verrassend genoeg een toename waar van OMVs in S. maltophilia na blootstelling aan zijn 
endogene DSF, cis-Δ2-11-methyl-dodecaanzuur. Bovendien werd ook een toename in OMV 
productie geïnduceed na blootstelling aan het Burkholderia cenocepacia DSF cis-Δ2-
dodecaanzuur. Imipenem, cis-Δ2-11-methyl-dodecaanzuur en cis-Δ2-dodecaanzuur leiden allen 
tot een abundante OMV-geassocieerde secretie van de twee Ax21 homologen, maar de expressie 
van beiden lijkt op een verschillende manier gereguleerd. Helaas is de werkelijke rol van Ax21 nog 
onbekend en dit omvat dus een interessant onderwerp voor toekomstig onderzoek. 
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Beide chromosomaal gecodeerde β-lactamasen werden geïdentificeerd als onderdeel van de 
OMV cargo. Daarom werd de intra- en interspecies impact op β-lactam tolerantie van OMVs 
onderzocht. Met behulp van een nitrocefin β-lactamase assay op intacte OMVs werd een gelijke 
L1-L2 activiteitsverdeling waargenomen, terwijl de cellulaire activiteit gedomineerd wordt door 
L1. Daarnaast worden ook de klinisch relevante β-lactams imipenem, amoxicilline en ticarcilline 
afgebroken door de β-lactamase-bevattende OMVs, weliswaar met verschillende efficiëntie. S. 
maltophilia leeft vaak in polymicrobiële biofilms met species zoals Pseudomonas aeruginosa en 
Burkholderia cenocepacia, ondermeer in mucoviscidose-geassocieerde chronische 
luchtweginfecties. Daarom onderzochten we de mogelijkheid of S. maltophilia β-lactamase-
bevattende OMVs intra- en interspecies bescherming verlenen tegen β-lactams. De OMVs 
verhoogden inderdaad niet enkel de β-lactam tolerantie van S. maltophilia culturen, maar 
vertoonden ook een drastisch effect op de tolerantie van de minder resistente P. aeruginosa en 
B. cenocepacia culturen. Deze resultaten wijzen op een mogelijks beschermende rol van S. 
maltophilia OMVs tegen β-lactam antibiotica, zowel op intra- als interspecies vlak. In 
verschillende species werd ook aangetoond dat OMVs belangrijk zijn voor biofilmvorming. Hier 
werd aangetoond dat β-lactam geïnduceerde vesikels van S. maltophilia de vorming van biofilm 
inhiberen, waarschijnlijk door vrije oppervlakten te blokkeren. Opmerkelijk is dat biofilmvorming 
gestimuleerd werd na toedienen van deze OMVs aan P. aeruginosa en B. cenocepacia culturen. 
 
Naast β-lactams werd ook het effect van het fluoroquinolone ciprofloxacine op OMV secretie in 
S. maltophilia bestudeerd. Van ciprofloxacin wordt verondersteld dat het de secretie van vesikels 
induceert via de SOS respons en verhoogde oxidatieve stress in de cel. Een verhoging in 
vesikelsecretie werd aangetoond na blootstelling van S. maltophilia aan ciprofloxacine, maar de 
vesikelmorfologie en eiwitcargo verschilt beduidend van de vesikels geïnduceerd na β-lactam 
stress. Twee morfologisch verschillende populaties van ciprofloxacine-geïnduceerde vesikels 
werden waargenomen: kleine vesikels (± 50 nm) vergelijkbaar met β-lactam-geïnduceerde 
vesikels en grote vesikels (± 100-200 nm) met filamenten aan het oppervlak gehecht. De 
eiwitcargo van ciprofloxacine-geïnduceerde vesikels omvat verschillende stress-gerelateerde 
eiwitten die doorgaans geïnduceerd worden na DNA schade, verkeerd gevouwen eiwitten, 
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eiwitten betrokken bij oxidatieve stress, en ook de ciprofloxacine target DNA gyrase. Daarnaast 
werden opmerkelijk meer cytoplasmatische en binnenste membraan eiwitten geïdentificeerd, 
wat wijst op de aanwezigheid van buitenste-binnenste membraan vesikels (outer-inner 
membrane vesicles; OIMVs). De aanwezigheid van zowel een binnenste als buitenste membraan 
werd bevestigd in de grote vesikels met behulp van cryo-elektronen microscopie. Een andere 
interessante observatie was de identificatie van een cluster van phage tail gerelateerde eiwitten, 
die uitsluitend in de ciprofloxacine-geïnduceerde vesikels voorkomen. De productie van 
bactericidale phage tails (of tailocins) werd reeds aangetoond in S. maltophilia P28, beschreven 
als maltocine P28. De filamenten aanwezig op de vesikels zijn hoogstwaarschijnlijk dergelijke 
phage tails. Het bactericidale effect van de ciprofloxacine-geïnduceerde vesikels ondersteunt 
deze veronderstelling. Onder de gebruikte stammen werd het bactericidaal effect enkel 
waargenomen tegen P. aeruginosa PAO1, niet tegen S. maltophilia 44/98 of de B. cenocepacia 
type stam.  
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Foreword 
 
On the 29th of July 2014, my son Max was born. His birth was anything but easy, especially for the 
mother. After a very long period of agonizing labour, an alarming drop in the baby’s heart rate 
eventually led to an emergency caesarean. But because of inhaled myconium breathing was 
difficult, so Max finally ended up in the neonatal intensive care unit (ICU). Luckily, everything 
turned out fine and today he is a healthy, active toddler. 
 
In his first months on earth, Max received several courses of antibiotics. During his time in the 
neonatal ICU he got a few preventive, intravenous antibiotic treatments because of the risk of 
lung infection. After a few month he also had a reoccurring infection in his belly button, treated 
cutaneously with mupirocine, bacitracin and polymyxin B. And later he suffered from a persistent 
ear infection, which was first treated with amoxicillin, and later with amoxicillin-clavulanic acid 
due to antibiotic resistance. So during his half year of life, he was exposed to several antibiotic 
treatments. I do not know how things would have turned out without the antibiotics, and the 
same question can be asked for all of our lives. On the other hand, one could wonder what impact 
it had (or still has) on his microbiome. We are living in a bacterial world, and bacteria are 
inextricably connected to our bodies. Although antibiotics improved the quality of human life and 
drastically prolonged the average human life span, its use is not without danger. 
 
Introducing antibiotics in our bodies may kill harmfull, pathogenic bacterial species, but also 
harmless or beneficial bacterial species. Especially when broad-spectrum antibiotics are used. The 
notable increase in several modern diseases like obesity, asthma, and juvernile diabetis are 
believed to be linked to the overuse of antibiotics (research regarding this topic is nicely described 
in the book ‘Missing microbes: How the overuse of antibiotics is fueling our modern plagues’ by 
Martin J. Blaser). Antibiotic overuse and misuse also enhances the selection of antibiotic resistant 
species due to selective pressure. And the resulting microbiome dysbiosis could create 
opportunies for other harmfull bacteria to take their place, above all when these species are 
resistant to the antibiotic compound that is used. The rise of multi-drug resistant (MDR) species 
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is truly problematic for public health and is compromising our optimistic view on treating bacterial 
infections. 
 
The scientific world agrees that antibiotics should be used in a more sensible manner to prevent 
the selection of MDR species, and that the knowledge about resistance should be broadened to 
develop new, more efficient ways of treating (MDR) infections. This doctoral dissertation reports 
on specific resistance mechanisms of the emerging MDR pathogen Stenotrophomonas 
maltophilia, one of many difficult-to-treat species due to its many intrinsic and acquired 
resistance strategies. 
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1.1 Stenotrophomonas maltophilia is an emerging multi-drug resistant pathogen 
 
Stenotrophomonas maltophilia is a non-fermenting Gram-negative environmental bacterium, of 
which some multi-drug resistant (MDR) strains are increasingly isolated from clinical settings as 
nosocomial pathogens (Brooke, 2012). S. maltophilia was initially classified as a member of the 
Pseudomonas genus, then of the Xanthomonas genus, until it was finally classified as a member 
of the Stenotrophomonas genus (Abbott et al., 2011) (Figure 1).  
 
 
Figure 1. Taxonomic classification of Stenotrophomonas maltophilia (left) and microscopy 
image of S. maltophilia cells (right) (picture: Wouter Van Putte, Riet De Rycke). 
 
S. maltophilia is growingly associated with human respiratory tract infections. In Europe, it now 
belongs to the ten most frequently isolated microorganisms in intensive care unit (ICU) acquired 
pneumonia (European Centre for Disease Prevention and Control, 2011). In Belgium, 
approximately 5-6 % of ICU acquired pneumonia cases are associated with this organism, ranking 
number five after Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and 
Enterobacter cloacae (WIV, 2012). S. maltophilia is also one of the emerging MDR organisms in 
the lungs of cystic fibrosis (CF) patients (Amin and Waters, 2014; Parkins and Floto, 2015). 
Furthermore, it is involved in bacteraemia, skin and soft tissue infections and urinary tract 
infections (Brooke, 2012). These infections are characterized by a high mortality rate due to its 
intrinsic and acquired resistance to many of the current antibiotics, and the ability to form biofilm 
Chapter 1: The multi-drug resistant species S. maltophilia 
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(Sánchez, 2015). The genome of the pathogenic S. maltophilia k279a strain is sequenced, and 
indicates an organism that is well adapted for living in antimicrobial environments (Crossman et 
al., 2008). It contains resistance genes to almost all classes of β-lactams, such as penicillins, 
cephalosporins and carbapenems, but also against a variety of other antibiotics like 
aminoglycosides, macrolides, quinolones, tetracyclines and sulfonamides (Brooke, 2012). 
 
1.2 Virulence, colonization and infection 
 
In most cases, S. maltophilia is associated with persistent airway colonization and chronic 
infection, among which also in patients with CF. Although it is still uncertain whether S. 
maltophilia plays a true pathogenic role in these patients, its presence could be linked to a 
profound state of lung disease and can influence clinical outcome (Hansen, 2012).  
 
The pathogenesis of this organism is not well understood. Few clinical strains produce true toxins 
(Adamek et al, 2014). However, all clinical strains sequenced so far contain a number of putative 
virulence factors. They produce flagella, fimbriae, pili, fimbrial adhesins, and lipopolysaccharides 
(LPS), all having immunostimulatory effects that may induce inflammation (Abbott et al., 2011). 
Moreover, these virulence factors are involved in biofilm formation, increasing the protection 
against antibiotics and host immunity and enhancing spread along surfaces (Pompilio et al., 2010). 
Other potential virulence genes encode for adhesins, hemolysin, proteases, phospholipases and 
hemoglobin binding proteins that may contribute to cell or tissue damage (Adamek et al., 2014). 
Another important factor in S. maltophilia virulence is diffusible signal factor (DSF) mediated cell-
cell communication, involved in regulating different virulence responses and antibiotic resistance 
(Ryan and Dow, 2010).  
 
The attachment and biofilm growth of S. maltophilia on abiotic surfaces is a serious problem in 
hospital settings. Colonized medical devices often lead to severe device-associated nosocomial 
infections like bacteraemia, urinary tract infection and pocket infections (Passerini de Rossi et al., 
2007). Healthcare associated sources of S. maltophilia include intravenous and urinary catheters, 
Chapter 1: The multi-drug resistant species S. maltophilia 
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nebulizers, dialysis machines, thermometers, ventilator circuits, and medical implants (Abbott et 
al., 2011) (Figure 2).  
 
 
Figure 2. Pacemaker pocket infection 
caused by Stenotrophomonas 
maltophilia (Aktuerk et al., 2014). 
 
1.3 Treatment and resistance 
 
The multi-drug resistance poses a threat for treating S. maltophilia infections, narrowing down 
the number of effective antibiotic compounds available. Also, being an intrinsically resistant 
environmental species, it can provide other pathogenic species with resistance genes via 
horizontal gene transfer (Sánchez, 2015).  
 
Most clinical isolates are not susceptible to β-lactam antibiotics like imipenem, meropenem or 
amoxicillin, even in combination with the β-lactamase inhibitor clavulanic acid (e.g. Amoxiclav, 
Augmentin). Ticarcillin-clavulanic acid is the most effective β-lactam antibiotic treatment against 
S. maltophilia, but resistance is on the rise (Abbott et al., 2011). The preferred treatment of S. 
maltophilia involves the bacteriostatic drug sulfamethoxazole-trimethoprim (SMX-TMP), or 
alternatively newer fluoroquinolones (e.g. moxifloxacin) and tetracycline derivatives (e.g. 
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tigecycline) (Brooke, 2012). However, resistance against these compounds is emerging, so new 
treatments typically include different antibiotic combinations that work in synergy. For example, 
SMX-TMP was shown to be more effective against S. maltophilia when used in combination with 
either ciprofloxacin, ceftazidime or tobramycin, than SMX-TMP administered alone (Zelenitsky et 
al., 2005). 
 
Interestingly, when S. maltophilia isolates from CF and non-CF patients were compared, the CF 
strains showed significantly higher resistance towards different antibiotics (e.g. SMX-TMP, 
ciprofloxacin) (Cantón et al., 2003). Most alarming, a study on CF sputum samples showed that 
only about one third of isolates were susceptible to SMX-TMP, only one fourth to ciprofloxacin, 
and all were resistant to imipenem (Valenza et al., 2008). 
 
1.4 Antibiotic resistance mechanisms 
 
After exposure to β-lactam compounds, S. maltophilia immediately starts expressing two 
chromosomal genes encoding β-lactamase enzymes. L1-β-lactamase is a Zn2+-dependent (Ambler 
class B) metallo-β-lactamase, and L2-β-lactamase is a (Ambler class A) serine-β-lactamase (Senol, 
2004) (Figure 3). The gene encoding for L2 (blaL2) is located in an operon together with the gene 
for the LysR-type transcriptional regulator (LTTR) AmpR (Yang et al., 2009), comparable with the 
AmpR-AmpC module which is widespread in various Enterobacteriaceae like Citrobacter fruendii 
and Escherichia coli (Jacobs et al., 1997), and also in Pseudomonas aeruginosa (Moya et al., 2009). 
In this AmpR-AmpC system the induction of the chromosomally encoded ampC gene (coding for 
a class A serine-β-lactamase) is intimately linked to the peptidoglycan (PG) recycling pathway 
(Park and Uehara, 2008). The L1 gene (blaL1) is not associated with an LTTR binding motif, despite 
the fact that AmpR is necessary for its expression (Lin et al., 2009). The L1 β-lactamase has a much 
broader specificity, and it is not susceptible to clavulanic acid, a β-lactamase inhibitor that is often 
used in combination with β-lactam therapeutics to counteract the induced resistance response 
(Mercuri et al., 2002).  
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Another important mechanism contributing to multi-drug resistance in S. maltophilia is the 
production of different multidrug efflux pumps (Brooke, 2012) (Figure 3). Efflux pumps are 
protein complexes capable of extruding a broad range of chemical compounds from the cell (Sun 
et al., 2014). S. maltophilia strains have different gene clusters encoding Resistance-Nodulation-
Division (RND) efflux pumps. These transporters are typically tripartite complexes spanning the 
inner and outer membrane of the cell wall, and actively pump out toxic compounds (Delmar et 
al., 2014). For example, the SmeABC and SmeDEF efflux pumps play an important role in antibiotic 
resistance in S. maltophilia by eliminating antibiotics like tetracyclins, (fluoro)quinolones, 
aminoglycosides, and even β-lactams (Li et al., 2002; Chang et al., 2004). While the RND pumps 
are driven by the proton motive force, multidrug ATP-binding cassette (ABC) transporters use ATP 
for compound translocation. S. maltophilia produces the multidrug ABC transporter SmrA, which 
establishes resistance to ciprofloxacin, norfloxacin and tetracycline derivates (Al-Hamad et al., 
2009).  
 
Resistance against some antibiotics can also be established by direct enzymatic modification, 
hereby inactivating the antibiotic compound (Figure 3). For example, aminoglycosides can be 
modified by the acetyltransferase AAC(6’)-Iz or by the phosphotransferase Aph(3’)-IIc, increasing 
resistance against compounds like kanamycin, neomycin and tobramycin (Li et al., 2003; Okazaki 
and Avison, 2007). Besides modifying the antibiotic compound itself, the target site can also be 
modified to avoid interaction and inhibition. This strategy is used in the resistance against 
fluoroquinolone type antibiotics, with the modification of DNA gyrase and topoisomerases 
(Sánchez and Martinez, 2010). 
 
A potent drug recommended for treating S. maltophilia infections is the folic acid biosynthesis 
inhibitory drug SMX-TMP. However, resistance against SMX-TMP is emerging because of the 
acquisition of alternative dihydropteroate synthase (DHPS) genes, or sul genes (Byrne-Bailey et 
al., 2009) (Figure 3). The sul resistance genes can be acquired through class 1 integrons (sul1), or 
through transposon-like structures located on plasmids (sul2) with the possibility of inter- and 
intra-generic transfer through insertional sequence common region (ISCR) elements (Hu et al., 
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2011; Chung et al., 2015). Instead of producing an alternative protein that is not recognized by 
the antibiotic compound, the target site can also be shielded from antibiotic interaction. S. 
maltophilia possesses Smqnr genes that encode for Qnr pentapeptide repeat proteins that 
protect DNA gyrase and topoisomerases from quinolone inhibition (Gordon and Wareham, 2010) 
(Figure 3). 
 
1.5 Biofilm formation in S. maltophilia 
 
The susceptibility of S. maltophilia to antibiotics is also largely affected by its capacity to grow as 
a biofilm. Biofilms are microorganism communities, consisting of single or multiple species that 
are growing attached to a surface (biotic or abiotic) (O’Toole et al., 2000). The initiation of biofilm 
formation is characterized by the attachment of cells to a surface, a process that is highly 
dependent on flagella (motility) and fimbriae (attachment) (Van Houdt and Michiels, 2005). The 
fimbriae-1 protein (SMF-1) plays a key role in the attachment of S. maltophilia cells, and 
subsequent biofilm formation (de Oliveira-Garcia et al., 2003).  
 
The biofilm mode of growth can aid in antibiotic resistance in different ways. First of all, the 
antibiotic compounds show limited penetration of the biofilm, making treatment far less efficient 
(Trautner and Darouiche, 2004). Compounds that do reach the cells inside the biofilm are 
immediately confronted with a high density of cells potentially equipped with different resistance 
mechanisms (Jolivet-Gougeon and Bonnaure-Mallet, 2014). The antibiotic stress also leads to an 
increase in mutagenesis and horizontal gene transfer, stimulating the acquisition and spread of 
resistance genes inside the biofilm (Wenzel, 2007). However, studies regarding the behavior of S. 
maltophilia inside biofilms, especially concerning antibiotic resistance and horizontal gene 
transfer, are scarce. 
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Figure 3. Overview of important resistance mechanisms of Stenotrophomonas maltophilia. Ticarcillin (TIC) 
is hydrolyzed by the L1- and L2-β-lactamases, of which only L2 is susceptible to the β-lactamase inhibitor 
clavulanic acid (CVA). The DNA gyrase (Gyr) inhibitor ciprofloxacin (CIP) can become ineffective by blocking 
the gyrase CIP binding site with the Qnr pentapeptide (encoded by the smqnr gene), or by removing CIP via 
the SmeDEF efflux pumps. Tetracycline (TET) and tobramycin (TOB) are removed via the SmeDEF efflux 
pump, TOB can be modified by acetyltransferase AAC(6’)-Iz or phosphotransferase Aph(3’)-IIc. 
Trimethoprim (TMP)-sulfamethoxazole (SMX) inhibition of dihydrofolate reductase (DHFR) and 
dihydropteroate synthase (DHPS) respectively, can be overcome by producing alternative DHPS’ proteins 
(encoded by sul genes). OM: outer membrane; PG: peptidoglycan; IM: inner membrane; RNAP: RNA 
polymerase; PABA: p-aminobenzoic acid. 
 
 
1.6 Cell-cell communication and quorum sensing in S. maltophilia 
 
It is now well established that bacterial cell-cell communication is of great importance, if not 
essential, for species survival. Bacteria release all kinds of small molecules into the environment, 
such as antibiotics, siderophores and metabolites that can function as cell-to-cell signaling 
molecules (Williams, 2007). A particular set of these cell-cell communication molecules are 
involved in a process called ‘quorum sensing’ (QS), which allows bacteria to monitor the 
population density and behave accordingly.  
 
In general, Gram-negative bacteria use acylated homoserine lactones. However, some species 
use another QS system that involves fatty acid diffusible signal factors (DSF). DSF was first 
described in the plant pathogen Xanthomonas campestris as a cis-unsaturated fatty acid that 
activates a cluster of ‘regulation of pathogenicity factor’ (rpf) genes (Barber et al., 1997; Ryan and 
Dow, 2011). The rpf cluster is conserved throughout the Xanthomonads, including S. maltophilia 
(Fouhy et al., 2007). Structurally similar DSF molecules are also produced by other important 
pathogens like Burkholderia cenocepacia (Boon et al., 2008) and Pseudomonas aeruginosa 
(Davies and Marques, 2009). DSF molecules produced by those human pathogens are involved in 
regulating virulence, biofilm formation, and antibiotic resistance, and some signals can even 
influence the behavior of non-producing species (Ryan et al., 2015) (Table 1).  In particular, the S. 
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maltophilia DSF cis-Δ2-11-methyl-dodecenoic acid has a broad specificity, influencing the 
behavior of both P. aeruginosa and B. cenocepacia, e.g. by inducing biofilm formation (Ryan et 
al., 2008). This cross-species effect of DSF has physiological implications, since these three species 
are often found together, for example in the lungs of patients with cystic fibrosis (CF) (Twomey 
et al., 2012). 
 
Table 1. Factors regulated by DSF family signal in different pathogens (adapted from Ryan et al., 2015). 
Organism Biological response 
 
 
Xanthomonas campestris 
Extracellular enzyme production; extracellular 
polysaccharide production; PilA-dependent motility; 
biofilm dispersal; small RNA synthesis; elongation 
factor P turnover; cyclic glucan synthesis; Arabidopsis 
stomatal opening factor(s) 
 
Xanthomonas oryzae pvs. oryzae and oryzicola 
Iron uptake; iron-dependent virulence to rice; 
extracellular proteases; extracellular 
polygalacturonase, asparagine synthase 
 
Xanthomonas axonopodis 
Extracellular enzyme production; extracellular 
polysaccharide production; flagellar-dependent biofilm 
formation 
Xanthomonas citri subsp. citri Host leaf surface adherence and penetration in lemon 
and grapefruit leaves 
Xanthomonas hortorum pv. pelargonii Virulence;  
in planta movement 
 
Xylella fastidiosa 
Insect vector colonization and attachment; 
transmission to plants; outer membrane vesicle 
release; extracellular enzyme production 
Pseudomonas aeruginosa Biofilm dispersal; reversal of dormant persister cell 
state 
Burkholderia cenocepacia Adherence, biofilm formation and swarming motility; 
virulence in mouse, zebrafish and insect models 
 
Stenotrophomonas maltophilia 
Heavy metal tolerance and antibiotic resistance; 
extracellular protease production; virulence to Galleria 
mellonella larvae 
 
 
In S. maltophilia, as in all DSF producing Xanthomonads, DSF signaling is regulated by the Rpf 
proteins (regulation of pathogenicity factors) (Figure 4). DSF synthesis, mainly cis-Δ2-11-methyl-
dodecenoic acid, is achieved by the RpfF DSF synthase (enoyl-CoA hydratase family enzyme) and 
RpfB (long-chain fatty acyl coenzyme A ligase) (Fouhy et al., 2007; Cheng et al, 2010; Deng et al, 
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2011). Cellular perception and signaling occurs through the two-component system (TCS) 
histidine sensor kinase RpfC. Upon binding with DSF at its periplasmic domain, RpfC gets 
autophosphorylated on a conserved histidine residue. This phosphate is passed onto an aspartic 
acid residue of the RpfG TCS response regulator. Consequently, the activated RpfG, containing a 
HD domain, is then acting as a cyclic diguanosine monophosphate (c-di-GMP) phosphodiesterase, 
catalyzing c-di-GMP degradation (Ryan and Dow, 2011). The c-di-GMP secondary messenger is 
important in linking environmental signals and subsequent alterations in cellular functions, like 
biofilm formation and virulence (Ryan, 2013). Moreover, in the absence of DSF, the RpfF synthase 
is interacting with RpfC and remains inactive. When DSF binds to the RpfC receptor, auto-
stimulation of its biosynthesis is initiated because RpfF is released and activated (Cheng et al., 
2010). The genes of these proteins are all located in the rpfBFCG gene cluster. A recent study of 
Huedo et al. (2014) analyzed the rpf gene cluster in 82 S. maltophilia clinical isolates, and 
demonstrated the presence of two different rpf cluster populations. The two populations show 
variation in the N-terminal regions of proteins RpfF and RpfC. One of the populations exhibited a 
DSF-deficient phenotype, due to a permanent repression of RpfF by RpfC.  
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Figure 4. Diffusible signal factor signalization. In the absence of cis-Δ2-11-methyl-dodecenoic acid (DSF), 
the DSF synthase rpfF is inhibited by the two-component system (TCS) histidine kinase receptor rpfC 
(Left). When DSF binds to rpfC, rpfF is released and synthesizes DSF. The activated rpfC gets 
autophosphorylated and passes the phosphoryl group to the TCS response regulator rpfG. The activated 
rpfG catalyzes c-di-GMP degradation (Right). 
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2.1 The Gram-negative bacterial cell wall 
 
The cell wall of Gram-negative bacteria is composed of an inner, cytoplasmic membrane and an 
outer membrane, with a periplasmatic peptidoglycan (PG) layer in between (Figure 5A; 
Schwechheimer and Kuehn, 2015). While the inner membrane is composed of a bilayer of 
phospholipids, the outer membrane consists of an inner phospholipid layer and an outer 
lipopolysaccharide (LPS) layer. Peptidoglycan is a N-acetylglucosamine-N-acetylmuramic acid 
(NAG-NAM) disaccharide polymer, most often interconnected with tetrapeptide side chains (such 
as L-alanine-D-glutamic acid-meso-diaminopimelic acid-D-alanine). The cell wall is further 
stabilized via different PG-protein interactions: examples are the covalent interaction with the 
Lpp lipoprotein, and non-covalent interactions with outer membrane protein A (OmpA) and the 
Tol-Pal protein complex spanning the inner membrane, the PG layer and the outer membrane. 
 
The PG layer is a crucial part of the cell wall, as it maintains cell shape and strength (Typas et al., 
2012). Its biosynthesis is initiated by the production of the UDP-bound NAM-pentapeptide, 
produced in the cytoplasm by a series of Mur proteins, which is eventually transferred to an 
undecaprenol lipid carrier in the cytoplasmic membrane (Lipid I). Then NAG is added (Lipid II) and 
the NAG-NAM-pentapeptide is flipped to the periplasmic side of the membrane. There it is 
connected to the growing glycan chain by a glycosyl transferase (GTase) and the peptide side 
chain is crosslinked with other peptide side chains or with Lpp by a transpeptidase (TPase). 
Peptide side chains can be trimmed by carboxypeptidases (CPase) and crosslinks cleaved by 
endopeptidases (EPase), and the glycan chain can be cleaved by endo- or exo-lytic 
transglycosylases (LT). A schematic representation of PG synthesis and cleavage is depicted in 
Figure 5B (Typas et al., 2012). 
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Figure 5. (A) Structure of the Gram-negative cell wall (Schwechheimer and Kuehn, 2015). (B) Synthesis and processing 
of peptidoglycan (Typas et al., 2012) 
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2.2 Outer membrane vesicles 
 
Outer membrane vesicles (OMVs) are secreted spheroid membrane nanoparticles (20-300 nm), 
formed through outer membrane budding. They encapsulate cell material and pinch off into the 
extracellular environment (Mashburn-Warren et al., 2008; Bonnington and Kuehn, 2014) (Figure 
6). OMV secretion is conserved in Gram-negative bacteria, both pathogenic and non-pathogenic 
(Kuehn and Kesty, 2005). OMVs are involved in important biological processes including virulence, 
pathogenesis, cell-cell communication, biofilm formation and antibiotic resistance (Olsen and 
Amano, 2015). The secretion of proteins, DNA/RNA, or other compounds as OMV cargo offers 
various advantages as opposed to ‘naked’ secretion, i.e. protection against degradative enzymes, 
enabling long-distance transport, efficient delivery by adhering to and interacting with target host 
cells, and the instant delivery of concentrated cargo packages (Bonnington and Kuehn, 2014).  
 
 
 
Figure 6.  Microscopy image of OMV secretion by Stenotrophomonas maltophilia (left), and purified S. 
maltophilia OMVs (right) (pictures: Wouter Van Putte, Riet De Rycke). 
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2.3 OMV biogenesis 
 
The biogenesis of OMVs and cargo selection is not yet entirely understood, but it is believed to 
be steered by an active process (Haurat et al., 2014). A passive formation of OMVs would entail 
an equal distribution of outer membrane proteins in the OMVs and the cell wall. Since this is not 
always the case, OMV formation is therefore potentially limited to specific areas on the cell 
surface, and/or differences exist in protein targeting towards the vesicles. Several studies have 
demonstrated the unequal OM-OMV distribution of proteins (Lappann et al., 2013; Aguilera et 
al., 2014; Jang et al., 2014).  
 
The secretion of OMVs would require a local disturbance in PG-OM crosslinking and the induction 
of membrane curvature (Haurat et al., 2014; Schwechheimer and Kuehn, 2015). The outer 
membrane lipoprotein Lpp seems to play a crucial role in the OMV biogenesis process. Lpp is an 
abundant lipoprotein, responsible for a large part of PG-OM crosslinks, and a reduction of Lpp-PG 
crosslinks leads to higher OMV production (Schwechheimer et al., 2015). However, increased 
OMV secretion can be induced independent of the number of Lpp-PG crosslinks. The 
accumulation of envelope components, for example PG degradation products or LPS, can 
potentially displace crosslinks and cause membrane bulging (Schwechheimer et al., 2014). 
Furthermore, the lipid composition of the outer membrane also plays a part in OMV biogenesis. 
Outer membrane lipid domains enriched with charged LPS types and/or unsaturated and 
branched fatty acids can lead to localized membrane bulging due to charge repulsion or increased 
membrane fluidity, resulting in increased OMV production (Schwechheimer and Kuehn, 2015; 
Tashiro et al., 2011; Murphy et al., 2014). Finally, OMV biogenesis is also associated with the 
formation of fimbriae. Deletion of the fimbrial fimA protein in Porphyromonas gingivalis led to a 
significant reduction in OMV secretion (Mantri et al., 2015). The question remains whether these 
fimbriae directly cause vesicle production, or if a difference in cell wall integrity between 
fimbriated and afimbriated cells is causing vesiculation.  
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Cell stress contributes in part or directly to OMV biogenesis. For example, β-lactam antibiotics 
inhibit penicillin binding proteins (PBPs), causing a reduction in PG crosslinking and the 
accumulation of PG degradation products in the periplasm. As mentioned above, these effects 
directly lead to increased OMV secretion. Other types of cell stress (e.g. oxidative stress, other 
types of antibiotics) provoke the accumulation of misfolded proteins in the periplasm, which 
could likewise stimulate vesicle production. Alternatively, extracellular signals can activate 
signaling cascades that indirectly lead to alterations in PG-OM crosslinking and/or OM LPS 
composition. For example, a link was established between the DSF QS system and OMV 
biogenesis in the plant pathogen Xylella fastidiosa (Ionescu et al., 2014). The deletion of the rpfF 
DSF synthase gene led to a significant increase in OMV secretion. This study implies a possible 
regulatory role for the DSF system, either directly or via the impact it has on the downstream pool 
of the c-di-GMP secondary messenger. 
 
2.4 OMV secretion and antibiotic resistance 
 
OMVs can actively contribute to antibiotic resistance via different modes (Schwechheimer and 
Kuehn, 2015). OMVs can serve as decoy ‘cells’ to bind or capture the antibiotic compound, or can 
transport antibiotics back to the outside of the cell (Figure 7, A). Next, OMVs have been reported 
to destroy the antibiotic extracellularly by the packing of antibiotic degrading enzymes inside the 
OMVs (Figure 7, B).  Also, OMVs are known to carry resistance genes aiding in the spread of 
resistance (Figure 7, C). 
 
The presence of β-lactamases in secreted OMVs was demonstrated in different species, for 
example in Pseudomonas aeruginosa, Staphylococcus aureus, Moraxella catarrhalis, group A 
Streptococci, and Bacteroides spp. (Ciofu et al., 2000; Schaar et al., 2011; Lee et al., 2013; Stentz 
et al., 2015). The OMV-associated β-lactamases were shown to be biologically active and capable 
to provide protection against β-lactam antibiotics. The mode of action of β-lactam antibiotics, and 
the periplasmic allocation of β-lactamases, raises the question whether the OMV-associated 
secretion of the β-lactamase enzymes is merely accidental or predestined. Nevertheless the 
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extracellular implications remain valid. Not only the enzymes, but also β-lactamase genes can be 
secreted through OMVs, potentially leading to horizontal gene transfer. For example, 
carbapenem-resistant Acinetobacter baumanni strains are able to secrete the plasmid-borne 
blaOXA-24 gene via OMVs, and protect carbapenem-susceptible A. baumanni strains (Rumbo et al., 
2011). 
 
 
Figure 7. Possible roles of OMVs in antibiotic resistance. OMVs can be used for exporting 
antibiotic compounds, or to capture antibiotic compounds extracellularly (A). OMVs can carry 
antibiotic degrading enzymes (B), and can assist in the transmission of resistance genes (C). OMV: 
outer membrane vesicle, OM: outer membrane, PG: peptidoglycan, IM: inner membrane. 
 
However, other antibiotic types (non-β-lactam) can also increase OMV secretion, meaning that 
the process is not only achieved through cell wall stress stricto senso, but potentially through 
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alternative regulatory mechanisms (e.g. through the DSF QS system). In P. aeruginosa it was 
shown that the fluoroquinolone ciprofloxacin induced vesiculation as part of the SOS response 
provoked by this type of antibiotic (Maredia et al., 2012).  This phenomenon was also observed 
in Acholeplasma laidlawii, where the vesicles mediate export of nucleotides containing the 
antibiotic target gene, as well as the ciprofloxacin itself (Medvedeva et al., 2014). 
 
2.5 OMV and biofilm formation 
 
An important feature of many pathogens is the ability to grow as part of a biofilm community. It 
provides protection against antimicrobial treats, enables coordinated responses to 
environmental changes, and promotes the spread of antibiotic resistance. OMVs were proven to 
be important constituents of biofilm. About 20% of the P. aeruginosa biofilm extracellular matrix 
proteome was shown to be common to OMV protein content (Couto et al., 2015). Remarkably, 
there are indications that biofilm associated OMVs differ considerable from planktonic OMVs 
(Schooling and Beverdige, 2006). Considering the aforementioned presence of β-lactamases and 
β-lactamase genes in OMVs, this could potentially increase the antibiotic resistance of biofilms, 
and the spread of resistance genes within the biofilms, respectively. 
 
OMVs are known to influence cell aggregation, surface attachment, and biofilm formation as well. 
However, a duality exist on the intra- or inter-species effect that these vesicle have on biofilm 
formation. In some cases OMVs stimulate biofilm formation, while in others they inhibit biofilm 
formation. For example, the OMVs from Porphyromonas gingivalis negatively influence the 
formation of Streptococcus gordonii biofilm, but stimulate Staphylococcus aureus biofilm 
formation (methicillin-resistant S. aureus, MRSA, included) (Ho et al., 2015). The plant pathogen 
Xylella fastidiosa secretes OMVs to block the surfaces in plant xylem vessels leading to deeper 
plant colonization (Ionescu et al., 2014). In contrast, OMVs from Helicobacter pylori stimulate 
biofilm formation by initiating cell aggregation (Yonezawa et al., 2009). So, most likely depending 
on the OMV cargo, these vesicles can either inhibit biofilm formation by blocking the available 
surfaces, or stimulate biofilm formation through OMV-mediated cell aggregation (Figure 8). 
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Figure 8. The effects of OMVs on biofilm formation. OMVs blocking surfaces hereby inhibiting cell 
attachment and biofilm formation (A), and OMVs inducing cell aggregation and biofilm formation 
(B). 
 
2.6 OMVs in bacterial communities 
 
OMVs can have different roles in bacterial communities. As mentioned above, by acting as decoy 
targets for antibiotics or by extracellularly degrading antibiotics, the OMVs can in certain 
conditions be considered as public goods that benefit the bacterial community (Schwechheimer 
and Kuehn, 2015). Furthermore, OMVs can facilitate community nutrient acquisition through the 
packing of proteases and glycosidases into vesicles (Elhenawy et al., 2014). Furthermore, many 
studies report on the important role of OMVs in iron acquisition in different species. For example, 
the capturing of iron by OMV associated iron acquisition proteins, and the delivery of iron back 
to the cells, was demonstrated in Mycobacterium tuberculosis (Prados-Rosales et al., 2014). 
 
Next to beneficiary roles of OMVs in bacterial communities, there are reports on harmfull effects 
as well. For example, Myxococcus xanthus uses OMVs to lyse E. coli and preys on its liberated cell 
content (Evans et al., 2012). When P. aeruginosa is treated with the aminoglycoside gentamicin, 
it secretes gentamicin- and peptidoglycan hydrolyse-containing membrane vesicles with 
bactericidal effects against B. cenocepacia group IIIa (Allen and Beveridge, 2003).   Another study 
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reports on the association of membrane vesicle secretion and the production of pyocin (a phage 
related tailocin bacteriocin) in P. aeruginosa as a response to stress (Toyofuku et al., 2014; 
Ghequire et al., 2015). However, the knowledge concerning the OMV-mediated secretion of 
bacteriocins for competitive purposes is limited.  
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Research aim 
 
Stenotrophomonas maltophilia is well known for its ability to resist different types of antibiotics. 
It is considered as a natural reservoir of resistance genes: environmental fresh water isolates do 
not differ significantly from clinical isolates. Its genome is sparked with transposable genetic 
elements, and therefore S. maltophilia is claimed to be at the origin of spreading resistance genes. 
As it is emerging as an opportunistic nosocomial pathogen, the host laboratory started to use this 
species as a model organism to study resistance mechanisms. It uses the S. maltophilia 44/98 
strain that was isolated from a respiratory secretion from an ICU patient at the Varese University 
Hospital in Italy (LMG 26824), and was kindly donated by Dr. Paola Mercuri (Ulg). Previous studies 
were focusing on the changes in the intracellular and membrane protein composition upon 
treatment of this strain with β-lactam antibiotics (Van Oudenhove et al., 2012). This revealed a β-
lactam-induced upregulation of two Ax21 homologues. Ax21 is an outer membrane protein 
involved in virulence and biofilm formation, and is known to be associated with outer membrane 
vesicles (OMVs) in related organisms (Bahar et al., 2014). Several studies report on the function 
of OMVs in the response of bacteria against antibiotics. For example, β-lactam-induced 
vesiculation was already demonstrated in different species and it was proven that these vesicles 
contain β-lactamase enzymes (Ciofu et al., 2000; Schaar et al., 2011; Lee et al., 2013; Stentz et al., 
2015). 
 
The first aim of this research was to study the effect of the β-lactam imipenem on S. maltophilia 
OMV secretion, by determining the OMV concentration, morphology, and protein cargo. Next to 
imipenem, diffusible signal factor (DSF) quorum sensing molecules from S. maltophilia, and from 
Pseudomonas aeruginosa and Burkholderia cenocepacia, were used as well to study intra- and 
inter-species effects on OMV secretion. Finally, the influence of these stimuli were analyzed on 
the expression and subsequent OMV mediated secretion of the Ax21 virulence factor. These 
findings are documented in chapter 3. 
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Proteomic characterization of the S. maltophilia OMVs indeed showed the presence of the L1 and 
L2 β-lactamases inside the OMVs. Therefore the β-lactamase activity of intact OMVs was assayed, 
and consequently we evaluated the potential of these OMVs to degrade clinically relevant β-
lactam antibiotics. The potential biological impact of β-lactamase carrying OMVs on polymicrobial 
communities was explored by looking at changes in antibiotic tolerance in S. maltophilia, P. 
aeruginosa and B. cenocepacia cultures. Besides direct antibiotic degradation by the OMVs, the 
vesicles may also influence biofilm formation. Biofilm assays were performed to investigate the 
effect of OMVs on biofilm formation on the aforementioned species. The research concerning the 
role of OMVs in antibiotic resistance is described in chapter 4. 
 
Next to β-lactam antibiotics, also other types of antibiotics may potentially induce vesiculation. 
In P. aeruginosa the fluoroquinolone ciprofloxacin leads to increased vesiculation through the 
induction of the SOS response (Maredia et al., 2012). Vesicles from ciprofloxacin-exposed S. 
maltophilia cultures were characterized and compared to imipenem-induced vesicles. Observed 
differences were investigated further into detail to generate insights about the potential impact 
of the ciprofloxacin-triggered vesiculation response. 
 
The proposed goals will contribute to a broader knowledge on antibiotic resistance in S. 
maltophilia and beyond, and will help us to gain perspective on the role of this species in 
polymicrobial infections. On the other hand, understanding how bacterial membrane vesicles are 
produced, how the beneficial or harmfull vesicle cargo is selected, and how the vesicles establish 
cell interactions, could lead to new or improved membrane vesicle-based treatments of bacterial 
infections. 
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Abstract 
 
Outer membrane vesicles (OMVs) are small nanoscale structures that are secreted by bacteria 
and that can carry nucleic acids, proteins and small metabolites. They can mediate intracellular 
communication and play a role in virulence. In this study, we show that treatment with the β-
lactam antibiotic imipenem leads to a dramatic increase in the secretion of outer membrane 
vesicles in the nosocomial pathogen Stenotrophomonas maltophilia. Proteomic analysis of their 
protein content demonstrated that the OMVs contain the chromosomal encoded L1 metallo-β-
lactamase and L2 serine-β-lactamase. Moreover, the secreted OMVs contain large amounts of 
two Ax21 homologues, i.e. outer membrane proteins known to be involved in virulence and 
biofilm formation. We show that OMV secretion and the levels of Ax21 in the OMVs are 
dependent on the quorum sensing diffusible signal system (DSF). More specific, we demonstrate 
that the S. maltophilia DSF cis-Δ2-11-methyl-dodecenoic acid and, to a lesser extent, the 
Burkholderia cenocepacia DSF cis-Δ2-dodecenoic acid, stimulate OMV secretion. By a targeted 
proteomic analysis, we confirmed that DSF-induced OMVs contain large amounts of the Ax21 
homologues, but not the β-lactamases. This work illustrates that both quorum sensing and 
disturbance of the peptidoglycan biosynthesis provoke the release of OMVs and that OMV 
content is context dependent. 
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Outer membrane vesicles, Stenotrophomonas maltophilia, antibiotic resistance, proteomics, 
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3.1 Introduction 
 
Stenotrophomonas maltophilia is the most frequently isolated unusual non-fermenting Gram-
negative bacterium in hospitalized patients (Fihman et al., 2012). It is associated with an 
expanding range of clinical syndromes like bacteraemia, pneumonia and soft-tissue infections. S. 
maltophilia is also one of the most common emerging multi-drug resistant organisms found in 
the lungs of cystic fibrosis (CF) patients, with increasing prevalence (Amin and Waters, 2014). The 
high mortality in immuno-compromised patients observed with these infections is associated 
with the intrinsic and acquired resistance of S. maltophilia to many of the currently used 
antibiotics, including those of the β-lactam carbapenem type (Fihman et al., 2012). Indeed, 
antibiotic stress induces the production of two different chromosomal encoded carbapenem-
hydrolyzing β-lactamases, the L1 metallo- and L2 serine-β-lactamases (Van Oudenhove et al., 
2012).  
 
In some species, chromosomal encoded β-lactamases can be secreted in outer membrane 
vesicles (OMVs), enabling extracellular β-lactam degradation (Ciofu et al., 2000). Such OMVs are 
actually secreted by all Gram-negative bacteria and have different biological functions including 
protection of the secreted cargo, long-distance transport of toxins and virulence factors, cell-cell 
communication, pathogenesis, antibiotic resistance and aiding in biofilm formation (Deatherage 
et al., 2009; Bonnington and Kuehn, 2013; Tiwari, 2014).  Recently, Ax21 was identified in S. 
maltophilia as an important OMV-associated virulence factor (McCarthy et al., 2011; Ferrer-
Navarro et al., 2013). While the actual function of the Ax21 protein in S. maltophilia is still 
uncertain, studies in the closely related plant pathogen Xanthomonas oryzae have provided 
evidence for a role in motility and biofilm formation (Park et al., 2014). Xanthomonas Ax21, 
recently renamed to omp1X, is an outer membrane beta barrel protein that is secreted by the 
general secretion (Sec) system, and it is associated with outer membrane vesicles (OMVs) as well 
(Bahar et al., 2014).  
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In X. oryzae pv. oryzicola, Ax21 expression was found to be regulated by the diffusible signal factor 
(DSF) quorum sensing (QS) system (Qian et al., 2013). The DSF system is a well-established QS 
system involved in cell-cell signaling and the regulation of biofilm formation in S. maltophilia 
(Fouhy et al., 2007; Ryan and Dow, 2010). DSF cell-cell signaling is managed by ‘regulation of 
pathogenicity factors’ (rpf) proteins, encoded in the rpfBFCG gene cluster (Huedo et al., 2014). 
The enoyl-CoA hydratase family enzyme RpfF and the long-chain fatty acyl coenzyme A ligase RpfB 
are responsible for the synthesis of cis-Δ2-11-methyl-dodecenoic acid, the main DSF molecule in 
S. maltophilia (Huang and Lee Wong, 2007). Extracellular DSF can be perceived by the two-
component system (TCS) histidine sensor kinase RpfC, which activates the RpfG response 
regulator. The activated RpfG then acts as a cyclic diguanosine monophosphate (c-di-GMP) 
phosphodiesterase, influencing cellular c-di-GMP levels and downstream regulation events (Ryan 
and Dow, 2010; Tao et al., 2010). Interestingly, the S. maltophilia DSF molecule can also influence 
other species like Pseudomonas aeruginosa and Burkholderia cenocepacia (Ryan and Dow, 2010), 
which often co-colonize in the lungs of patients with cystic fibrosis (CF) (Twomey et al., 2012). 
 
It is still unknown what mechanisms are responsible for OMV biogenesis, and how its content is 
selected. However, it is believed that it entails an active process, and based on the OMV cargo, 
several models have been proposed (Haurat et al., 2014). A recent study on another species 
within the Xanthomonadaceae, the plant pathogen Xylella fastidiosa, showed that OMV 
biogenesis (and virulence) is suppressed by the DSF system (Ionescu et al., 2014). The aim of this 
study was to investigate the effect of different DSFs on the secretion of OMVs in S. maltophilia, 
as well as the influence of β-lactam antibiotic treatment. We also report on the OMV-associated 
secretion of two Ax21 homologues and on how DSFs affect the abundance of these homologues 
in OMVs. 
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3.2 Material and methods 
 
3.2.1 Materials 
 
Urea was obtained from GE Healthcare (Diegem, Belgium). Tris-HCl (UltraPureTM, 1M, pH 8) was 
purchased from Invitrogen (Carlsbad, CA, US). Bovine serum albumin (MS grade protein standard) 
was purchased from Protea Biosciences Group (Morgantown, WV, US). Sequencing grade 
modified trypsin was obtained from Promega (Madison, WI, US). ULC-MS grade water, 
acetonitrile (ACN) and formic acid was procured from Biosolve (Valkenswaard, The Netherlands). 
Imipenem was kindly donated by Prof. M. Galleni (CIP, University of Liège, Belgium). Other 
chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO, US). 
 
3.2.2 Bacterial cell culture 
 
The imipenem-resistant S. maltophilia strain 44/98 (LMG 26824, a kind gift of Dr. Paola Mercuri, 
Ulg, Belgium) was isolated at the Clinical Microbiology Unit of the Varese University hospital in 
Italy. Cultures were grown aerobically overnight in Luria Broth (LB) until the stationary phase. The 
cell suspensions were then diluted to an OD600nm of 0.2, grown until the mid-exponential growth 
phase (OD600nm = 0.65-0.75), and then stimulated with either 25 μg/mL imipenem, 1 mM 
Stenotrophomonas maltophilia DSF (cis-Δ2-11-methyl-dodecenoic acid), 1 mM Burkholderia 
cenocepacia DSF (BDSF, cis-Δ2-dodecenoic acid), or 1 mM Pseudomonas aeruginosa DSF (PDSF, 
cis-Δ2-decenoic acid), and allowed to grow further for 3 h. 
 
3.2.3 Time-kinetic, quantitative proteome study 
 
Methodology is provided in Addendum A1. 
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3.2.4 Isolation of outer membrane vesicles 
 
To obtain cell free culture supernatant from S. maltophilia, cells were pelleted by centrifugation 
at 6,000 x g for 5 min, and the culture supernatant was filtered through a 0.2 µm V25 vacuum 
filter (Sarstedt, Numbrecht, GE). The OMVs were pelleted by ultracentrifugation at 100,000 x g 
for 1 h (Avanti J-30I, Beckman Coulter, Fullerton, CA). One milliliter of the filtered culture 
supernatant was spread onto an LB agar plate and incubated at 37°C for 24 h to confirm the 
absence of intact, living cells.  
 
3.2.5 OMV protein extraction and digestion 
 
OMV proteins were extracted by dissolving the OMV pellet in 1 ml 8 M urea in 50 mM Tris-HCl pH 
8. Proteins were precipitated with trichloroacetic acid (20%) and consequently the pellet was 
washed twice with ice-cold acetone, and finally dissolved in 2 M urea in 50 mM ammonium 
bicarbonate (pH 8). The protein concentration was assessed using the Coomassie Plus BradfordTM 
Assay kit (Thermo Scientific, San Jose, CA, US). Proteins were reduced with 10 mM dithiothreitol 
for 30 min at 60 °C, alkylated with 20 mM iodoacetamide at ambient temperature for 30 min, and 
then digested with trypsin (1:50 w/w) overnight at 37 °C.  
 
3.2.6 LCMSE analysis of outer membrane vesicle content 
 
Peptide mixtures (0.5 µg/µl in 100 mM ammonium formate, pH 10) were separated on a 
NanoAcquity UPLC® system (Waters Corporation, Milford, MA) in 2D mode. For the first 
dimension (high pH), solvent A1 and B1 were composed of 20 mM ammonium formate in water 
and ACN (pH 10), respectively. For the second dimension (low pH), solvent A2 and B2 were 
composed of 0.1% formic acid in water and 0.1% formic acid in ACN, respectively. The sample (1 
μg) was loaded onto an XbridgeTM BEH130 C18 column (300 µm x 50 mm, 5 µm; Waters) at 3% 
solvent B1 at 2 μL/min. Peptides were eluted from the first dimension column in 5 fractions 
(11.1%, 14.5%, 17.4%, 20.8% and 45.0% of solvent B1), and fractions were trapped on a 
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Symmetry® C18 trapping column (180 µm x 20 mm, 5 µm; Waters). Each fraction was separated 
on a HSS T3 C18 analytical column (75 μm x 250 mm, 1.8 μm; Waters) at 40°C at 250 nL/min by 
increasing the acetonitrile concentration from 5-50% B2 over 60 min. 
 
The outlet of the column was directly connected to a PicoTip Emitter (uncoated SilicaTipTM 10 +/- 
1 μm, New Objective, Woburn, MA, US) mounted on a Nanolockspray source of a SYNAPTTM G1 
HDMS mass spectrometer (Waters). The time-of-flight (TOF) analyzer was externally calibrated 
with MS/MS fragments of human [glu1]-fibrinopeptide B (Glu-fib) from m/z 72 to 1285, and the 
data was corrected post-acquisition using the monoisotopic mass of the doubly charged precursor 
of Glu-fib (m/z 785.8426) (lock mass correction). Accurate mass data were collected in a data 
independent positive mode of acquisition (MSE) by alternating between low (5 V) and high 
(ramping from 15 to 35 V) energy scan functions (Geromanos et al., 2009). The selected m/z range 
was 125 to 2000 Da. The capillary voltage was set to 3.0 kV, the sampling cone voltage was 26 V 
and the extraction cone voltage on 2.65 V. The source temperature was set on 65 °C. 
 
The LCMSE data were processed using the ProteinLynx Global SERVERTM v2.5 (PLGS, Waters 
Corporation) (Geromanos et al., 2009). In brief, lock mass-corrected spectra (0.250 Da window 
allowed) were automatically centroided, deisotoped and charge-state reduced to produce a 
single monoisotopic peak for each peptide and associated fragment ion. The correlation of a 
precursor and a potential fragment ion was achieved by means of time alignment. The following 
parameters were used for the data processing in PLGS: the chromatographic peak width, the TOF 
resolution and retention time window, which were determined automatically by the software, 
and the low energy, high energy, and intensity thresholds, which were set to 250, 100 and 1500 
counts respectively. A database containing 4380 protein entries from the closely related 
Stenotrophomonas maltophilia K279a (downloaded from the Uniprot website, April 2014), 
together with a decoy database consisting of the randomized entries of all the proteins, was 
interrogated by PLGS (Li et al., 2009). The precursor and fragment ion tolerance were determined 
automatically. The default protein identification criteria used included a maximal protein mass of 
250,000 Da, a detection of minimal 3 fragment ions per peptide, minimal 7 fragment ions per 
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protein and minimal 1 peptide per protein. Carbamidomethyl-C (fixed) and methionine oxidation 
(variable) were selected as modifications. Maximally one missed cleavages and a false positive 
rate of 4% was allowed.  
 
3.2.7 Sample preparation for liquid chromatography-multiple reaction monitoring (LC-
MRM) analysis 
 
Cells, obtained from 10 ml of culture, were pelleted by centrifugation at 6,000xg for 5 min, and 
the culture supernatant was filtered through a syringe-driven 0.22 µm PES membrane filter unit 
(Merck Millipore, Darmstadt, GE). OMV proteins were isolated as described above, and finally 
dissolved in 50 µl 2 M urea in 50 mM ammonium bicarbonate. Protein solutions were spiked with 
100 ng BSA (MS grade protein standard), reduced and alkylated, and digested with 0.5 µg trypsin. 
Digested samples were dried and dissolved in 50 µl 0.1% formic acid in water for LC-MRM analysis 
(5 µl injection). This procedure was followed for 2 biological replicates. 
 
3.2.8 LC-MRM analysis 
 
The digested samples were first separated by RPLC on a U3000-RSLC system (Thermo). Briefly, 
the sample was loaded onto an Acclaim PepMap100 pre-concentration column (L x ID 2 cm x 100 
µm, C18, 5 µm, 100Å) at a flow rate of 5 µl/min, and flushed for 3 min with 0.1% HCOOH / 2% 
ACN. The sample was then separated on a Thermo Acclaim PepMap100 analytical column (L x ID 
15 cm x 75 µm, C18, 3 µm, 100Å) at a flow rate of 300 nl/min, with mobile phases 0.1% HCOOH 
in water (solvent A) and 0.1% HCOOH in ACN (solvent B). Peptides were separated with a 30 min 
gradient, going from 2% to 40% solvent B, and eluting peptides were sprayed directly in a 4000 
QTRAP mass spectrometer (AB Sciex, Framingham, MA) with a NanoSpray II ESI source (AB Sciex), 
using a PicoTip Emitter (uncoated SilicaTipTM 10 +/- 1 μm). The ion spray voltage was set at 3.5 
kV, curtain gas at 10 (arbitrary units), nebulizing gas at 5, and interface heater temperature at 
60°C. We analysed 2 technical replicates per biological samples. 
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Target peptides (two for each protein) were measured in multiple reaction monitoring (MRM) 
acquisition mode, with the Q1/Q3 resolution set at LOW and with a maximum total cycle time of 
3 sec. The double charged peptide was selected as precursor (Q1), and for each precursor three 
fragment ions were selected from the y-ions (Q3). The collision energy (CE) and declustering 
potential (DP) were calculated with the following equations:  
CE (V) = (0.5 x m/z) + 5 
DP (V) = (0.0729 x m/z) + 31.117 
 
The MRM data was imported in Skyline v2.5 (MacLean et al., 2010) and peak traces were 
subjected to a Savitzky-Golay Smoothing transformation. The total area under curve (AUC) of 
each target peptide was calculated, and normalized to the spiked BSA standard. A student’s t-test 
was performed to evaluate the significance of differential protein abundancy levels between 
stimulated and unstimulated cultures. 
 
3.2.9 OMV quantification 
 
OMVs from 25 ml cultures were harvested as described above, and the pellet was dissolved in 
100 µl phosphate buffered saline (PBS). The OMV concentration and size was determined by light 
scattering based single particle tracking using a NanoSight LM10-HS instrument (NanoSight, 
Amesbury, UK; Dr. A. Hendrix, Laboratory of Experimental Cancer Research, Ghent University 
Hospital) equipped with a 405 nm laser. Prior to analysis, the purified OMVs were diluted in PBS-
buffer (Invitrogen). Movies of 60 seconds were recorded and analyzed with the NTA Analytical 
Software version 2.3. Each individual sample was diluted and measured 3 times. Calculations were 
performed according to Van der Pol et al. (2010). 
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3.2.10 Transmission electron microscopy 
 
The S. maltophilia strain 44/98 was cultured overnight, as described above. At the mid 
exponential growth phase, cultures were diluted in LB medium supplemented with 25 μg/mL 
imipenem, and allowed to grow further for 2 h. A control culture was treated similarly except for 
the addition of imipenem. A 4 μL drop of culture was placed on a Formvar/carbon-coated cupper 
grid, made hydrophilic by glow discharging for 30 s. The grid was then washed by placing it 
sequentially onto 5 drops of milliQ water. After these washing steps, the grid was placed on 2 
drops of 2% uranyl acetate and incubated for 30 to 40 s. The grid was blotted with filter paper 
between each washing step. The created specimens were examined using a JEM 1010 
transmission electron microscope (JEOL, Tokyo, Japan) operating at 60 kV using Image Plate 
Technology from Ditabis (Pforzheim, Germany). 
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3.3 Results 
 
3.3.1 Imipenem stimulates the expression of two Ax21 homologues 
 
A preliminary time-kinetic, quantitative proteome study on the imipenem response of S. 
maltophilia was performed to address the proteome dynamics after antibiotic treatment. Among 
the few proteins of which we found a gradual increase in abundancy over time after exposure to 
imipenem, we found mainly the two β-lactamases, outer membrane proteins and proteins 
involved in motility (flagellins). Two of these proteins showed strong homology to X. oryzae Ax21 
(PXO_03968), i.e. Smlt0387 and Smlt0184 (Figure 9, A). Former studies on Ax21 in S. maltophilia 
report only a single Ax21 homologue (Smlt0387) (McCarthy et al., 2011; Ferrer-Navarro et al., 
2013). We found now thus two homologues with respectively 60% identity for Smlt0387 (e-value 
7.0e-80) and 56% identity for Smlt0184 (e-value 4.0e-73) with the X. oryzae protein. Alignment of 
Smlt0387 and Smlt0184 learned that the two proteins display 63% identity. The alignment of the 
two S. maltophilia Ax21 sequences with the X. oryzae Ax21 sequence is depicted in Figure 9B. 
Both proteins contain a typical signal sequence (Figure 9, B; green box) implicating that, like the 
X. oryzae Ax21 protein, they are processed by the Sec secretion system (Bahar et al., 2014). 
Analyzing the protein sequences of the S. maltophilia Ax21 homologues Smlt0387 and Smlt0184 
with Pfam (Finn et al., 2014) showed that they belong to the outer membrane protein β-barrel 
domain family, with e-values 1.5e-09 and 5.7e-11 respectively. This is consistent with the 
structural model, representing a porin-like structure, proposed recently (Park et al., 2014). 
 
3.3.2 Imipenem-treated Stenotrophomonas maltophilia cells secrete more OMVs 
 
A recent study demonstrated that the X. oryzae Ax21 protein is secreted in association with OMVs 
(Bahar et al., 2014). Therefore, we verified the production of OMVs by S. maltophilia upon 
imipenem stress. As a matter of fact, it was shown in Acinetobacter baumanii (ATCC19606T) that 
exposure to subinhibitory concentrations of ceftazidime (cephalosporine, also a β-lactam) caused 
ruffling along the whole outer membrane resulting in the formation of more OMVs (Koning et al., 
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2013). Using TEM, we indeed observed a similar increase in OMV secretion in S. maltophilia, when 
exposed to imipenem (Figure 10, A-B). When we applied light scattering based single particle 
tracking to quantify the isolated OMVs from an equal volume of stimulated and unstimulated 
cultures (25 ml culture, 3h imipenem stimulation), the stimulated cultures contained considerable 
more OMVs than the unstimulated cultures (Figure 10, C).  
 
 
 
Figure 9. (A) Time-dependent increase in abundancy of the two S. maltophilia Ax21 homologues (Smlt0387 
and Smlt0184). For each time point, the abundance ratio with reference to time point 0 is plotted. (B) 
Alignment of Smlt0387 and Smlt0184 with the Xanthomonas Ax21 protein (PXO_03968). Red: identical 
amino acid residues. Green box: signal sequence. 
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Figure 10. OMV visualization with TEM: (A) control, (B) after imipenem treatment. 
OMV concentration determination with light scattering based single particle 
tracking after imipenem treatment (C). Error bars plot the standard deviation. 
 
 
3.3.3 Proteomic analysis of S. maltophilia OMVs 
 
To confirm the presence of both Ax21 proteins in OMVs, a profile of the S. maltophilia OMV 
proteome was assessed with LCMSE. Cells were grown in the presence of the broad-spectrum β-
lactam antibiotic imipenem (3h). After collection of the OMVs and protein extraction, one 
microgram of digested protein was separated with 2D-UPLC (high pH – low pH RPLC) on a 
NanoAcquity UPLC® system, and eluting peptides were analyzed online with a SYNAPTTM HDMS 
Q-TOF mass spectrometer. The acquisition of MS/MS spectra in a data-independent acquisition 
mode (MSE) resulted in the identification of 234 proteins (identified in at least two of the three 
technical replicate LCMSE runs) (Addendum A2). Indeed, the Ax21 proteins Smlt0387 and 
Smlt0184 were identified in all three technical replicate runs with, on average, a sequence 
coverage of 82.1% and 70.0 % respectively. These findings confirm the secretion of Ax21 as an 
outer membrane protein associated with outer membrane vesicles in S. maltophilia. 
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The proteins identified in the OMVs were further annotated with Blast2GO v.2.7.1 and PSORTb 
v.3.0.2. Several proteins were identified that are involved in the assembly of β-barrel proteins: 
SecA and SecB for protein translocation to the periplasm, the SurA chaperone which prevents 
misfolding in the periplasm, and BamA, BamB, BamD and BamE, responsible for β-barrel protein 
assembly in the outer membrane (Selkrig et al., 2013). Apart from the Ax21 homologues, several 
other outer membrane proteins were identified, for example TonB-dependent receptor proteins, 
Omp family proteins, autotransporters, lipoproteins, and the SmeX efflux protein (part of the 
Resistance-Nodulation-Cell Division (RND) SmeVWX efflux pump). During OMV formation, 
periplasmic proteins can be encapsulated, as well as inner membrane (associated) proteins. This 
is illustrated by the identification of proteins involved in peptidoglycan turnover (penicillin-
binding proteins (PBPs), carboxypeptidases, transglycosylases). Furthermore, fimbrial adhesins 
and flagellins were identified, involved in adhesion and motility, respectively. Interestingly, the 
OMVs also contain the L1-metallo- and L2-serine-β-lactamases (Smlt2667 and Smlt3722) when 
exposed to imipenem. Both β-lactamases are translocated to the periplasm via different systems: 
the L1-β-lactamase uses the Sec export system, the L2-β-lactamase uses the Tat export system 
(Pradel et al., 2009; Brooke, 2012). Finally, the OMV proteome profile also includes cytoplasmic 
proteins, mostly highly abundant proteins (e.g. elongation factors) and ribosomal proteins.  
 
3.3.4 Influence of diffusible signaling factors on the secretion of OMVs 
 
Next to the β-lactam antibiotic imipenem, also DSF quorum sensing molecules were tested for 
their ability to stimulate OMV secretion (Figure 11, A). A study on the plant pathogen Xylella 
fastidiosa showed a link between OMV secretion and the DSF quorum sensing system (Ionescu et 
al., 2014). The authors postulated that OMVs are affecting plant colonization by blocking surfaces, 
leading to a deeper spread of X. fastidiosa into the plant host, which increases virulence. The X. 
fastidiosa DSF system suppresses the release of OMVs (and virulence), causing cells to grow more 
locally, attached to unblocked surfaces. However, in S. maltophilia, growing cells in presence of 
its own DSF cis-Δ2-11-methyl-dodecenoic acid resulted in a remarkable increase in OMV secretion 
(Figure 11, B), comparable to the amount secreted in the presence of imipenem. The DSF cis-Δ2-
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dodecenoic acid produced by B. cenocepacia (BDSF) also led to a slight increase in OMV secretion 
in S. maltophilia, while the DSF cis-Δ2-decenoic acid produced by P. aeruginosa (PDSF) did not. 
This is in accordance with the known responsiveness of S. maltophilia to these DSF molecules. S. 
maltophilia can perceive the DSFs produced by itself and B. cenocepacia, but not the one 
produced by P. aeruginosa (Ryan and Dow, 2010). The endogenous methyl-branched DSF was 
shown to be far more active than the unbranched BDSF and PDSF. 
 
 
 
Figure 11. (A) Structure of DSF, BDSF and PDSF. (B) Effect of DSF and its structural 
homologues on OMV secretion determined with light scattering based single particle 
tracking. Error bars plot the standard deviation. 
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3.3.5 Relative quantification of OMV-associated proteins with multiple reaction 
monitoring (MRM) 
 
The differential OMV-associated secretion of the Ax21 homologues was validated with a label-
free, targeted LC-MRM approach. Two proteotypic peptides for each Ax21 protein were 
quantitatively analysed with MRM: (K-)VGAGYNVEIAPSTDFVAR(-V) and (K-)LNQNWGLNGELK(-M) 
for Smlt0387, and (R-)IGAGYNYGIAPNTDLVAR(-V) and (K-)FNQNWGLSGEVK(-L) for Smlt0184. 
Three MS/MS transitions for each peptide were chosen (Addendum A3). The peptides are unique 
within the S. maltophilia K279a proteome, and a UniPept search (Mesuere et al., 2012) also 
revealed uniqueness for S. maltophilia species. These peptides also show good MRM 
compatibility in terms of length, hydrophobicity, and ionization properties. In addition, the 
dominant L1 β-lactamase (Smlt2667) (target peptides GVAPQDLR and IAYADSLSAPGYQLK) and 
the spiked-in BSA standard (target peptides AEFVEVTK and QTALVELLK) were monitored. The 
MRM analysis was performed on OMV protein extracts from equal culture volumes grown in 
presence of imipenem, DSF, BDSF and PDSF (3h stimulation).  
 
These experiments confirmed a huge increase in OMV-associated secretion of both Ax21 proteins, 
when S. maltophilia cultures were stimulated with the β-lactam antibiotic imipenem, and with 
the DSF and BDSF quorum sensing molecules (Figure 12, A-B). When comparing the two Ax21 
homologues, the previously overlooked homologue Smlt0184 is actually much more prevalent 
than Smlt0387, both in the imipenem-stimulated culture, as well as in the DSF- and BDSF-
stimulated cultures. Also remarkable is that the highest amount of Smlt0184 was measured in the 
BDSF-induced OMVs (Figure 12, A), while the OMV production elicited by BDSF is in fact much 
lower than for imipenem and DSF (Figure 11, B). Smlt0387 secretion seems to be more 
pronounced after imipenem exposure, than it is for DSF or BDSF (Figure 12, B). S. maltophilia is 
again unresponsive to the P. aeruginosa PDSF in terms of Ax21 secretion, as it was for OMV 
production (Figure 12, B). 
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The large increase in L1 β-lactamase expression in response to imipenem is also represented here 
in the secreted OMVs (Figure 12, C), as previously observed at the cellular level (Van Oudenhove 
et al., 2012). The fast production of β-lactamases, especially the L1 metallo-β-lactamase, 
represents the important early line of defense of S. maltophilia against the imipenem challenge. 
Since imipenem leads to substantial L1 levels in the cell, and the periplasm, it is not entirely 
surprising that this protein is also prevalent in the secreted OMVs. Nevertheless, whether its 
presence in the OMVs is accidental or predestined, its biological relevance is obvious. Finally, only 
a slight increase in OMV-associated L1 secretion was observed when stimulated with DSF, and 
even more with BDSF (Figure 12, C). 
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Figure 12. Relative abundancy of OMV-associated Ax21 homologues (A-B) and L1 β-lactamase (C) in response to 
imipenem and diffusible signaling factors, determined by targeted proteomics (LC-MRM). The plot display the 
average normalized area-under-the-curve for each peptide used as marker for the different proteins. The error bars 
plot the standard deviation. Target peptides: VGA: VGAGYNVEIAPSTDFVAR, LNQ: LNQNWGLNGELK, IGA: 
IGAGYNYGIAPNTDLVAR, FNQ: FNQNWGLSGEVK, GVA: GVAPQDLR, IAY: IAYADSLSAPGYQLK. 
 
 
 
 
 
  
Chapter 3: Proteomics of imipenem-induced OMVs 
66 
 
3.4 Discussion 
 
The genome sequence of the pathogenic Stenotrophomonas maltophilia K279a strain revealed 
an organism that is well adjusted for living in an environment with antibiotics (Crossman et al., 
2008). We here add the capacity of S. maltophilia to secrete OMVs packed with β-lactamases as 
an additional property to adapt to antibiotic stress. 
 
In this work, we quantified the amount of OMV secretion as a response to the β-lactam antibiotic 
imipenem. As expected, imipenem led to a significant increase in OMV secretion, probably owing 
to the disturbed cell wall structure or alteration in peptidoglycan dynamics (Haurat et al., 2014). 
Proteomic analysis on the isolated OMVs revealed the OMV-mediated secretion of the 
chromosomal encoded β-lactamases in S. maltophilia. This is not the case when OMVs are 
induced by DSF. Whether the presence of β-lactamases in the OMVs is merely due to their high 
abundance in the periplasm upon -lactam stress or whether they are deliberately delivered in 
the OMVs is not clear. Anyway, by exporting the β-lactamases in the environment, S. maltophilia 
not only provides resistance against the imipenem at the cell level, but could also protect other 
cells from the same species, or from other species. Additionally, packed in OMVs, the β-
lactamases are protected against extracellular degradative enzymes and are able to travel long 
distances (Bonnington and Kuehn, 2013).  
 
In Xylella fastidiosa, the production of OMVs is suppressed by the DSF quorum sensing system 
(Ionescu et al., 2014). Therefore, the DSF quorum sensing molecules cis-Δ2-11-methyl-
dodecenoic acid (DSF), cis-Δ2-dodecenoic acid (BDSF) and cis-Δ2-decenoic acid (PDSF), produced 
by S. maltophilia, B. cenocepacia and P. aeruginosa respectively, were also tested for their effect 
on OMV production in S. maltophilia. In contrast to X. fastidiosa, DSF led to a comparable increase 
in the amount of OMV secretion as with imipenem. BDSF led to a slight increase in OMV secretion, 
and PDSF did not have any effect. These fatty acid analogues do not have any known perturbation 
effects on the cell wall, as opposed to imipenem, and the OMV response is in agreement with 
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their signaling activity in S. maltophilia. These results therefore suggest a quorum sensing 
controlled OMV biogenesis. 
 
Finally, the OMV proteome analysis revealed the production of two Ax21 proteins in S. 
maltophilia. The Ax21 protein was shown to be involved in biofilm formation and virulence, and 
is highly conserved in all Xanthomonas species, and in S. maltophilia. Recently, it was shown that 
the Xanthomonas Ax21 is an outer membrane protein, secreted in OMVs (Bahar et al., 2014), and 
regulation of expression is dependent on the DSF system (Qian et al., 2013). With a targeted and 
label-free MRM method, we quantified the OMV-mediated secretion of the Ax21 homologues as 
a response to imipenem, DSF, BDSF and PDSF. All conditions led to substantial amounts of OMV-
associated Ax21 secretion. The results indicate a deliberate and regulated secretion of Ax21, 
rather than a coincidental presence due to an increased OMV biogenesis. The production of OMVs 
and packing with large quantities of Ax21 protein, point to an important role of it in antibiotic 
resistance and biofilm formation. However, the exact role of Ax21 in S. maltophilia remains 
unclear, and should be further investigated, more specific by confirming its porin transporter 
function and determination of its cargo. 
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Abstract 
 
The treatment of Stenotrophomonas maltophilia with β-lactam antibiotics leads to increased 
release of outer membrane vesicles (OMV), which are packed with two chromosomal encoded β-
lactamases. Here we show that these β-lactamase-packed OMVs are capable of establishing 
extracellular β-lactam degradation. We also show that they dramatically increase the apparent 
MIC of imipenem and ticarcillin for co-habituating species Pseudomonas aeruginosa and 
Burkholderia cenocepacia. In addition to conferring OMV-mediated resistance by direct 
inactivation of the β-lactam antibiotics, OMVs are also involved in initiating and maintaining 
biofilm growth. Although OMVs from S. maltophilia have a negative effect on biofilm formation 
of its own species, these same OMVs display a positive effect on biofilm formation of P. 
aeruginosa and B. cenocepacia. 
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4.1 Introduction 
 
The multidrug resistant bacterium Stenotrophomonas maltophilia exploits a variety of 
mechanisms to resist antibiotic threats, i.e. the active extrusion of antibiotics by efflux pumps, 
alteration of cell membrane permeability, shielding by growing as a biofilm, or direct enzymatic 
inactivation of the antibiotic compounds (Abbott et al., 2011). β-lactam antibiotics like imipenem 
(IPM), amoxicillin (AMX) and ticarcillin (TIC) are frequently used to treat Gram-negative bacterial 
infections. Unfortunately these compounds are often ineffective for S. maltophilia infections due 
to the presence of two chromosomal encoded β-lactamase genes encoding the L1 metallo-β-
lactamase and the L2 serine-β-lactamase, of which the expression immediately increases after 
exposure (Brooke et al., 2011).  
 
In a previous study we revealed a significant increase in the release of outer membrane vesicles 
(OMVs) by S. maltophilia upon exposure to the broad spectrum carbapenem IPM (Chapter 3; 
Devos, Van Oudenhove et al., 2015). We showed that these vesicles are packed with L1 and L2 β-
lactamases. OMVs are membranous nanostructures secreted by most Gram-negative bacteria. 
OMV secretion is typically higher under cellular stress conditions (Deatherage et al., 2009). The 
spherical outer membrane capsules enclose periplasmic material (e.g. proteins, peptidoglycan 
intermediates, signaling molecules) and transport them into the extracellular environment. This 
allows for long-distance transport and protection of cargo proteins (Bonnington and Keuhn, 
2013). Several studies have shown the involvement of OMVs in antibiotic resistance (Ciofu et al., 
2000; Schaar et al., 2011; Lee et al., 2013; Stentz et al., 2015). For example, OMVs have the 
potential to serve as vehicles for β-lactamases, allowing for the inactivation of β-lactam antibiotics 
before they can reach planktonic cells or biofilm communities.  
 
OMVs have also been identified as important constituents of biofilm (Schooling and Beveridge, 
2006). The formation of biofilm is an important property of S. maltophilia, as it is for many other 
pathogenic species, since it provides a protective environment against the host immune system 
and against antibiotic threats (Brooke et al., 2011; Jolivet-Gougeon and Bonnaure-Mallet, 2014; 
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de Oliveira-Garcia et al., 2003; Passerini de Rossi et al., 2007). In several species it was shown 
that OMVs influence cell aggregation, surface attachment and biofilm formation, both at inter- 
and intraspecies level. For example, OMVs produced by Helicobacter pylori enhance biofilm 
formation by establishing OMV-mediated cell-cell interactions (Yonezawa et al., 2009). OMVs 
from Porphyromonas gingivalis have a negative impact on biofilm formation of Streptococcus 
gordonii (Ho et al., 2015), but stimulate biofilm formation of Staphylococcus aureus, including 
methicillin-resistant S. aureus (MRSA) (Kamaguchi et al., 2003).  
 
Multiresistant S. maltophilia is increasingly found in respiratory specimens from patients with 
cystic fibrosis (CF) (Raidt et al., 2015). The presence of S. maltophilia is a risk factor to generate a 
decline in the forced expiratory volume in 1 sec (FEV1) (Cogen et al., 2015). While the actual 
impact of this organism on CF disease is debated, its presence is of concern given its capacity to 
acquire antibiotic resistance (Looney et al., 2009; Sánchez, 2015). Considering that S. maltophilia 
co-colonizes with organisms like Pseudomonas aeruginosa and Burkholderia cenocepacia, the 
presence of OMVs could potentially play an important role in multispecies biofilm initiation and 
maintenance, and thus biofilm-related resistance. Cell-cell communication is crucial for the 
survival of species in these communities, and interactions between the different species, whether 
synergistic or antagonistic, can influence the infection process, progress and treatment. The 
exposure of S. maltophilia inhabited communities to β-lactam antibiotics, and the subsequent 
secretion of β-lactamase-packed OMVs, could therefore potentially influence the effect of the β-
lactams. 
 
In this work, we explored the potential of β-lactam-induced OMVs to protect S. maltophilia cells, 
as well as P. aeruginosa and B. cenocepacia cells, against β-lactam treatment. 
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4.2 Material and methods 
 
4.2.1 Materials 
 
Nitrocefin was purchased from TOKU-E (Ghent, Belgium). ULC-MS grade water and acetonitrile 
(ACN) was procured from Biosolve (Valkenswaard, The Netherlands). Sequencing grade modified 
trypsin was obtained from Promega (Madison, WI, US). Acetic acid was purchased from VWR. All 
other chemicals and antibiotics were purchased from Sigma-Aldrich (St. Louis, MO, US). 
 
4.2.2 Bacterial Cell Culture 
 
The bacterial strains Stenotrophomonas maltophilia 44/98 (LMG 26824), Pseudomonas 
aeruginosa PAO1 (LMG 24986), and Burkholderia cenocepacia type strain (LMG 16656) were 
grown aerobically overnight in Luria Broth (LB) until the stationary phase. The cell suspensions 
were then diluted to an OD600nm of 0.2, and allowed to grow further under the same conditions.  
 
4.2.3 Preparation of outer membrane vesicles 
 
S. maltophilia cells were grown for 2 hours until the mid-exponential growth phase (OD600nm = 
0.65-0.75), and then grown for an additional 3 hours in the presence of 1 mg/ml penicillin G (PEN). 
Cells were pelleted by centrifugation at 4,000 x g for 15 min. The culture supernatant was filtered 
through a syringe-driven 0.22 µm PES membrane filter unit (Merck Millipore, Darmstadt, GE), and 
the OMVs were pelleted by ultracentrifugation at 100,000 x g for 1 h (Avanti J-30I, Beckman 
Coulter, Fullerton, CA). The OMV pellet was resuspended in phosphate buffered saline (PBS) or 
LB. One milliliter of the filtered culture supernatant was spread onto an LB agar plate and 
incubated at 37°C for 24 h to confirm the absence of intact, living cells. 
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4.2.4 OMV quantification 
 
Isolated OMVs from 50 ml cultures were harvested and resuspended in 1 ml PBS. The OMV 
concentration was determined by light scattering based single particle tracking using a NanoSight 
LM10-HS instrument (NanoSight, Amesbury, UK; Dr. A. Hendrix, Laboratory of Experimental 
Cancer Research, Ghent University Hospital) equipped with a 405 nm laser. Prior to analysis, the 
purified OMVs were diluted in PBS-buffer (Invitrogen). Movies of 60 seconds were recorded and 
analyzed with the NTA Analytical Software version 2.3. Each individual sample was diluted and 
measured 3 times. Calculations were performed according to Van der Pol et al. (2010). 
 
Fluorescent single particle tracking measurements were used to determine the concentration of 
true membranous particles (Braeckmans et al., 2010). Prior to analysis, purified OMVs were 
fluorescently labeled with the membrane labeling dye PKH67 (Sigma-Aldrich). To this end OMVs 
were diluted 1 in 5 in diluent C and mixed with an equal volume of 140 µM PKH67 in diluent C. 
The mixture was incubated at 37 °C for 30 minutes and unincorporated dye was washed away by 
means of size exclusion chromatography using an exosome spin column (MWCO 3000) 
(Invitrogen) according to the manufacturer’s instructions. Next, labeled OMVs were diluted in PBS 
and movies of the fast diffusing, individual vesicles were obtained at ambient temperature 
(22.5°C) using a swept field confocal microscope (LiveScan SFC, Nikon BeLux, Belgium) equipped 
with an Ixon Ultra EMCDD camera (AndorTM technologies), a 488 nm laser and a 60X oil immersion 
lens (NA 1.4; Nikon). Videos were analyzed with in-house developed software in Matlab® for 
particle detection, motion trajectory construction with calculation of diffusion coefficients and 
finally calculation of the OMV concentration according to a recently developed method with 
inherent calibration of the detection volume by Roding et al. (2011). 
 
4.2.5 OMV proteomics 
 
The OMV protein content from penicillin G stimulated S. maltophilia cultures was determined 
with a 2D-LCMSE proteomics workflow as previously described (Chapter 3; Devos, Van Oudenhove 
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et al., 2015). Briefly, OMV proteins were reduced with 10 mM dithiothreitol for 30 min at 60 °C, 
alkylated with 20 mM iodoacetamide at ambient temperature for 30 min, and then digested with 
trypsin (1:50 w/w) overnight at 37 °C. Peptide mixtures were separated on a NanoAcquity UPLC® 
system (Waters Corporation, Milford, MA) in 2D mode. The LC outlet was directly connected to a 
PicoTip Emitter (uncoated SilicaTipTM 10 +/- 1 μm, New Objective, Woburn, MA, US) mounted on 
a Nanolockspray source of a SYNAPTTM G1 HDMS mass spectrometer (Waters). Accurate mass 
data were collected in a data independent positive mode of acquisition (MSE) (selected m/z range 
125 to 2000 Da). The LCMSE data were processed using the ProteinLynx Global SERVERTM v2.5 
(PLGS, Waters Corporation). A database containing 4380 protein entries from the closely related 
Stenotrophomonas maltophilia K279a (downloaded from the Uniprot website, April 2014), 
together with a decoy database consisting of the randomized entries of all the proteins, was 
interrogated by PLGS. The precursor and fragment ion tolerance were determined automatically. 
The default protein identification criteria used included a maximal protein mass of 250,000 Da, a 
detection of minimal 3 fragment ions per peptide, minimal 7 fragment ions per protein and 
minimal 1 peptide per protein. Carbamidomethyl-C (fixed) and methionine oxidation (variable) 
were selected as modifications. Maximally one missed cleavages and a false positive rate of 4% 
was allowed. 
 
4.2.6 β-lactamase assay 
 
OMVs (isolated from 25 ml culture, dissolved in 1 ml PBS) were mixed with 50 µl of a 0.5 mg/ml 
nitrocefin solution (1 mg nitrocefin in 100 µl dimethylsulfoxide, diluted to 2 ml with PBS). The 
OD490nm was measured at different time points. The hydrolysis of nitrocefin by β-lactamases 
generates an absorbance shift from yellow (intact nitrocefin, 380 nm) to red (hydrolyzed 
nitrocefin, 490 nm), which was monitored using a SmartSpecTM 3000 spectrophotometer (BioRad, 
Hercules, CA). 
 
For the β-lactamase assay on crude cell lysate, cells from 0.5 ml PEN stimulated culture were 
collected by centrifugation at 4,000 x g for 15 min. The cell pellet was suspended in 500 µl PBS, 
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an equal volume of acid-washed glass beads (1-1.25 mm) was added, and cells were lysed by 
shaking vigorously for 5 minutes at 2500 rpm. The lysate was transferred to a new Eppendorf and 
the volume adjusted to 1 ml with PBS. Insoluble material was removed by centrifugation at 16,000 
x g for 15 min. β-lactamase activity in the lysate was determined as described above. 
 
To differentiate between the L1 metallo-β-lactamase and the L2 serine-β-lactamase, prior to the 
assay, 50 mM ethylenediaminetetraacetic acid (EDTA) was added and incubated for 30 min at 
4°C.  
 
4.2.7 Extraction of antibiotics 
 
From a 25 µg/ml antibiotic suspension (start concentration) in 1 ml OMVs (isolated from 25 ml 
culture, dissolved in 1 ml PBS) or 1 ml crude cell lysate (as described in 2.6), 40 µl was collected 
at different time-points and mixed with 160 µl ACN. After shaking (5 minutes at 2500 rpm), the 
mixture was centrifuged at 16,000 x g for 15 minutes. The supernatant was collected and dried in 
a SpeedVac (SC110, Thermo Savant, Holbrook, NY). Finally, the pellet was resuspended in 15 µl 
10 mM ammonium formate for RP-HPLC analysis.  
 
4.2.8 RP-HPLC analysis of antibiotics  
 
Antibiotic extracts were separated by RP-HPLC on an Ettan LC system (GE Healthcare), controlled 
by Unicorn® 5.11 software. Briefly, the sample (10 µl) was separated on a Zorbax Eclipse Plus C18 
column (4.6x100 mm, 3.5 µm; Agilent) at a flow rate of 1 ml/min, with mobile phases 10 mM 
ammonium formate (solvent A) and ACN (solvent B) (ambient temperature). Analytes were 
separated with a 7.5 min gradient, going from 2% to 90% solvent B. Eluting compounds were 
detected with a UV detector (IPM: 298 nm, AMX: 230 nm, TIC: 220 nm). 
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4.2.9 Antibiotic tolerance plate assay 
 
Cultures from S. maltophilia, P. aeruginosa and B. cenocepacia were grown in a 96-well plate, 
with different concentrations of the antibiotics IPM, AMX or TIC, with or without OMVs derived 
from a PEN stimulated S. maltophilia culture. Briefly, 50 µl of LB with a certain concentration of 
antibiotics (0, 1, 5, 10, 50, 100, 500, 1000, 5000 µg/ml) were mixed with 50 µl LB (control) or 50 
µl OMVs in LB (OMVs from 50 ml culture in 1 ml LB) and to this mixture, 5 µl of cells were added 
(culture diluted to OD600nm 0.2). Cultures were grown at 37°C for 16 h, after which the OD600nm 
was measured with a 680XR micro plate reader (Bio-Rad, Hercules, CA). 
 
4.2.10 Biofilm plate assay 
 
Cultures from S. maltophilia, P. aeruginosa and B. cenocepacia were grown in a 96-well plate, 
with or without OMVs derived from a PEN stimulated S. maltophilia culture. Briefly, 50 µl of cells 
(culture diluted to OD600nm 0.4) were mixed with 50 µl of LB (control) or OMVs in LB (OMVs from 
25 ml culture in 500 µl LB). Cultures were grown at 37°C for 4 h to allow adhesion. In a third 
condition, the OMVs were first added to the wells and incubated for 1 h at 37°C. Then the 
supernatant was removed and the wells were washed with 300 µl of PBS (2x), after which 50 µl 
of cells and 50 µl of LB was added, followed by 4 h of adhesion. After adhesion, the culture 
supernatant (non-adhered cells) was removed, and the wells were washed with 300 µl PBS (2x). 
Finally, 100 µl of fresh LB medium was added to each well, and the plate was incubated at 37°C 
for 18 h.  
 
Biofilm was quantified with crystal violet as described by Peeters et al. (2008) (two biological 
replicates, each with two technical replicates). Briefly, biofilm was fixed by adding 100 µl 
methanol to the cultures (15 min incubation), after which the wells were emptied and air dried. 
Then 100 µl of a crystal violet (0.1% w/v in water) was added to the wells. After 20 min incubation 
excess crystal violet was removed and the wells were rinsed with running tap water. Finally, 
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bound crystal violet was solubilized with 150 µl 33 % acetic acid and the absorbance was 
measured at 595 nm. 
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4.3 Results 
  
4.3.1 Characterization of penicillin G induced OMVs 
 
Previous work has shown that the exposure of S. maltophilia cells to the β-lactam antibiotic IPM 
led to a significant increase in the secretion of OMVs. Proteomics on isolated OMVs also revealed 
that these included large amounts of the two chromosomal encoded β-lactamases, the L1 
metallo-β-lactamase and the L2 serine-β-lactamase (Chapter 3; Devos et al., 2015). In this study, 
OMVs were used from PEN stimulated cultures (1 mg/ml, sub-lethal concentration; Addendum 
A4). When OMVs were quantified with light scattering based single particle tracking, the amount 
of particles detected was comparable to the amount measured after IPM stimulation (2.91e12 
particles/ml; Addendum A5). In addition, the OMVs were analyzed by fluorescent single particle 
tracking after incubation with the membrane specific fluorescent PKH67 label, which allows to 
quantify exclusively true membranous particles. Again, the results were similar as obtained for 
IPM (Addendum A5). 
 
PEN-induced OMVs were also subjected to a 2D-LCMS proteomics study to identify the protein 
cargo. Both β-lactamases were again found to be included into OMVs. Furthermore, the OMV 
protein profile is strongly comparable to that of IPM-induced OMVs (87 % of identified protein 
were also identified in IPM OMVs; Addendum A6) (Chapter 3; Devos et al., 2015). The 2D-LCMS 
data was subjected to a label-free quantitative analysis with ProgenesisTM (Nonlinear Dynamics, 
Newcastle, UK), but no big differences in protein abundances were observed (Addendum A6). 
Overall, these results indicate that OMVs obtained from PEN treated cells are very similar to those 
induced by IPM treatment and that their biogenesis, structure and composition is a result from 
the cell stress provoked by the inhibition of peptidoglycan synthesis.  
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4.3.2 OMV-associated β-lactamase activity 
 
The β-lactamase activity of intact OMVs was examined (isolated from a 25 ml culture stimulated 
with 1 mg/ml PEN) using a nitrocefin β-lactamase assay (25 µg nitrocefin). The results show rapid 
nitrocefin hydrolysis by the β-lactamase packed OMVs (Figure 13, A). The rate of hydrolysis, 
derived from the linear part of the curve (5-15 min), was calculated as 0.571 µg/min (Addendum 
A7). In order to assess the contribution of the L1 metallo-β-lactamase, the same assay was 
performed after incubating the OMVs with the zinc-chelating agent EDTA (Hu et al., 2008). The 
initial rate of hydrolysis was now 0.262 µg/min, about half of the rate observed without EDTA. 
This demonstrates the OMV-associated activity of both β-lactamases. Remarkably, the β-
lactamase assay on crude culture lysate obtained after PEN stimulation showed almost complete 
activity loss after the addition of EDTA (Figure 13, B).  This points to a dominant role for L1 in 
cellular β-lactam resistance, as previously reported (Van Oudenhove et al., 2012). However, 
OMVs seem to have an equal activity distribution between L1 and L2. This could be explained by 
a more balanced targeting of both β-lactamases towards the OMVs, or the periplasm. 
 
4.3.3 OMV-mediated degradation of β-lactam antibiotics 
 
For the detection and quantification of hydrolysis of β-lactam antibiotics by PEN generated OMV 
samples, a fast and robust RP-HPLC method was set up. IPM, AMX and TIC were analysed with a 
short-gradient RPLC method (7.5 min gradient on a C18 Zorbax Eclipse Plus column) and each 
monitored with their optimal absorbance wavelength (IPM: 298 nm, AMX: 230 nm, TIC: 220 nm). 
The linear dynamic range was set from 50 ng to 5 µg (Addendum A8). For IPM, two peaks were 
detected, representing its two tautomeric forms. This was previously described, and was found 
to be stable (Verdier et al., 2011). Therefore, to perform the calculations of OMV-mediated 
degradation of IPM, only the first peak was considered. 
 
To explore the potential of OMVs to degrade the different β-lactam antibiotics, OMVs (isolated 
from a 25 ml culture stimulated with 1 mg/ml PEN) were exposed to 25 µg/ml of IPM, AMX or 
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TIC. Reaction products were extracted immediately after starting the treatment (t0), and after 10 
minutes (t10), 20 minutes (t20) and 30 minutes (t30) incubation at room temperature, and 
analyzed by RPLC. All three β-lactams were gradually degraded by the β-lactamase-packed OMVs, 
albeit with different efficiency (Figure 14). IPM and TIC are degraded rather slowly, as compared 
to AMX which is rapidly degraded. Former studies reported on an equal rate of hydrolysis of L1 
towards AMX and IPM, but a 10-fold higher rate of hydrolysis by L2 towards AMX as compared to 
IPM (Paton et al., 1994; Walsh et al., 1997). 
 
 
Figure 13. UV-VIS spectroscopy analysis of nitrocefin 
hydrolysis (OD490) at different time points during 
incubation with intact penicillin G induced OMVs (A), 
and crude penicillin G stimulated culture lysate (B), with 
and without the addition of EDTA. Error bars plot the 
standard deviation. 
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Figure 14. Results of the time-kinetic RP-HPLC analysis of imipenem (IPM), amoxicillin (AMX) and 
ticarcillin (TIC) at the start, and 10 min, 20 min and 30 min after incubation with intact penicillin G 
induced OMVs. Error bars plot the standard deviation. 
 
 
4.3.4 Effect of OMVs on the antibiotic tolerance of S. maltophilia, P. aeruginosa and B. 
cenocepacia 
 
As S. maltophilia is often part of polymicrobial communities, we investigated whether OMVs from 
S. maltophilia influence the tolerance of P. aeruginosa, B. cenocepacia and itself to different β-
lactam antibiotics. S. maltophilia, P. aeruginosa and B. cenocepacia were grown in the presence 
of different concentrations of the β-lactam antibiotics IPM, AMX or TIC, with or without OMVs 
derived from a S. maltophilia culture exposed to PEN. 
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S. maltophilia shows a high resistance towards the three β-lactam antibiotics, with growth 
inhibition at 500 µg/ml, 2500 µg/ml and 250 µg/ml of IPM, AMX and TIC respectively (Figure 15, 
left column). When isolated OMVs (containing β-lactamases) were added, the inhibitory 
concentration increases to 2500 µg/ml for IPM and TIC, and even higher for AMX (> 2500 µg/ml). 
The effect of the antibiotics, and the OMVs, on P. aeruginosa and B. cenocepacia is very much 
alike (Figure 15, middle and right column). Both species are as resistant to AMX as S. maltophilia, 
and the addition of the OMVs also lead to an increase in the inhibitory concentration (> 2500 
µg/ml). P. aeruginosa and B. cenocepacia are naturally less resistant to IPM and TIC, but the 
presence of S. maltophilia OMVs drastically increases the antibiotic tolerance for these species. A 
100-fold increase in inhibitory concentration was observed: from 2.5 µg/ml to 250 µg/ml and 
from 25 µg/ml to 2500 µg/ml for IPM and TIC respectively.  
 
4.3.5 Influence of OMVs on biofilm formation 
 
We also analysed the influence of S. maltophilia derived OMVs on biofilm formation of S. 
maltophilia itself and of P. aeruginosa and B. cenocepacia. Cultures were incubated in the 
presence of OMVs (‘OMV’), in the absence of OMVs (‘control’), or in the absence of OMVs but 
after pre-incubation of the growth chamber with OMVs (‘block’). The OMVs have a clear negative 
effect on biofilm formation in S. maltophilia itself, possible through blocking of the surface (Figure 
16). Indeed, when the growth chamber was pre-incubated with OMVs, followed by a washing 
step and the addition of fresh culture (without OMVs), the same decrease was observed. In 
contrast, the OMVs of S. maltophilia have a stimulatory effect on biofilm formation in P. 
aeruginosa and B. cenocepacia.  
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Figure 15. Optical density (OD600) of S. maltophilia, P. aeruginosa and B. cenocepacia cultures exposed to different 
concentrations of imipenem, amoxicillin and ticarcillin, in the absence and presence of penicillin G induced OMVs. 
Error bars plot the standard deviation. 
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Figure 16. Crystal violet biofilm quantification analysis of S. maltophilia, P. aeruginosa and 
B. cenocepacia cultures grown without OMVs (control), together with penicillin G induced 
OMVs (OMV), and after pre-incubation of the growth chamber with penicillin G induced 
OMVs (block). Error bars plot the standard deviation. (Student’s t-test; n = 4; *, p < 0.05; **, 
p < 0.005; n.s., not significant). 
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4.4 Discussion 
 
Exposure of S. maltophilia cells to β-lactam antibiotics such as imipenem (Chapter 3; Devos et al., 
2015) and penicillin G (present study) leads to a significant increase in the biogenesis of OMVs, 
which are packed with β-lactamases. Since the S. maltophilia L1 and L2 β-lactamases are targeted 
to the periplasm, this raises the question whether their presence in OMVs is merely accidental 
considering their location, or if the β-lactamases are specifically targeted for OMV-associated 
secretion.  
 
We showed here by means of a nitrocefin assay that β-lactamase-packed OMVs (generated by 
stimulating cells with penicillin G) indeed exhibit β-lactamase activity. OMVs provide the enzymes 
shelter against proteases, keeping them stable and active for longer periods (Aldick et al., 2009). 
The extracellular β-lactamase activity associated with OMVs could hereby also affect other 
species, possibly co-habitants in a polymicrobial community. It was already shown that S. 
maltophilia often lives together with the species P. aeruginosa and B. cenocepacia, especially in 
lungs of cystic fibrosis patients where these are found in polymicrobial biofilm communities (Raidt 
et al., 2015). Here we show that the exposure of S. maltophilia to β-lactam antibiotics leads to 
the secretion of β-lactamase-packed OMVs, which are in turn capable of protecting not only other 
S. maltophilia cells, but also P. aeruginosa and B. cenocepacia, against β-lactam antibiotics. 
Although it is not clear whether S. maltophilia can be considered as a true CF pathogen (Hansen, 
2012), its ability to secrete OMVs upon antibiotic stress can influence the susceptibility of the 
pathogens to antibiotic treatment. 
 
For many organisms, OMVs represent a common constituent of biofilm, and studies have also 
shown a role in cell aggregation and biofilm initiation (Schooling and Beveridge, 2006). Here we 
observed a negative effect of penicillin G induced S. maltophilia OMVs on S. maltophilia biofilm 
formation. Most likely the OMVs attach to available surfaces and hereby prevent cell attachment 
and subsequent biofilm formation. This was confirmed by first incubating the growth chamber 
with OMVs, after which the chamber was washed and culture was added without OMVs. The 
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same negative effect is observed in the closely related plant pathogen Xylella fastidiosa. OMVs of 
X. fastidiosa block surfaces, hereby inhibiting biofilm formation, leading to an increased virulence 
through deeper plant colonization (Ionescu et al., 2014). 
 
On the other hand, S. maltophilia OMVs stimulated biofilm formation of P. aeruginosa and B. 
cenocepacia, regardless if OMVs were mixed with the culture or if the growth chamber was pre-
incubated with the OMVs. This suggests that S. maltophilia OMVs might accommodate cell-cell 
interactions and/or communication that promote cell attachment and aggregation. It was already 
proven that diffusible signal factors (DSF) produced by S. maltophilia can influence P. aeruginosa 
and B. cenocepacia behavior (Ryan and Dow, 2011; Twomey et al., 2012). Signaling molecules 
packed in OMVs could potentially be delivered to other cells through vesicle docking and uptake 
by these cells. Our work indicates that OMV biology is complex and that inter-species interactions 
should be considered when developing OMVs as an antimicrobial drug target. 
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Abstract 
 
Alike β-lactam antibiotics, the exposure of Stenotrophomonas maltophilia to the fluoroquinolone 
ciprofloxacin leads to stress-induced membrane vesicle secretion. Ciprofloxacin-induced vesicles 
differ considerable from previously characterized imipenem-induced outer membrane vesicles 
(OMV). Ciprofloxacin leads to the secretion of two distinct populations of vesicles: small OMVs 
morphologically similar to vesicles produced upon imipenem challenge, and larger vesicles 
containing both inner- and outer membrane (outer-inner membrane vesicles, OIMVs) with 
filamentous structures at the surface. The ciprofloxacin-induced vesicles have a strong toxic effect 
towards Pseudomonas aeruginosa, presumably caused by the phage tail bactericidal protein 
maltocin P28, carried by the vesicles. 
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5.1 Introduction 
 
The release of bacterial outer membrane vesicles (OMVs) is widely described as a cellular 
response to stress conditions, and is now recognized as a true secretion system (Schwechheimer 
and Kuehn, 2015). The spheroid membrane nanoparticles (20-300 nm) are formed through outer 
membrane budding, whilst encapsulating cell material, followed by pinching off into the 
environment (Mashburn-Warren et al., 2008; Bonnington and Kuehn, 2014). OMV secretion is 
conserved in Gram-negative bacteria, both pathogenic as non-pathogenic (Kuehn and Kesty, 
2005), and the vesicles have important biological functions related to virulence, biofilm formation 
and antibiotic resistance (Olsen and Amano, 2015; Chapter 4). 
 
Former studies on multidrug resistant Stenotrophomonas maltophilia demonstrated a significant 
increase in OMV secretion after exposure to β-lactam antibiotics (Devos et al., 2015). The two 
chromosomal encoded β-lactamases were proven to be an important constituent of such OMVs, 
and they are able to establish an extracellular OMV-mediated degradation of β-lactam antibiotics 
(Chapter 4). The effect of β-lactam antibiotics on bacterial cell vesiculation can be in part 
explained by their mechanism of action. The accumulation of peptidoglycan degradation products 
in the periplasmic space and the loss of peptidoglycan-outer membrane crosslinks are proposed 
as possible causes of OMV biogenesis (Haurat et al., 2014; Schwechheimer and Kuehn, 2015). 
However, how other stimuli are able to induce OMV biogenesis is still not clear. For example, high 
concentrations (1 mM) of the S. maltophilia diffusible signal factor cis-11-methyl-2-dodecenoic 
acid (DSF) also led to substantial OMV secretion, and to a lesser extent the Burkholderia 
cenocepacia cis-2-dodecenoic acid (BDSF) did too (Devos et al., 2015). In contrast, deletion of the 
rpfF gene in the related plant pathogen Xylella fastidiosa, coding for the DSF synthase rpfF, 
stimulated the OMV biogenesis process (Ionescu et al., 2014). This points to a possible important 
role of the DSF quorum sensing system in regulating OMV biogenesis.  
 
Considering that cell vesiculation is often a mechanism to cope with cell stress (Schwechheimer 
and Kuehn, 2015), also other types of antibiotics can lead to increased membrane vesicle 
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secretion.  In Pseudomonas aeruginosa, the fluoroquinolone ciprofloxacin induces OMV secretion 
which was proven to be linked to the SOS response provoked by DNA damage through DNA gyrase 
inhibition (Maredia et al., 2012). The ciprofloxacin-induced vesiculation was also observed in 
Acholeplasma laidlawii, where it was demonstrated that the vesicles mediate ciprofloxacin export 
(Medvedeva et al., 2014). These findings all suggest that bacterial vesiculation is a regulated 
process that is an important aspect of the antibiotic stress response and in antibiotic resistance.  
 
In the present work, we studied the effect of the fluoroquinolone ciprofloxacin on S. maltophilia 
membrane vesicle secretion. We compared the protein content of ciprofloxacin raised vesicles 
with OMVs resulting from β-lactam antibiotic cell wall stress, and analyzed the effect of these 
vesicles on the viability of species with which S. maltophilia co-inhabits the lungs of cystic fibrosis 
(CF) patients. Ciprofloxacin is often prescribed to patients with CF, especially for treating chronic 
respiratory infections with P. aeruginosa (Langton Hewer and Smyth, 2014). 
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5.2 Material and methods 
 
5.2.1 Materials 
 
ULC-MS grade water and acetonitrile (ACN) was procured from Biosolve (Valkenswaard, The 
Netherlands). Sequencing grade modified trypsin was obtained from Promega (Madison, WI, US). 
Acetic acid was purchased from VWR. All other chemicals and antibiotics were purchased from 
Sigma-Aldrich (St. Louis, MO, US). 
 
5.2.2 Bacterial cell culture 
 
The bacterial strains Stenotrophomonas maltophilia 44/98 (LMG 26824), Pseudomonas 
aeruginosa PAO1 (LMG 24986), and Burkholderia cenocepacia type strain (LMG 16656) were 
grown aerobically overnight in Luria Broth (LB) until the stationary phase. The cell suspensions 
were then diluted to an OD600nm of 0.2 in fresh medium, and allowed to grow further under the 
same conditions.  
 
5.2.3 Preparation of outer membrane vesicles 
 
S. maltophilia (50 ml cultures) were grown for 2 hours until the mid-exponential growth phase 
(OD600nm = 0.65-0.75), and then grown for an additional 3 hours in the presence of antibiotics (25 
µg/ml imipenem or 2 µg/ml ciprofloxacin). Cells were pelleted by centrifugation at 4,000 x g for 
15 min. The culture supernatant was filtered through a 0.2 µm V25 vacuum filter (Sarstedt, 
Numbrecht, GE), and the OMVs were pelleted by ultracentrifugation at 100,000 x g for 1 h (Avanti 
J-30I, Beckman Coulter, Fullerton, CA). One milliliter of the filtered culture supernatant was 
spread onto an LB agar plate and incubated at 37°C for 24 h to confirm the absence of intact, 
living cells. 
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5.2.4 OMV quantification with single particle tracking 
 
OMVs from 50 ml cultures were harvested as described above, and the pellet was dissolved in 
100 µl phosphate buffered saline (PBS). The OMV concentration and size was determined by light 
scattering based single particle tracking using a NanoSight LM10-HS instrument (NanoSight, 
Amesbury, UK; Dr. A. Hendrix, Laboratory of Experimental Cancer Research, Ghent University 
Hospital) equipped with a 405 nm laser. Prior to analysis, the purified OMVs were diluted in PBS-
buffer (Invitrogen). Movies of 60 seconds were recorded and analyzed with the NTA Analytical 
Software version 2.3. Each individual sample was diluted and measured 3 times. Calculations were 
performed according to Van der Pol et al. (2010). 
 
5.2.5 Transmission electron microscopy 
 
A 4 μL drop of isolated OMVs was placed on a Formvar/carbon-coated cupper grid, made 
hydrophilic by glow discharging for 30 s. The grid was then washed by placing it sequentially onto 
5 drops of milliQ water. After these washing steps, the grid was placed on 2 drops of 2% uranyl 
acetate and incubated for 30 to 40 s. The grid was blotted with filter paper between each washing 
step. The created specimens were examined using a JEM 1400 Plus transmission electron 
microscope (JEOL, Tokyo, Japan) operating at 80 kV equipped with a 11 MegaPixel Bottom-
Mounted Quemesa CCD camera (Olympus, Germany). 
 
For cryo-TEM, the OMVs were supplemented with 5% of 10 nm gold beads, placed on holey 
carbon grids (Quantifoil Micro Tools GMBH, Germany), quickly vitrified using a FEI Vitrobot IV (FEI 
Corp, Hillsboro), and imaged at liquid nitrogen temperatures in an FEI Titan Krios (FEI Corp, 
Hillsboro) operated at 300 kV acceleration voltage and equipped with a GIF and a post-GIF K2 DED 
detector (Gatan Inc, Pleasanton). Cryo-images were obtained using a magnifiction of 33kX and a 
defocus of 5µm. 
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5.2.6 OMV protein extraction and digestion 
 
OMV proteins were extracted by dissolving the OMV pellet in 1 ml 8 M urea in 50 mM Tris-HCl pH 
8. Proteins were precipitated with trichloroacetic acid (20%) and consequently the pellet was 
washed twice with ice-cold acetone, and finally dissolved in 2 M urea in 50 mM ammonium 
bicarbonate (pH 8). The protein concentration was assessed using the Coomassie Plus BradfordTM 
Assay kit (Thermo Scientific, San Jose, CA, US). Proteins were reduced with 10 mM dithiothreitol 
for 30 min at 60 °C, alkylated with 20 mM iodoacetamide at ambient temperature for 30 min, and 
then digested with trypsin (1:50 w/w) overnight at 37 °C.  
 
5.2.7 2D-LCMSE analysis 
 
Peptide mixtures (0.5 µg/µl in 100 mM ammonium formate, pH 10) were separated on a 
NanoAcquity UPLC® system (Waters Corporation, Milford, MA) in 2D mode. For the first 
dimension (high pH), solvent A1 and B1 were composed of 20 mM ammonium formate in water 
and ACN (pH 10), respectively. For the second dimension (low pH), solvent A2 and B2 were 
composed of 0.1% formic acid in water and 0.1% formic acid in ACN, respectively. The sample (0.5 
µg) was loaded onto an Xbridge® Peptide BEH C18 NanoEaseTM column (130 Å, 5 µm, 300 µm x 50 
mm; Waters) at 3% solvent B1 at 2 μL/min. Peptides were eluted from the first dimension column 
in 6 fractions (11.1%, 14.5%, 17.4%, 20.8%, 45% and 65.0% of solvent B1), and fractions were 
trapped on a Symmetry® C18 trapping column (5 µm, 180 µm x 20 mm; Waters). Each fraction 
was separated on a Acquity UPLC® M-Class HSS T3 column (1,8 µm, 75 µm x 250 mm; Waters) at 
40°C at 280 nL/min by increasing the acetonitrile concentration from 5-50% B2 over 60 min. 
 
The outlet of the column was directly connected to a PicoTip Emitter (uncoated SilicaTipTM 10 +/- 
1 μm, New Objective, Woburn, MA, US) mounted on a Nanolockspray source of a SYNAPTTM G1 
HDMS mass spectrometer (Waters). The time-of-flight (TOF) analyzer was externally calibrated 
with MS/MS fragments of human [glu1]-fibrinopeptide B (Glu-fib) from m/z 72 to 1285, and the 
data was corrected post-acquisition using the monoisotopic mass of the doubly charged precursor 
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of Glu-fib (m/z 785.8426) (lock mass correction). Accurate mass data were collected in a data 
independent positive mode of acquisition (MSE) by alternating between low (5 V) and high 
(ramping from 15 to 35 V) energy scan functions (Geromanos et al., 2009). The selected m/z range 
was 125 to 2000 Da. The capillary voltage was set to 3.0 kV, the sampling cone voltage was 26 V 
and the extraction cone voltage on 4 V. The source temperature was set on 80 °C. 
 
The LCMSE data were processed using the ProteinLynx Global SERVERTM v2.5 (PLGS, Waters 
Corporation). A database containing 4380 protein entries from the closely related 
Stenotrophomonas maltophilia K279a (downloaded from the Uniprot website, April 2014), 
together with a decoy database consisting of the randomized entries of all the proteins, was 
interrogated by PLGS. The precursor and fragment ion tolerance were determined automatically. 
The default protein identification criteria used included a maximal protein mass of 250,000 Da, a 
detection of minimal 5 fragment ions per peptide, minimal 10 fragment ions per protein and 
minimal 2 peptides per protein. Carbamidomethyl-C (fixed) and methionine oxidation (variable) 
were selected as modifications. Maximally one missed cleavages and a false positive rate of 4% 
was allowed. 
 
5.2.8 OMV toxicity assay 
 
Cultures from S. maltophilia, P. aeruginosa and B. cenocepacia were grown in a 96-well plate, 
with or without OMVs derived from imipenem or ciprofloxacin stimulated S. maltophilia cultures. 
Briefly, 100 µl LB (control) or 100 µl OMVs in LB (OMVs from 2.5 ml culture) were mixed with 5 µl 
of cells (from culture diluted to OD600nm 0.2). Cultures were grown at 37°C for 16 h, after which 
the OD600nm was measured with a 680XR micro plate reader (Bio-Rad, Hercules, CA). A total of 4 
replicate analysis were performed: 2 biological OMV replicates mixed with 2 biological culture 
replicates. 
 
To address the importance of the vesicles and vesicle associated proteins in toxicity, the assay 
was repeated on P. aeruginosa cultures, but after treatment with 1 mg/ml proteinase K, 2.5 % 
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Triton X-100, or both. The vesicles were incubated for 30 minutes at room temperature before 
mixing with the cells. 
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5.3 Results 
 
5.3.1 OMV quantification and size determination 
 
The previously reported increase in vesiculation in S. maltophilia is supposed to be a direct 
consequence of the cell wall damage inflicted by the β-lactam type antibiotics that were used (i.e. 
accumulation of peptidoglycan degradation products, loss of peptidoglycan crosslinking and/or 
peptidoglycan-outer membrane connections). We compared the effect of the β-lactam antibiotic 
imipenem and the fluoroquinolone antibiotic ciprofloxacin by quantifying and sizing the vesicles 
with light scattering based single particle tracking. As reported before, imipenem led to a 
substantial increase in vesiculation (Figure 17). However, while not supposed to have a direct 
effect on peptidoglycan stability, ciprofloxacin also led to a significant increase in vesicle 
secretion, which makes antibiotic stress a potential inducer of cell vesiculation, in a broader 
sense. Although the vesicle concentration is lower in ciprofloxacin-stimulated cultures, the 
average size of the vesicles is larger (imipenem: 140 nm, ciprofloxacin: 231 nm; Addendum A9) 
 
 
Figure 17. Quantification of membrane vesicles isolated from 
unstimulated, and imipenem and ciprofloxacin stimulated S. maltophilia 
cultures. Vesicles were quantified with light scattering based single 
particle tracking. Error bars plot the standard deviation. 
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Figure 18. Transmission electron microscopy visualization of isolated membrane vesicles from imipenem (A-B) and 
ciprofloxacin (C-D) stimulated S. maltophilia cultures. Filament structures on ciprofloxacin-induced vesicles (E; 
picture zoom of red box in D). Cryo-TEM image of ciprofloxacin-induced outer-inner membrane vesicle (F). 
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5.3.2 Vesicle morphology 
 
The vesicles isolated from imipenem- and ciprofloxacin-stimulated cultures were visualized with 
transmission electron microscopy (TEM) (Figure 18). Confirming data from the single particle 
tracking analysis, the ciprofloxacin-stimulated cultures produced overall less vesicles, but bigger 
vesicular structures were observed. Imipenem stimulation leads to vesicles with an estimated size 
of around 50 nm (Figure 18, A-B), while ciprofloxacin stimulation also leads to vesicles with an 
estimated size between 100-200 nm, next to the smaller vesicles as observed with imipenem 
(Figure 18, C-D) (the smaller size in TEM is potentially a consequence of vesicle shrinking during 
fixation). Moreover, these bigger vesicles often carry fiber-like structures at the surface (Figure 
18, E). Further analysis with cryo-TEM revealed the presence of both inner and outer membrane 
in most of the larger vesicles (Figure 18, F). Therefore, the large vesicles are actually outer-inner 
membrane vesicles (OIMV), a different type of secreted membrane vesicles (Perez-Cruz, 2015). 
 
5.3.3 Proteomic analysis of imipenem- and ciprofloxacin-induced OMVs 
 
OMVs from imipenem- and ciprofloxacin-stimulated cultures were isolated, and extracted 
proteins were digested and analyzed with 2D-LCMSE. Proteins were only further considered when 
identified in all three biological replicate samples. A total of 184 proteins were identified in the 
imipenem-induced OMV samples, and 170 proteins were identified in the ciprofloxacin-induced 
OMV samples (Addendum A10). Proteins were further annotated with Psortb v3.0 and UniProt 
(gene ontology). 
 
The protein profile from imipenem-induced OMVs is very much alike as previously obtained (more 
than 90% of the proteins were identified in the former proteomics experiment) (Devos et al., 
2015). However when comparing the protein profiles of both types of OMVs, the large amount of 
cytoplasmic proteins identified in the ciprofloxacin samples is striking: 36.5% of the proteins are 
predicted to be cytoplasmic as compared to 14.1% in the imipenem samples (Figure 19). 
Presumably this is due to the presence of OIMVs in ciprofloxacin-stimulated cultures. Roughly half 
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of these are actually ribosomal proteins. Interestingly, among the ciprofloxacin-specific 
cytoplasmic proteins are the Recombinase A protein (RecA) involved in DNA repair and inducing 
the SOS response to DNA damage, and the ciprofloxacin target itself, DNA gyrase. Several other 
cytoplasmic proteins are also involved in the cellular stress response, for example the lon 
protease protein, the universal stress protein, the general stress protein CTC, and the poly-
hydroxy-butyrate synthesis protein. Other (often cytoplasmic) proteins are involved in protein 
folding, for example the GroEL-GroES chaperonin complex, chaperone proteins DnaK (heat shock 
protein 70, HSP70) and HtpG (high temperature protein G), and several peptidyl-prolyl isomerases 
including the periplasmic SurA chaperone were found. However, this last group is found in both 
ciprofloxacin- and imipenem-induced membrane vesicles. In addition, several superoxide 
dismutases (SodA, SodC1, SodC2) and a subunit from the alkyl hydroperoxide reductase (AhpC) 
were identified in imipenem- and ciprofloxacin-induced vesicles, indicating oxidative stress in 
both conditions. 
 
 
Figure 19. Protein location distribution of identified proteins from 2D-LCMSE analysis of imipenem- (A) and 
ciprofloxacin- (B) induced membrane vesicles. Protein location was annotated with Psortb v3.0 and UniProt (GO). 
 
Interestingly, the ciprofloxacin samples contained more plasma membrane proteins, but less 
periplasmic and outer membrane proteins were identified. For example, several ATP synthase 
complex subunits (F-ATPase α-subunit, β-subunit, ε-subunit, γ-subunit, b-subunit), NADH-
quinone oxidoreductase complex subunits (subunits B, C and D), and the succinate 
Chapter 5: Characterization of ciprofloxacin-induced membrane vesicles 
111 
 
dehydrogenase flavoprotein subunit were found, all involved in electron transport and oxidative 
phosphorylation. The ciprofloxacin samples also contained several components of the pyruvate 
dehydrogenase complex and proteins part of the citric acid cycle (2-oxoglutarate dehydrogenase 
complex, succinate dehydrogenase and malate dehydrogenase). 
 
Finally, a cluster of phage-related proteins are exclusively present in ciprofloxacin-induced 
membrane vesicles: phage tail protein, major tail tube protein, major tail sheath protein, 
baseplate assembly protein, and phage-related protein. The identified major tail sheath protein 
was previously described in S. maltophilia strain P28 as maltocin, a phage tail-like bacteriocin (Liu 
et al., 2013).  
 
 
Figure 20.  Transmission electron microscopy image of ciprofloxacin-induced vesicle carrying the 
maltocin tailocins (A). Detached maltocin after Triton X-100 treatment (B), morphologically 
comparable to the tailocin structure (C; figure adapted from Ghequire and De Mot, 2015). 
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5.3.4 Bactericidal effect of ciprofloxacin-induced vesicles 
 
Maltocin is morphologically similar to the bacteriocin pyocin produced by P. aeruginosa. Maltocin 
and pyocin are phage-related bactericidal tailocins, multiprotein particles similar to phage tails 
(Ghequire et al., 2015). Microscopy (and proteomics) revealed the vesicle-mediated secretion by 
S. maltophilia of these phage tails after ciprofloxacin exposure (Figure 20, A). Vesicle-detached 
phage tails can be obtained by lysing the purified vesicles with Triton X-100 (2.5 %) (Figure 20, B). 
The observed structure corresponds well to the bacterial tailocins (Figure 20, C). Also, the 
tailocins showed strong resistance to protease treatment. There was no visible reduction in the 
amount of vesicle-associated tailocins after treating the vesicles with 1 mg/ml protease K (30 
minutes at room temperature; data not shown). 
 
The phage tail-like maltocin P28 has been shown to provide bactericidal activity against other 
strains of S. maltophilia then the P28 strain from which it was originally isolated (Liu et al., 2013). 
Therefore, we also addressed the bactericidal activity of the ciprofloxacin-induced membrane 
vesicles. Ciprofloxacin-induced vesicles, as well as imipenem-induced vesicles, were administered 
to cultures of S. maltophilia 44/98 itself, but also of P. aeruginosa PAO1 and B. cenocepacia type 
strain. Imipenem-induced vesicles did not lead to growth inhibition in any of the above cultures. 
Surprisingly, the ciprofloxacin-induced vesicles did had a very dramatic effect on the viability of 
P. aeruginosa PAO1 cultures, but not for the S. maltophilia and B. cenocepacia strains (Figure 21, 
A). P. aeruginosa PAO1 has a low MIC for ciprofloxacin (± 0.05 µg/µl; data not shown), so the toxic 
effect could be from residual ciprofloxacin in the membrane vesicle preparations. However, a 
negative control preparation with ciprofloxacin-medium did not lead to any growth inhibition 
towards P. aeruginosa PAO1 (data not shown).  
 
To verify whether the toxicity towards P. aeruginosa PAO1 is dependent on the membrane 
vesicles, or on other vesicle-associated proteins, the bactericidal activity assay was repeated after 
treatment of the ciprofloxacin-induced vesicles with proteinase K (1 mg/ml), with Triton X-100 
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(2.5 %), or both. Apparently, the toxicity endures regardless of the used treatments (Figure 21, 
B). 
 
 
Figure 21. Membrane vesicle toxicity assay. (A) Boxplot showing optical 
density (OD600) of S. maltophilia 44/98, P. aeruginosa PAO1 and B. 
cenocepacia type strain cultures exposed to imipenem- (IMI-OMV) and 
ciprofloxacin-induced (CIP-OMV) membrane vesicles. (B) Boxplot showing 
OD600 of P. aeruginosa PAO1 cultures exposed to CIP-OMV, treated with 
proteinase K (1 mg/ml), Triton X-100 (2.5 %), and both. 
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5.4 Discussion 
 
The release of membrane vesicles by Gram-negative bacteria is now recognized as a genuine 
secretion process, rather than a passive process, in response to different stimuli (Schwechheimer 
and Kuehn, 2015). In several studies it was shown that OMVs play important roles in β-lactam 
resistance (Ciofu et al., 2000; Schaar et al., 2011; Lee et al., 2013; Stentz et al., 2015). However, 
since vesiculation is often a strategy for cells to deal with stress, it should not be surprising that 
they are also involved in responses to other types of antibiotics. 
 
The number of studies on OMV secretion in response to non-β-lactam antibiotics is scarce. 
However, few studies report on vesiculation after ciprofloxacin exposure. In P. aeruginosa it was 
shown that membrane vesicles are secreted in response to ciprofloxacin, and that the process is 
intimately linked to the cell SOS response caused by the fluoroquinolone-induced DNA damage 
(Maredia et al., 2012). Here we confirmed that ciprofloxacin also leads to an increase in vesicle 
secretion in S. maltophilia as revealed by light-scattering based single particle tracking. Electron 
microscopy showed a notable presence of two different sub-populations of vesicles after 
ciprofloxacin stimulation. Next to the ‘classic’ OMVs, i.e. comparable to those observed after 
imipenem stimulation, also many bigger vesicles were observed. Moreover, these bigger vesicles 
were often decorated at the surface with fibrous structures.  
 
The ciprofloxacin-induced vesicles were subjected to a 2D-LCMS proteomics experiment, and the 
acquired protein profile was compared to that of imipenem-induced vesicles. Several proteins 
were identified that are involved in cell stress, oxidative stress and stress response to DNA 
damage (SOS), similar as reported in P. aeruginosa (Maredia et al., 2012). Also, the ciprofloxacin 
vesicles contained considerable more cytoplasmic proteins, and few more inner membrane 
proteins. Remarkably, many of those inner membrane proteins belong to protein complexes 
involved in primary metabolism, for example the citric acid cycle, electron transport chain and 
the ATP synthase complex for oxidative phosphorylation. This suggested that the larger vesicles 
in the samples are in fact outer inner membrane vesicles (OIMVs), recently reported as a different 
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type of bacterial membrane vesicle (Perez-Cruz et al., 2015). Indeed, cryo-TEM confirmed the 
presence of a double membrane layer in those bigger vesicles observed after ciprofloxacin 
stimulation. 
 
The ciprofloxacin-induced vesicles were shown to contain a cluster of phage-related proteins, of 
which the identified major tail sheath protein was previously described in S. maltophilia strain 
P28 as maltocin, a phage tail bacteriocin, or tailocin (Liu et al., 2013). Maltocin is morphologically 
comparable with R-type pyocin tailocins produced by P. aeruginosa (Ghequire et al., 2015). The 
tailocin structure consist of a rigid tube inside a contractile sheath, and lipopolysaccharide-
recognizing tail fibers attached to a base plate (Ghequire and De Mot, 2015). The tailocins are 
able to dock specific target strain cells and inject toxins. Their production was also shown to be 
associated with membrane vesicle formation (Toyofuku et al., 2014). Considering the bactericidal 
activity of maltocin, the ciprofloxacin-induced maltocin carrying vesicles were tested for toxicity 
towards S. maltophilia (strain 44/98), and the frequently cohabitating species P. aeruginosa 
(strain PAO1) and B. cenocepacia (type strain). Interestingly, the toxic effect of the vesicles is 
limited towards P. aeruginosa. It was previously demonstrated that imipenem-induced OMVs 
from S. maltophilia 44/98 are packed with β-lactamases and increased the β-lactam tolerance, 
and hereby the viability, of P. aeruginosa PAO1 during β-lactam stress (Chapter 4). In contrast, 
the exposure of S. maltophilia 44/98 to ciprofloxacin leads to the secretion of vesicles that are 
toxic for P. aeruginosa PAO1. Therefore the composition of membrane vesicles and their impact 
in bacterial communities is highly dependent on the circumstances that induces them.  
 
The specific toxic effect of the S. maltophilia ciprofloxacin-induced vesicles towards P. aeruginosa 
could have valuable applications in treating P. aeruginosa infections. However, the specificity 
should be further explored on other P. aeruginosa strains, and other species, and the role of the 
membrane vesicles as a carrier should be investigated. 
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Nowadays, antibiotic resistance is becoming an important risk for global health. The ‘wonder 
drug’ years are over, because misuse and overuse of antibiotic drugs have selected for organisms 
armed with a range of counter attack mechanisms, leaving certain treatments useless. 
Stenotrophomonas maltophilia is an environmental bacteria, that is loaded with a variety of 
resistance mechanisms against a whole range of antibiotics (β-lactams, (fluoro)quinolones, 
aminoglycosides, tetracyclines, sulfonamides), and is increasingly isolated from hospitalized 
patients and medical devices (Brooke, 2012). Its presence is associated with syndromes like 
pneumonia (especially in patients with cystic fibrosis), bacteremiae and soft tissue infections, 
leading to higher mortality rates among these patients. 
 
There is an ongoing debate about the true role of S. maltophilia in infection: should it be 
considered as a bona fide pathogen, or as a mere opportunistic colonizer (Hansen, 2012). 
Whether the first or last statement is correct (or both), its presence in infectious bacterial 
communities has an impact on infection start, progress and outcome. S. maltophilia is considered 
an important cystic fibrosis (CF) associated pathogen/colonizer, together with the classic CF 
pathogens Pseudomonas aeruginosa, Burkholderia cenocepacia and Staphylococcus aureus 
(Parkins and Floto, 2015). In such polymicrobial communities, inter- and intra-species 
communication is key for survival. A crucial communication system for S. maltophilia, and its co-
habitants P. aeruginosa and B. cenocepacia, is the diffusible signal factor (DSF) fatty acid quorum 
sensing (QS) system (Ryan and Dow, 2010). S. maltophilia produces cis-Δ2-11-methyl-dodecenoic 
acid (DSF), which can activate its RpfC-RpfG two-component system, eventually leading to c-di-
GMP degradation. The cellular pool of c-di-GMP is an important determinant for coordinated 
responses concerning motility, biofilm formation, and virulence. DSF produced by S. maltophilia 
can also be perceived by P. aeruginosa and B. cenocepacia, and therefore evoke intra-special 
responses. For example, DSF led to higher persistence and enhanced antibiotic resistance in P. 
aeruginosa airway biofilms (Twomey et al., 2012). Indeed, while in planktonic growth mode S. 
maltophilia encounters aggressive, competitive behavior of P. aeruginosa, in biofilm mode of 
growth S. maltophilia is capable of modulating the P. aeruginosa virulence profile leading to 
cooperative pathogenicity (Pompilio et al., 2015).  
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The phenomenon of outer membrane vesicle (OMV) secretion in bacteria has gained a lot of 
interest during the last years, because of the diverse biological functions that the vesicles 
perform. OMVs are known to be involved in pathogenesis, virulence, cell-cell communication, 
biofilm formation, and antibiotic resistance. For now, the OMV biogenesis process is not entirely 
understood, besides hypothetical models that include the involvement of the number of 
peptidoglycan (PG)-outer membrane (OM) crosslinks, the outer membrane lipopolysaccharide 
(LPS) and phospholipid fatty acid composition, and the accumulation of cell material in the 
periplasm (Schwechheimer and Kuehn, 2015). Furthermore, a link was established between the 
DSF system and the secretion of OMVs in the plant pathogen Xylella fastidiosa (Ionescu et al., 
2014), suggesting a possible regulatory role for the QS system. Here the DSF system inhibits the 
OMV biogenesis process, but stimulates local biofilm formation. A DSF synthase mutant strain 
produces more OMVs, which most likely block available surfaces for attachment, and eventually 
this leads to deeper colonization of the host plant. However, in the current work it was shown 
that S. maltophilia produces far more OMVs after stimulating cultures with synthetic DSF (chapter 
3, Devos et al., 2015). The stimulatory effect on OMV secretion was only observed at a DSF 
concentration of 1 mM, while lower concentrations had no effect. The effect of DSF on OMV 
secretion is therefore concentration-dependent, reflecting a QS-based mechanism. Moreover, 
the DSF compound produced by B. cenocepacia, cis-Δ2-dodecenoic acid (BDSF), also induced 
OMV biogenesis in S. maltophilia, albeit with lower activity compared to DSF (chapter 3, Devos et 
al., 2015). In B. cenocepacia, the BDSF binds to the RpfR receptor and activates its 
phosphodiesterase activity, leading to c-di-GMP breakdown (Deng et al., 2012). The S. maltophilia 
genome contains a homologous rpfR gene, which could explain this effect. 
 
S. maltophilia is particularly known for its intrinsic resistance to β-lactam antibiotics, a 
consequence of the presence of two chromosomal encoded β-lactamase genes, blaL1 and blaL2. 
These genes are immediately induced after β-lactam exposure. The exposure of S. maltophilia to 
the β-lactam antibiotics penicillin G and imipenem also leads to a strong increase in OMV 
secretion (chapter 3-4; Devos et al., 2015). The β-lactam-induced reduction in peptidoglycan 
crosslinks and accumulation of peptidoglycan degradation products is most likely the main cause 
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of this effect, considering the proposed OMV biogenesis models. Interestingly, a proteomic 
analysis of the OMV protein cargo revealed the presence of both the L1- and L2-β-lactamase. The 
packing of β-lactamases in OMVs was already described in P. aeruginosa, Moraxella catarrhalis, 
Staphylococcus aureus and Bacteroides spp.  (Ciofu et al., 2000; Schaar et al., 2011; Lee et al., 
2013; Stentz et al., 2015). Since the site of action of β-lactams is the periplasm, and the β-
lactamases are targeted towards the periplasm (Pradel et al., 2009; Brooke, 2012), it is not 
entirely surprising that they are picked up during the OMV biogenesis process. What is more 
intriguing is the secretion of biologically active β-lactamase enzymes into the environment. We 
showed that both S. maltophilia β-lactamases display activity while enclosed in the intact OMVs. 
The β-lactamase-packed OMVs were capable of hydrolyzing the β-lactam antibiotics imipenem, 
amoxicillin and ticarcillin, drugs that are frequently used to treat Gram-negative bacterial 
infections. When these β-lactamase-packed OMVs were administered to cultures of P. aeruginosa 
and B. cenocepacia, a drastic increase in antibiotic tolerance was observed for the β-lactams 
imipenem and ticarcillin. These species are far more susceptible to these drugs than S. 
maltophilia, but could tolerate a 100-fold (or more) increase in drug concentration in the presence 
of the S. maltophilia OMVs. However, we realize that it concerns in vitro experiments with purified 
OMVs, so no intact S. maltophilia cells were present. The situation in mixed bacterial cultures 
could be very different. For example, the presence of P. aeruginosa and/or B. cenocepacia in the 
vicinity of S. maltophilia could trigger the latter to secrete OMVs with a different cargo, perhaps 
toxic for other species. Nonetheless, the presence of β-lactamase-packed OMVs in infectious 
microbial communities could potentially influence treatment outcome, and even facilitate the 
selection of antibiotic resistance bacteria by lowering the antibiotic concentration to sub-lethal 
doses. 
 
Next to β-lactams, exposure of S. maltophilia to the fluoroquinolone ciprofloxacin also strongly 
induces OMV secretion. In P. aeruginosa it was shown that ciprofloxacin indeed induces OMV 
secretion (Maredia et al., 2012). The ciprofloxacin-induced OMV secretion was proven to be 
linked to the cellular SOS response that is evoked as a consequence of DNA damage. When 
compared to the β-lactam-induced vesicles, ciprofloxacin-induced vesicles show some interesting 
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differences (chapter 5). Transmission electron microscopy (TEM) revealed a population of vesicles 
that are considerable larger than the ‘classic’ OMVs as seen in β-lactam-induced S. maltophilia 
cultures. Furthermore, these larger vesicles often contain long filaments at their surface. Next to 
vesicle morphology, also the vesicle protein content was analyzed and compared to that of the 
imipenem-induced (classic) vesicles. What is striking is the enrichment of cytoplasmic and inner 
membrane proteins in the ciprofloxacin-induced vesicles. The cytoplasmic proteins are mainly 
represented by ribosomal proteins, but also by proteins involved in protein folding- and DNA 
damage- related stress. The toxic effect of ciprofloxacin leads to the accumulation of misfolded 
proteins, which triggers the production of chaperones and heat shock proteins (GroEL-GroES 
complex, DnaK, HtpG, SurA). DnaK and GroEL were already shown to be induced in response to 
antibiotic stress in Acinetobacter baumannii (Cardoso et al., 2010). Whether the GroEL protein 
complex in S. maltophilia is associated with the secreted membrane vesicles is not sure. The 
electron microscopy images show the abundant co-purification of protein complexes next to the 
vesicles, from which the shape resembles that of GroEL. Furthermore, the ciprofloxacin-induced 
vesicles contained more inner membrane proteins, with the striking presence of several ATP 
synthase complex subunits (α-, β-, ε-, γ- and b-subuit), almost entirely absent in the imipenem-
induced vesicles. This raised the question whether the inner membrane is part of the secreted 
vesicles, constituting so called outer-inner membrane vesicles (OIMV) recently described as a new 
type of bacterial membrane vesicles (Pérez-Cruz et al., 2015). This was confirmed with cryo-TEM, 
where it was shown that most of the larger ciprofloxacin-induced vesicles contained a double 
membrane layer. Unfortunately, the exact mechanism how ciprofloxacin induces vesicle secretion 
is not known. The accumulation of misfolded protein in the periplasm could be an explanation. 
However, in P. aeruginosa it was found that vesiculation was increased through the synthesis of 
B-band LPS induced by oxidative stress (Macdonald and Kuehn, 2013). B-band LPS contains longer 
and highly charged O antigen, capable of causing curvature in the outer membrane. Ciprofloxacin-
induced oxidative stress has been demonstrated in Escherichia coli, as well as in P. aeruginosa 
(Goswami et al., 2006; Jensen et al., 2014). The reactive oxygen species (ROS) superoxide (O2-) 
and hydrogen peroxide (H2O2) are believed to amplify the bactericidal effect of ciprofloxacin. The 
presence of several superoxide dismutases (sodA, sodC1, sodC2) and a subunit from the alkyl 
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hydroperoxide reductase (ahpC) in the membrane vesicles agrees with this premise. Though, 
since these proteins are also found in the imipenem-induced vesicles, this response is probably 
not specific for ciprofloxacin. 
 
An interesting finding in the ciprofloxacin vesicles is the identification of a group of phage related 
proteins that are not found in the imipenem-induced vesicles (chapter 5). The S. maltophilia 
genome contains a cluster of prophage genes, similar to that of the P2 phage. The major tail 
sheath protein that was identified was previously described in S. maltophilia strain P28 as the 
phage tail-like maltocin P28 (Liu et al., 2013). The phage tail major structural components, the tail 
sheath and tail tube proteins, compose a contractile and rigid phage tail filament, resembling the 
pyocin phage tail particles found in P. aeruginosa (Michel-Briand and Baysse, 2002). Maltocin P28 
is a bacteriocin showing bactericidal activity against many S. maltophilia strains. As mentioned 
before, the ciprofloxacin-induced vesicles carry filament structures at the surface, and this now 
raised the question if these could be phage tail filaments. Since these potential phage filaments 
are thus attached to the membrane vesicles, the purified intact vesicles were tested for 
bactericidal activity against S. maltophilia itself (strain 44/98), but also against the frequent 
cohabitating species P. aeruginosa (strain PAO1) and B. cenocepacia (type strain). Remarkably, 
the phage filament carrying vesicles only show a bactericidal effect towards P. aeruginosa PAO1. 
What aspect determines the species specificity is unclear, but worthwhile to find out. 
Furthermore, the vesicles do not lose their toxicity after treating the intact vesicles with 
proteinase K (up to 1 mg/ml), Triton X-100, or both. This means that the toxic entity is highly 
resistant to protease treatment, and independent from the intact vesicles as carriers.  
 
Other abundant cargo constituents identified in S. maltophilia membrane vesicles, are two Ax21 
homologs (chapter 3). Ax21 is an OMV associated outer membrane β-barrel protein proven to be 
involved in motility and biofilm formation (Park et al., 2014). Studies have shown that Ax21 
expression is regulated by the DSF QS system (Qian et al., 2013). The stimulation of S. maltophilia 
cultures with imipenem, and DSF and BDSF, all stimulated the OMV-mediated secretion of both 
Ax21 homologs. However, the results point to a stimuli-dependent difference in the proportion 
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of the homologs secreted in the vesicles. And, although BDSF induces far less vesicle secretion 
than DSF, the overall vesicular Ax21 content is more or less the same. Unfortunately, the exact 
function of the Ax21 protein remains unclear. Considering its structure resembles that of protein 
translocators for autotransporters (e.g. OmpF), it is likely to be involved in the translocation of 
virulence factors. Appropriate knockout mutants should be generated to identify potential Ax21 
mediated translocated proteins.  
 
Besides the Ax21 protein, OMVs on their own too seem to influence biofilm formation. However, 
studies report on both positive and negative effects of OMVs on biofilm formation (Yonezawa et 
al., 2009; Ho et al., 2015; Ionescu et al., 2014). β-lactam-induced OMVs from S. maltophilia 
demonstrated an inhibitory effect on its own biofilm formation, but stimulated biofilm formation 
in P. aeruginosa and B. cenocepacia cultures (chapter 4). When the cultures were grown in the 
growth chambers pre-incubated with OMVs, followed by washing the chambers, the same effect 
was observed. This means that the OMVs adhere to the growth chamber surfaces, and then either 
inhibit (by blocking) or stimulate (by interaction) cell attachment and subsequent biofilm 
formation. The molecular mechanism behind this phenomenon is still to be elucidated. 
Investigating how the OMVs establish intra- and inter-species interactions would be helpful in 
understanding the roles of OMVs in polymicrobial communities, under different circumstances. 
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Allthough there are several models describing the process of OMV biogenesis, the knowledge is 
still incoherent and incomplete (Schwechheimer and Kuehn, 2015). How do cells perceive a 
certain signal and then respond by secreting membrane vesicles? As it is often the case in system 
biology, OMV biogenesis is probably complex and dependent on several factors. This work 
showed significant differences in the Stenotrophomonas maltophilia OMV secretion process 
when comparing the β-lactam imipenem and the fluoroquinolone ciprofloxacin as stimulatory 
agents. While the increased OMV secretion during β-lactam stress fits the proposed models quite 
well (accumulation of peptidoglycan degradation products, reduced number of cell wall 
crosslinks), the link between ciprofloxacin-induced stress and vesicle secretion is not completely 
understood. Oxidative stress and the SOS response have been proposed as potential inducers, 
but this needs further investigation (Maredia et al., 2012). Also it was observed that ciprofloxacin 
leads to the secretion of two different types of vesicles, OMVs and outer-inner membrane vesicles 
(OIMVs), pointing to parallel vesiculation processes. Moreover, the diffusible signal factor (DSF) 
system influenced OMV secretion as well. The S. maltophilia DSF molecule cis-Δ2-11-methyl-
dodecenoic acid and the Burkholderia cenocepacia DSF molecule cis-Δ2-dodecenoic acid both had 
a stimulatory effect on OMV secretion in S. maltophilia. In contrast, in the closely related plant 
pathogen Xylella fastidiosa the DSF system showed inhibitory effects on OMV secretion. How this 
DSF quorum sensing system is involved in OMV biogenesis is still to be determined. A time-kinetic, 
multi-level system biology analysis approach (transcriptomics, proteomics, lipidomics, 
metabolomics) during the OMV production will determine potential important players and 
regulatory mechanisms in the OMV biogenesis process.  
 
The current work characterized OMVs in vitro, with pure cultures under controlled conditions. S. 
maltophilia is often part of polymicrobial communities causing chronic pulmonary infections in 
patient with cystic fibrosis (CF). Therefore it would be interesting to analyze OMVs in mixed-
species cultures in artificial sputum medium (ASM) mimicking CF sputum, or actual sputum, 
whether or not exposed to antibiotics. This will broaden the knowledge about the beneficial 
and/or harmfull roles of OMVs in polymicrobial communities, depending on different antibiotic 
treatments. Stand-alone OMV functions like extracellular degradation of antibiotics by enzyme 
Chapter 7: Future perspectives 
136 
 
cargo is evident, but the delivery of the vesicle content to other cells (intra- or inter-species) is 
less straightforward. This would imply the docking of vesicles on target cells, fusing with the outer 
membrane, and the delivery of the functional cargo into the cell. However, the ability of S. 
maltophilia OMVs to deliver functional resistance proteins or genes to other cells still needs to be 
proven. 
 
The ability of S. maltophilia to grow as a biofilm is an important trait contributing to the survival 
of the species. OMVs are believed to play an important role in the biofilm formation process. This 
work showed that β-lactam-induced S. maltophilia OMVs have an inhibitory effect on its 
transition to biofilm mode of growth, presumably through the blocking of available surface areas. 
Meanwhile these same OMVs stimulated biofilm formation in Pseudomonas aeruginosa and B. 
cenocepacia cultures. The molecular mechanisms behind this phenomenon are unknown, and an 
interesting topic for future research. Also related to biofilm formation, two Ax21 homologues 
were identified in S. maltophilia, showing abundant OMV-associated secretion after antibiotic 
treatment. Ax21 was shown to be important for virulence and biofilm formation in S. maltophilia 
and closely related species, but its actual function is still not clear. The outer membrane protein 
is structurally homologues to the transporter domains of autotransporters, and could therefore 
be involved in the translocation of virulence factors. Secretome analysis of wild type versus Ax21 
knock-out strains could potentially clarify the Ax21 function.  
 
Finally, ciprofloxacin-induced membrane vesicles appeared to be highly toxic for the P. 
aeruginosa strain PAO1. The cell stress evoked by ciprofloxacin led to the expression of a cluster 
of phage-related genes, and the subsequent OMV-associated secretion of phage tail bacteriocins 
(tailocins). In this work, the bactericidal effect of these vesicles was specific towards P. aeruginosa 
(strain PAO1), and not towards S. maltophilia 44/98 itself or the B. cenocepacia type strain. The 
spectrum of activity should be further explored on a range of other P. aeruginosa strains, and 
other species. The bactericidal effect of the S. maltophilia tailocins can potentially be exploited 
for treating P. aeruginosa infections. In S. maltophilia these tailocins are attached to the surface 
of membrane vesicles, but the reason for this is unclear. The use of vesicles as carriers may have 
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different advantages: more efficient delivery of toxins to the target cells, long distance transport, 
or improved penetration in biofilms. Membrane vesicles, or artificial liposomes, show great 
potential in the delivery of antimicrobials to biofilms (Forier et al., 2014), and are already used in 
vaccine development (Acevedo et al., 2014). For example, membrane vesicle-based vaccines exist 
for meningitis, cholera, pertussis and tuberculosis. The exact mechanism of action of the S. 
maltophilia tailocin, the molecular basis of specificity and the role of membrane vesicles as 
carriers should be clarified if it would be considered as a potential antibacterial drug. 
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A1. Material and methods for the time-kinetic, quantitative proteome study 
 
Materials 
 
Urea was obtained from GE Healthcare (Diegem, Belgium). ‘Complete mini’ EDTA-free protease inhibitor mix was 
purchased from Roche Diagnostics (Vilvoorde, Belgium). Rapigest detergent and the rabbit glycogen phosphorylase 
B standard peptide mixture were from Waters Corporation (Milford, MA, US). Sequencing grade modified trypsin 
was obtained from Promega (Madison, WI, US), while mass spectrometry grade lysyl endopeptidase was from Wako 
Chemicals (GmbH, Neuss, Germany). ULC-MS grade water, acetonitrile (ACN) and formic acid was procured from 
Biosolve (Valkenswaard, The Netherlands). Imipenem was kindly donated by Prof. M. Galleni (CIP, University of Liège, 
Belgium). Other chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO, US). 
 
Bacterial cell culture 
 
The imipenem-resistant S. maltophilia strain 44/98 (BCCM/LMG bacteria collection, LMG 26824) was isolated at the 
Clinical Microbiology Unit of the Varese University hospital in Italy. Cells were grown aerobically overnight as two 
separate cultures until the stationary phase. The cell suspensions were then separately diluted 10-fold in 300 mL of 
fresh Luria Broth (LB) medium, and allowed to grow further until they reached the mid-exponential growth phase 
(OD600nm = 0.65-0.75). From these two culture flasks, samples were harvested by centrifugation at 2,500 x g for 5 min 
(Time 0). The remaining cultures were stimulated with 25 μg/mL imipenem. Samples were also harvested 30 minutes, 
1 h, 2 h and finally 3 h after the imipenem challenge (Time 0.5, 1, 2 and 3 respectively, each in duplicate). 
 
Sample preparation for LCMSE 
 
The pellets were resuspended in a solution containing 6 M urea, 2 M thiourea, 0.2% Rapigest, and an EDTA-free 
protease inhibitor mixture in 50 mM ammonium bicarbonate. The cells were disrupted with acid-washed glass beads 
(diameter of 1-1.25 mm) for 180 s in a Precellys 24 instrument (Bertin Technologies, Orléans, France). The protein 
solutions were cleaned-up and concentrated by acetone precipitation, followed by resuspension and rinsing on a 10 
kDa cut-off spin column (Ultracel Amicon, Millipore, MA, US) with 0.2% Rapigest, 1 mM DTT and 50 mM ammonium 
bicarbonate as the buffer. The protein concentration was assessed using the Coomassie Plus BradfordTM Assay kit 
(Thermo Scientific, San Jose, CA, US). Ten μg of each protein extract was heated at 80 °C for 15 min, reduced with 2.5 
mM DTT for 45 min at 60 °C and subsequently alkylated with 7.5 mM iodoacetamide at ambient temperature for 30 
min. The proteins were first digested with 1:50 (w/w) lysyl endopeptidase for 3 h at ambient temperature, followed 
by trypsin digestion (1:50 w/w) overnight at 37 °C. The Rapigest detergent was hydrolyzed by the addition of formic 
acid to the solution, and removed by centrifugation. Each sample was diluted with a glycogen phosphorylase B 
Addendum 
142 
 
standard peptide mixture and 0.1% formic acid in water to give a final protein concentration of 0.5 μg/μl per sample 
and 50 fmol/μl phosphorylase B. 
 
LCMSE analysis 
 
The peptide mixtures were separated on a NanoAcquity UPLC® system (Waters Corporation) using a Symmetry® C18 
trapping column (180 μm x 20 mm, 5 μm) and a BEHTM C18 analytical column (75 μm x 250 mm, 1.7 μm) at 40 °C. 
Solvent A and B were composed of 0.1% formic acid in water and 0.1% formic acid in ACN, respectively. Each sample 
(0.5 μg of total protein and 50 fmol of phosphorylase B) was loaded onto the trapping column with 0.1% solvent B 
for 1 min at 15 μL/min and eluted at 250 nL/min by increasing the organic solvent concentration from 3-40% B over 
90 min. Analyses were performed in quadruplicate. The eluting peptides were directly ionized and analyzed with a 
SYNAPTTM HDMS using a PicoTip Emitter from New Objective (uncoated silicaTipTM 10 +/- 1 μm, Woburn, MA, US). 
The time-of-flight (TOF) analyzer was externally calibrated with MS/MS fragments of human [glu1]-fibrinopeptide B 
(GFP) from m/z 72 to 1285, and the data was corrected post-acquisition using the monoisotopic mass of the doubly 
charged precursor of GFP (m/z 785.8426), which was measured with a collision energy of 6.0 V and sampling cone 
voltage of 45 V (lockmass correction). The GFP was delivered at 500 fmol/μL to the mass analyzer by a NanoLockSpray 
interface using the auxiliary pump of the NanoAcquity system at a flow rate of 300 nL/min. The reference sprayer 
was sampled every 30 s. Accurate mass data were collected in a data independent positive mode of acquisition (MSE) 
from 15 to 120 minutes by alternating between low (5 V) and high (ramping from 15 to 35 V) energy scan functions. 
The spectral acquisition scan rate was 0.48 s with a 0.1 s inter-scan delay. The selected m/z range was 125 to 2000 
Da. The capillary voltage was set to 3.0 kV, the sampling cone voltage was 26 V and the extraction cone voltage on 
2.65 V. The source temperature was set on 65 °C. 
 
Identification of proteins 
 
The LCMSE data were processed using the ProteinLynx Global SERVERTM v2.5 (PLGS, Waters Corporation). In brief, 
lockmass-corrected spectra (0.250 Da window allowed) were automatically centroided, deisotoped and charge-state 
reduced to produce a single monoisotopic peak for each peptide and associated fragment ion. The correlation of a 
precursor and a potential fragment ion was achieved by means of time alignment, in the first instance. The following 
parameters were used for the data processing in PLGS: the chromatographic peak width, the TOF resolution and 
retention time window, which were determined automatically by the software, and the low energy, high energy, and 
intensity thresholds, which were set to 250, 100 and 1500 counts respectively. A database containing 4369 protein 
entries from the closely related Stenotrophomonas maltophilia K279a (Uniprot website, June 2011), phosphorylase 
B (spiked into each sample) and potential contaminating proteins, as well as the randomized entries of all the proteins 
was interrogated by PLGS. The precursor and fragment ion tolerance were determined automatically. The default 
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protein identification criteria used included a maximal protein mass of 500,000 Da, a detection of minimal 3 fragment 
ions per peptide, minimal 7 fragment ions per protein and minimal 1 peptide per protein. Fixed modification of 
carbamidomethyl-C and the variable modifications included acetylation (N-terminus), deamidation (N/Q) and 
oxidation of the methionines were selected. Maximally two missed cleavages and a false positive rate of 4% was 
allowed. The quality of the LCMSE runs was examined with MassLynx v 4.1 (Waters Corporation), IBM® SPSS Statistics 
v 19, and Excel. 
 
Label-free quantitative analysis with ExpressionE from PLGS 
 
A relative quantification analysis of the protein abundances at the different time points, before and after the 
antibiotic challenge, was performed using the ExpressionE software integrated in PLGS v.2.5. The algorithm uses the 
weighted sum of the peak intensities of all peptides for the relative quantification of the proteins. The contribution 
of a peptide intensity in the protein quantification is based on the uniformity of the intensities of this peptide in the 
technical replicates, as well as the peptide identification score. Protein ratios were normalized to the intensity of the 
dominant background of proteins showing no change in abundance between the different time collections. The 
proteins had to be identified in at least 2 technical replicates, with a score of 150 and a probability of 95%, as well as 
a confidence limit of maximally 2.5. The significance level of regulation was set at 30% fold change, corresponding to 
an average relative fold change of -0.3 and 0.3 on a natural log scale. This is 2-3 times higher than the estimated error 
on the intensity measurement. The results were exported to Excel and IBM® SPSS Statistics v 19 for further analysis. 
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A2. OMV proteomics on imipenem-induced OMVs 
 
Protein identification list of the 2D-LCMS OMV proteome analysis (identified in minimum 2/3 replicate runs) 
 
Entry Protein names Gene names 
B2FIV0 10 kDa chaperonin (GroES protein) (Protein Cpn10) groS groES Smlt4215 
B2FNP5 30S ribosomal protein S1 rpsA Smlt2043 
B2FN87 30S ribosomal protein S15 rpsO Smlt3386 
B2FIA9 30S ribosomal protein S2 rpsB Smlt1507 
B2FQ51 30S ribosomal protein S3 rpsC Smlt0912 
B2FJU4 50S ribosomal protein L13 rplM Smlt4302 
B2FQ52 50S ribosomal protein L16 rplP Smlt0913 
B2FQK9 50S ribosomal protein L17 rplQ Smlt0933 
B2FQ48 50S ribosomal protein L2 rplB Smlt0909 
B2FN76 50S ribosomal protein L20 rplT Smlt3375 
B2FTD1 50S ribosomal protein L21 rplU Smlt1278 
B2FQ20 50S ribosomal protein L25 (General stress protein CTC) rplY ctc Smlt0876 
B2FQJ6 50S ribosomal protein L5 rplE Smlt0918 
B2FQ37 50S ribosomal protein L7/L12 rplL Smlt0897 
B2FKJ7 50S ribosomal protein L9 rplI Smlt3148 
B2FIU9 60 kDa chaperonin (GroEL protein) (Protein Cpn60) groL groEL Smlt4214 
B2FT48 Adenylate kinase (AK) (EC 2.7.4.3) (ATP-AMP transphosphorylase) (ATP:AMP 
phosphotransferase) (Adenylate monophosphate kinase) 
adk Smlt3886 
B2FKK2 Asparagine--tRNA ligase (EC 6.1.1.22) (Asparaginyl-tRNA synthetase) asnS Smlt3154 
B2FHZ0 ATP synthase subunit alpha (EC 3.6.3.14) (ATP synthase F1 sector subunit alpha) (F-
ATPase subunit alpha) 
atpA Smlt4113 
B2FHY8 ATP synthase subunit beta (EC 3.6.3.14) (ATP synthase F1 sector subunit beta) (F-
ATPase subunit beta) 
atpD Smlt4111 
B2FUV6 ATP-dependent protease ATPase subunit HslU (Unfoldase HslU) hslU Smlt4075 
B2FJU0 Bacterioferritin (EC 1.16.3.1) bfr Smlt4297 
B2FNP1 Cell division protein ftsA ftsA Smlt0759 
B2FTA6 Cell division topological specificity factor minE Smlt1250 
B2FMY5 Chaperone protein DnaK (HSP70) (Heat shock 70 kDa protein) (Heat shock protein 
70) 
dnaK Smlt1992 
B2FLW2 Chaperone protein HtpG (Heat shock protein HtpG) (High temperature protein G) htpG Smlt1809 
B2FPG7 Chaperone SurA (Peptidyl-prolyl cis-trans isomerase SurA) (Rotamase SurA) surA Smlt0820 
B2FSI7 Citrate synthase gltA Smlt3835 
B2FI05 Conserved hypothetical exported protein Smlt4128 
B2FJC6 Conserved hypothetical exported protein Smlt1634 
B2FKV7 Conserved hypothetical exported protein Smlt0483 
B2FL62 Conserved hypothetical exported protein Smlt1774 
B2FLW5 Conserved hypothetical exported protein Smlt1812 
B2FMI3 Conserved hypothetical exported protein Smlt4500 
B2FN54 Conserved hypothetical exported protein Smlt3351 
B2FNH0 Conserved hypothetical exported protein Smlt4628 
B2FP55 Conserved hypothetical exported protein Smlt4642 
B2FQN8 Conserved hypothetical exported protein Smlt0965 
B2FQX4 Conserved hypothetical exported protein Smlt2334 
B2FQY5 Conserved hypothetical exported protein Smlt2345 
B2FR42 Conserved hypothetical exported protein Smlt3680 
B2FR48 Conserved hypothetical exported protein Smlt3686 
B2FRX3 Conserved hypothetical exported protein Smlt1121 
B2FRX4 Conserved hypothetical exported protein Smlt1122 
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B2FRX9 Conserved hypothetical exported protein Smlt1127 
B2FRZ2 Conserved hypothetical exported protein Smlt1140 
B2FSE9 Conserved hypothetical exported protein Smlt3796 
B2FTB2 Conserved hypothetical exported protein Smlt1256 
B2FN59 Conserved hypothetical repetitive protein Smlt3358 
B2FT86 Conserved hypothetical TPR repeat family protein Smlt0008 
B2FLD3 Dihydrolipoyl dehydrogenase (EC 1.8.1.4) odhL Smlt3199 
B2FQK8 DNA-directed RNA polymerase subunit alpha (RNAP subunit alpha) (EC 2.7.7.6) (RNA 
polymerase subunit alpha) (Transcriptase subunit alpha) 
rpoA Smlt0931 
B2FQ39 DNA-directed RNA polymerase subunit beta' (RNAP subunit beta') (EC 2.7.7.6) (RNA 
polymerase subunit beta') (Transcriptase subunit beta') 
rpoC Smlt0899 
B2FQ38 DNA-directed RNA polymerase subunit beta (RNAP subunit beta) (EC 2.7.7.6) (RNA 
polymerase subunit beta) (Transcriptase subunit beta) 
rpoB Smlt0898 
B2FQ42 Elongation factor G (EF-G) fusA Smlt0903 
B2FIA8 Elongation factor Ts (EF-Ts) tsf Smlt1506 
B2FQ31 Elongation factor Tu (EF-Tu) tufB tuf Smlt0890 Smlt0904 
B2FK88 Enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (2-phosphoglycerate 
dehydratase) 
eno Smlt1715 
B2FU50 Glucans biosynthesis protein D opgD Smlt0091 
B2FQR4 Lon protease (EC 3.4.21.53) (ATP-dependent protease La) lon Smlt0991 
B2FPG8 LPS-assembly protein LptD (Organic solvent tolerance protein) lptD ostA Smlt0821 
B2FQL8 Malate dehydrogenase (EC 1.1.1.37) mdh Smlt0944 
B2FNQ5 Nucleoside diphosphate kinase (NDK) (NDP kinase) (EC 2.7.4.6) (Nucleoside-2-P 
kinase) 
ndk Smlt2054 
B2FIA0 Outer membrane protein assembly factor BamA bamA Smlt1498 
B2FNR0 Outer membrane protein assembly factor BamB bamB Smlt2059 
B2FRR9 Outer membrane protein assembly factor BamD comL bamD Smlt3748 
B2FMX8 Outer membrane protein assembly factor BamE bamE Smlt1985 
B2FQY6 Outer-membrane lipoprotein carrier protein Smlt2346 
B2FQ17 Outer-membrane lipoprotein LolB lolB Smlt0873 
B2FLB8 Peptidyl-prolyl cis-trans isomerase Smlt3182 
B2FIF8 Peptidyl-prolyl cis-trans isomerase (EC 5.2.1.8) Smlt1559 
B2FN86 Polyribonucleotide nucleotidyltransferase (EC 2.7.7.8) (Polynucleotide 
phosphorylase) (PNPase) 
pnp Smlt3385 
B2FSQ8 Probable malate:quinone oxidoreductase (EC 1.1.5.4) (MQO) (Malate dehydrogenase 
[quinone]) 
mqo Smlt1234 
B2FMY4 Protein GrpE (HSP-70 cofactor) grpE Smlt1991 
B2FRM9 Protein TolB tolB Smlt3704 
B2FPB2 Protein translocase subunit SecA secA Smlt0764 
B2FHD7 Protein-export protein SecB secB Smlt0171 
B2FKN2 Putative 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27) Smlt4330 
B2FP85 Putative ABC transporter toluene tolerance exported protein Smlt4673 
B2FT31 Putative ACR family protein Smlt3869 
B2FP33 Putative alkaline phosphatase Smlt3463 
B2FPY7 Putative alkyl hydroperoxide reductase subunit c (EC 1.11.1.15) ahpC Smlt0841 
B2FJX9 Putative aminopeptidase Smlt0418 
B2FL11 Putative aminopeptidase Smlt0541 
B2FQE3 Putative angiotensin-converting enzyme like peptidyl dipeptidase protein Smlt3574 
B2FR62 Putative autotransporter Smlt1001 
B2FPV5 Putative autotransporter subtilisin-like protease sphB Smlt3524 
B2FRP5 Putative beta-lactamase Smlt3722 
B2FT88 Putative biopolymer transport exbB protein exbB1 Smlt0010 
B2FT89 Putative biopolymer transport ExbD1 protein exbD1 Smlt0011 
B2FPM6 Putative calcineurin phosphoesterase Smlt2170 
B2FJY2 Putative carboxy-terminal processing protease (EC 3.4.21.102) ctpA Smlt0421 
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B2FK12 Putative dehydrogenase Smlt0451 
B2FUE8 Putative diaminobutyrate--2-oxoglutarate aminotransferase (EC 2.6.1.76) dat Smlt1415 
B2FSF8 Putative endonuclease P1 (EC 3.1.30.1) Smlt3806 
B2FP18 Putative endopeptidase O (EC 3.4.24.-) pepO Smlt3447 
B2FMI6 Putative exported dipeptidyl peptidase IV Smlt4503 
B2FP20 Putative exported endopeptidase Smlt3450 
B2FI03 Putative exported lipoprotein Smlt4126 
B2FTA3 Putative exported peptidase (EC 3.4.14.-) Smlt1246 
B2FUT3 Putative exported rare lipoprotein A rlpA Smlt4051 
B2FUS7 Putative exported tail-specific protease (EC 3.4.21.102) Smlt4045 
B2FJY4 Putative fatty acid transport system, membrane protein Smlt0423 
B2FR50 Putative ferritin DPS-family DNA binding protein Smlt3688 
B2FNJ3 Putative fimbria adhesin protein Smlt0709 
B2FNJ0 Putative fimbrial adhesin protein smf-1 Smlt0706 
B2FNQ7 Putative fimbrial biogenesis protein Smlt2056 
B2FIR8 Putative fimbrial protein (Pilin) Smlt4182 
B2FQU5 Putative flagellin fliC Smlt2304 
B2FQU6 Putative flagellin flaA Smlt2305 
B2FST5 Putative glucan 1,4-beta-glucosidase Smlt2569 
B2FP87 Putative intercellular spreading VacJ lipoprotein Smlt4675 
B2FRZ9 Putative iron transport receptor protein Smlt1148 
B2FHT9 Putative iron transporter Smlt2858 
B2FJR8 Putative isocitrate dehydrogenase [NADP] (EC 1.1.1.42) icd Smlt4273 
B2FQQ5 Putative isocitrate/isopropylmalate dehydrogenase Smlt0982 
B2FP30 Putative lipoprotein Smlt3460 
B2FUS6 Putative lipoprotein Smlt4044 
B2FU57 Putative lipoprotein E (Outer membrane protein p4) hel Smlt0098 
B2FNM5 Putative LppC family lipoprotein Smlt0742 
B2FP06 Putative membrane-bound lytic murein transglycosylase d (EC 3.2.1.-) mltD Smlt3434 
B2FTM1 Putative metallo-beta-lactamase l1 (Beta-lactamase type ii) (Ec 3.5.2.6) (Penicillinase) 
(EC 3.5.2.6) 
Smlt2667 
B2FRQ3 Putative MltA scaffolding protein Smlt3731 
B2FH96 Putative modulator of DNA gyrase Smlt0129 
B2FQU7 Putative motility flagellin protein Smlt2306 
B2FUT4 Putative murein hydrolase (EC 3.2.1.-) mltB Smlt4052 
B2FHC0 Putative N-acetylmuramoyl-L-alanine amidase Smlt0154 
B2FJB1 Putative oar family adhesion protein Smlt1619 
B2FRW6 Putative OstA family protein Smlt1114 
B2FLE9 Putative outer membrane antigen lipoprotein Smlt3215 
B2FLE4 Putative outer membrane antigen protein Smlt3210 
B2FLY6 Putative outer membrane efflux protein smeX Smlt1833 
B2FSC8 Putative outer membrane esterase Smlt3773 
B2FLX9 Putative outer membrane lipoprotein Smlt1826 
B2FPV8 Putative outer membrane lipoprotein Smlt3527 
B2FR78 Putative outer membrane lipoprotein Smlt1018 
B2FI00 Putative outer membrane Omp family protein Smlt4123 
B2FSF7 Putative outer membrane Omp family protein Smlt3805 
B2FLU3 Putative outer membrane protein Smlt0613 
B2FLU4 Putative outer membrane protein Smlt0614 
B2FQM8 Putative outer membrane protein Smlt0955 
B2FTS5 Putative outer membrane protein tolC Smlt3928 
B2FSS7 Putative outer membrane regulator of pathogenicity factors protein rpfN Smlt2559 
B2FNJ2 Putative outer membrane usher protein mrkc mrkC Smlt0708 
B2FU40 Putative patatin-like phospholipase Smlt0080 
B2FUT2 Putative penicillin-binding protein (EC 3.4.16.4) dacC Smlt4050 
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B2FR43 Putative penicillin-binding protein 1B (EC 2.4.1.129) mrcB Smlt3681 
B2FHG8 Putative peptidase Smlt0203 
B2FJ20 Putative peptidase Smlt0348 
B2FT85 Putative peptidase Smlt0007 
B2FUU5 Putative PEPTIDASE Smlt4064 
B2FRM8 Putative peptidoglycan-associated lipoprotein Smlt3703 
B2FLG2 Putative peptidyl dipeptidase/oligopeptidase Smlt3229 
B2FI43 Putative peptidyl-dipeptidase Dcp (Dipeptidyl carboxypeptidase) (EC 3.4.15.5) dcp Smlt0223 
B2FR55 Putative peptidyl-prolyl cis-trans isomerase Smlt0993 
B2FU43 Putative phosphatase Smlt0084 
B2FTU3 Putative phosphate selective porin Smlt3950 
B2FHJ5 Putative phosphodiesterase-nucleotide pyrophosphatase Smlt1449 
B2FNJ1 Putative pili chaperone protein Smlt0707 
B2FTT7 Putative porin P (Outer membrane protein d1) oprP Smlt3943 
B2FJ52 Putative protease Smlt0381 
B2FUA1 Putative quinol oxidase subunit 1 qoxB Smlt1361 
B2FPR6 Putative rare lipoprotein B family protein Smlt3484 
B2FUU0 Putative rod shape-determining protein mreB Smlt4059 
B2FPY1 Putative signal peptidase I (EC 3.4.21.89) lepB Smlt3551 
B2FK97 Putative subfamily M23B unassigned peptidase Smlt1724 
B2FQC5 Putative subfamily S1C unassigned peptidase Smlt3553 
B2FTY8 Putative thiol:disulfide interchange protein Smlt3994 
B2FQ11 Putative thioredoxin electron transport related protein Smlt0866 
B2FRN0 Putative TolA transmembrane protein tolA Smlt3705 
B2FRN2 Putative TolQ transport transmembrane protein tolQ Smlt3707 
B2FRN1 Putative TolR-related protein tolR Smlt3706 
B2FN47 Putative TonB dependent receptor Smlt3340 
B2FP16 Putative TonB dependent receptor Smlt3444 
B2FR08 Putative TonB dependent receptor Smlt3645 
B2FRR1 Putative TonB dependent receptor Smlt3740 
B2FST2 Putative TonB dependent receptor Smlt2566 
B2FT66 Putative TonB dependent receptor Smlt3905 
B2FJ30 Putative TonB dependent receptor protein Smlt0359 
B2FKT0 Putative TonB dependent receptor protein Smlt4387 
B2FM99 Putative TonB dependent receptor protein Smlt3254 
B2FP17 Putative TonB dependent receptor protein Smlt3446 
B2FU42 Putative TonB dependent receptor protein Smlt0083 
B2FHH2 Putative TonB dependent siderophore receptor Smlt1426 
B2FKE5 Putative TonB domain protein Smlt3093 
B2FPN5 Putative TonB-dependent outer membrane receptor protein Smlt2179 
B2FUR1 Putative TonB-dependent outer membrane receptor protein Smlt4026 
B2FRC4 Putative TonB-dependent receptor Smlt1067 
B2FRM7 Putative TPR repeat exported protein Smlt3702 
B2FUP4 Putative transglycosylase Smlt4007 
B2FP62 Putative transglycosylase protein Smlt4650 
B2FL08 Putative transmembrane anchor protein Smlt0538 
B2FLQ3 Putative transmembrane anchor protein Smlt0569 
B2FHD1 Putative transmembrane HemY porphyrin biosynthesis protein Smlt0165 
B2FHE8 Putative transmembrane protein Smlt0182 
B2FN01 Putative transmembrane protein Smlt2010 
B2FQ16 Putative transmembrane protein Smlt0872 
B2FIV3 Putative transmembrane Thiol:disulfide Interchange Protein Smlt4218 
B2FLR8 Putative vitamin B12 receptor protein Smlt0585 
B2FJ75 Putrescine-binding periplasmic protein potF Smlt1581 
B2FM92 Ribonuclease E (RNase E) (EC 3.1.26.12) rnE rne Smlt3247 
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B2FTA7 Site-determining protein minD Smlt1251 
B2FRS2 Succinyl-CoA ligase [ADP-forming] subunit alpha (EC 6.2.1.5) sucD Smlt3752 
B2FHC6 Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) sodC1 Smlt0160 
B2FHC7 Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) sodC2 Smlt0161 
B2FTY7 Thiol:disulfide interchange protein dsbA Smlt3993 
B2FQ33 Transcription termination/antitermination protein NusG nusG Smlt0892 
B2FQR1 Trigger factor (TF) (EC 5.2.1.8) (PPIase) tig Smlt0988 
B2FHB5 Uncharacterized protein Smlt0149 
B2FHE7 Uncharacterized protein Smlt0181 
B2FHF0 Uncharacterized protein Smlt0184 
B2FHG9 Uncharacterized protein Smlt0204 
B2FHL9 Uncharacterized protein Smlt1474 
B2FHN9 Uncharacterized protein Smlt2799 
B2FHZ6 Uncharacterized protein Smlt4119 
B2FII7 Uncharacterized protein Smlt2905 
B2FIM5 Uncharacterized protein Smlt2944 
B2FJR9 Uncharacterized protein Smlt4275 
B2FJV0 Uncharacterized protein Smlt0387 
B2FJV9 Uncharacterized protein Smlt0397 
B2FJY0 Uncharacterized protein Smlt0419 
B2FL09 Uncharacterized protein Smlt0539 
B2FLG5 Uncharacterized protein Smlt3232 
B2FME4 Uncharacterized protein Smlt3304 
B2FND4 Uncharacterized protein Smlt4590 
B2FND7 Uncharacterized protein Smlt4593 
B2FNK9 Uncharacterized protein Smlt0725 
B2FQ57 Uncharacterized protein Smlt2204 
B2FQN1 Uncharacterized protein Smlt0958 
B2FQN3 Uncharacterized protein Smlt0960 
B2FQN5 Uncharacterized protein Smlt0962 
B2FTS4 Uncharacterized protein pcm Smlt3927 
B2FUD6 Uncharacterized protein Smlt1403 
B2FUU4 Uncharacterized protein Smlt4063 
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A3. MRM target peptide transition list 
 
 
Protein 
 
Peptide precursor 
 
Fragment ion 
 
Precursor m/z 
(Da) 
Fragment ion m/z 
(Da) 
Dwell time 
(msec) 
DP (V) 
 
CE (V) 
 
Smlt0184 IGAGYNYGIAPNTDLVAR (2+) y10 (+) 932.98 1069.60 100 99.1 51.6 
   y9 (+) 932.98 956.52 100 99.1 51.6 
    y8 (+) 932.98 885.48 100 99.1 51.6 
  FNQNWGLSGEVK (2+) y8 (+) 689.84 875.46 100 81.4 39.5 
   y7 (+) 689.84 689.38 100 81.4 39.5 
    y5 (+) 689.84 519.28 100 81.4 39.5 
Smlt0387 VGAGYNVEIAPSTDFVAR (2+) y10 (+) 933.47 1076.57 100 99.2 51.7 
   y9 (+) 933.47 963.49 100 99.2 51.7 
    y8 (+) 933.47 892.45 100 99.2 51.7 
  LNQNWGLNGELK (2+) y8 (+) 693.36 916.49 100 81.7 39.7 
   y7 (+) 693.36 730.41 100 81.7 39.7 
    y5 (+) 693.36 560.30 100 81.7 39.7 
Smlt2667 GVAPQDLR (2+) y6 (+) 428.24 699.38 100 62.3 26.4 
   y5 (+) 428.24 628.34 100 62.3 26.4 
    y4 (+) 428.24 531.29 100 62.3 26.4 
  IAYADSLSAPGYQLK (2+) y10 (+) 798.92 1063.58 100 89.4 44.9 
   y8 (+) 798.92 863.46 100 89.4 44.9 
    y6 (+) 798.92 705.39 100 89.4 44.9 
BSA AEFVEVTK (2+) y6 (+) 461.75 722.41 100 64.8 28.1 
   y5 (+) 461.75 575.34 100 64.8 28.1 
    y4 (+) 461.75 476.27 100 64.8 28.1 
  QTALVELLK (2+) y7 (+) 507.81 785.51 100 68.1 30.4 
   y6 (+) 507.81 714.48 100 68.1 30.4 
    y5 (+) 507.81 601.39 100 68.1 30.4 
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A4. Penicillin G tolerance plate assay 
 
Optical density (OD600) of S. maltophilia cultures exposed to different concentrations of penicillin G (2 biological 
replicate analysis) 
 
 
Penicillin G 
concentration 
(mg/ml)  
Bio 1 
 
Bio 2 
 
Average 
 
STD 
 
0 0.593 0.613 0.603 0.014 
0.01 0.636 0.628 0.632 0.006 
0.05 0.569 0.517 0.543 0.037 
0.1 0.523 0.512 0.518 0.008 
0.5 0.601 0.558 0.580 0.030 
1 0.615 0.564 0.590 0.036 
5 0.024 0.014 0.019 0.007 
10 0.004 -0.008 -0.002 0.008 
50 0 -0.014 -0.007 0.010 
100 0.054 0.002 0.028 0.037 
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A5. Quantification of penicillin G induced OMVs 
 
OMV quantification with light scattering based single particle tracking (lsSPT) and fluorescent single particle 
tracking (fSPT) (3 technical replicate analysis) 
 
 
Method Conditiona  Particles/ml  Average STD Ratio 
  Tech 1 Tech 2 Tech 3   +/- 
lsSPT -  1.354e11 1.290e11 1.276e11 1.306e11 2.079e7 22.23 
 + 2.900e12 2.820e12 2.996e12 2.905e12 2.203e7  
fSPT - 2.840e9 2.240e9 3.040e9 2.707e9 4.163e8 17.27 
 + 4.610e10 4.940e10 4.470e10 4.673e10 2.413e9  
          a control (-), penicillin G stimulated (+) 
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A6. Qualitative and quantitative comparison of the penicillin G- and imipenem-induced OMV 
proteome 
 
Label-free quantitative analysis with ProgenesisTM 
 
The 2D-LCMSE data was loaded into the ProgenesisTM LC-MS 4.0 software from Nonlinear Dynamics (Newcastle, UK), 
and the runs were aligned to a reference run (with the most common features with all runs). The detected features 
(charge > 1) were normalized, and peptides with different abundances in the penicillin G- and imipenem-OMV 
proteome data were further considered (p ≤ 0.01). Identifications were further refined by excluding those with a 
mass error > 10 ppm and less than 2 peptide identification hits for the feature. Using the peptide abundances, 
proteins were quantified and subjected to similar statistic analysis (p ≤ 0.01). 
 
Protein identification list of the 2D-LCMS OMV proteome analysis with normalized abundances of differentially 
secreted OMV proteins (X: identified in that condition; NA: normalized abundance; * no significant difference in 
abundance; ** present in only one of the two conditions) 
 
Entry Gene names Protein names IMI PEN NAIMI NAPEN Fold 
B2FIV0 groS groES Smlt4215 10 kDa chaperonin (GroES protein) (Protein Cpn10) X X - - * 
B2FNP5 rpsA Smlt2043 30S ribosomal protein S1 X X - - * 
B2FN87 rpsO Smlt3386 30S ribosomal protein S15 X X 3696.3 559.15 6.61 
B2FIA9 rpsB Smlt1507 30S ribosomal protein S2 X  - - ** 
B2FQ51 rpsC Smlt0912 30S ribosomal protein S3 X X 3060.16 1884.77 1.62 
B2FJU4 rplM Smlt4302 50S ribosomal protein L13 X  - - ** 
B2FQ52 rplP Smlt0913 50S ribosomal protein L16 X  - - ** 
B2FQK9 rplQ Smlt0933 50S ribosomal protein L17 X X 1102.42 466.89 2.36 
B2FQ48 rplB Smlt0909 50S ribosomal protein L2 X X - - * 
B2FN76 rplT Smlt3375 50S ribosomal protein L20 X X - - * 
B2FTD1 rplU Smlt1278 50S ribosomal protein L21 X X - - * 
B2FQ20 rplY ctc Smlt0876 50S ribosomal protein L25 (General stress protein CTC) X X - - * 
B2FQJ6 rplE Smlt0918 50S ribosomal protein L5 X X - - * 
B2FQ37 rplL Smlt0897 50S ribosomal protein L7/L12 X X - - * 
B2FKJ7 rplI Smlt3148 50S ribosomal protein L9 X X - - * 
B2FIU9 groL groEL Smlt4214 60 kDa chaperonin (GroEL protein) (Protein Cpn60) X X - - * 
B2FU43 Smlt0084 Acid phosphatase (EC 3.1.3.2) X X - - * 
B2FT48 
 
adk Smlt3886 
 
Adenylate kinase (AK) (EC 2.7.4.3) (ATP-AMP 
transphosphorylase) (ATP:AMP phosphotransferase) 
(Adenylate monophosphate kinase) 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FKK2 
 
asnS Smlt3154 
 
Asparagine--tRNA ligase (EC 6.1.1.22) (Asparaginyl-
tRNA synthetase) 
X 
  
- 
 
- 
 
** 
 
B2FHZ0 
 
atpA Smlt4113 
 
ATP synthase subunit alpha (EC 3.6.3.14) (ATP synthase 
F1 sector subunit alpha) (F-ATPase subunit alpha) 
X 
  
- 
 
- 
 
** 
 
B2FHY8 
 
atpD Smlt4111 
 
ATP synthase subunit beta (EC 3.6.3.14) (ATP synthase 
F1 sector subunit beta) (F-ATPase subunit beta) 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FUV6 
 
hslU Smlt4075 
 
ATP-dependent protease ATPase subunit HslU 
(Unfoldase HslU) 
X 
  
- 
 
- 
 
** 
 
B2FRP5 Smlt3722 Beta-lactamase (EC 3.5.2.6) X X - - * 
B2FNP1 ftsA Smlt0759 Cell division protein ftsA X  - - ** 
B2FTA6 minE Smlt1250 Cell division topological specificity factor X  - - ** 
B2FMY5 
 
dnaK Smlt1992 
 
Chaperone protein DnaK (HSP70) (Heat shock 70 kDa 
protein) (Heat shock protein 70) 
X 
 
X 
 
- 
 
- 
 
* 
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B2FLW2 
 
htpG Smlt1809 
 
Chaperone protein HtpG (Heat shock protein HtpG) 
(High temperature protein G) 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FPG7 
 
surA Smlt0820 
 
Chaperone SurA (Peptidyl-prolyl cis-trans isomerase 
SurA) (Rotamase SurA) 
X 
 
X 
 
11300 
 
21400 
 
1.9 
 
B2FSI7 gltA Smlt3835 Citrate synthase (EC 2.3.3.16) X X - - * 
B2FI05 Smlt4128 Conserved hypothetical exported protein X X - - * 
B2FJC6 Smlt1634 Conserved hypothetical exported protein X X - - * 
B2FKV7 Smlt0483 Conserved hypothetical exported protein X  - - ** 
B2FL62 Smlt1774 Conserved hypothetical exported protein X X - - * 
B2FLW5 Smlt1812 Conserved hypothetical exported protein X X - - * 
B2FMI3 Smlt4500 Conserved hypothetical exported protein X X - - * 
B2FMI4 Smlt4501 Conserved hypothetical exported protein  X - - ** 
B2FN54 Smlt3351 Conserved hypothetical exported protein X X - - * 
B2FNH0 Smlt4628 Conserved hypothetical exported protein X X - - * 
B2FP55 Smlt4642 Conserved hypothetical exported protein X X 11300 25600 2.27 
B2FPN6 Smlt2180 Conserved hypothetical exported protein  X - - ** 
B2FQN8 Smlt0965 Conserved hypothetical exported protein X  - - ** 
B2FQX4 Smlt2334 Conserved hypothetical exported protein X X 9848.42 16200 1.65 
B2FQY5 Smlt2345 Conserved hypothetical exported protein X X - - * 
B2FR42 Smlt3680 Conserved hypothetical exported protein X X - - * 
B2FR48 Smlt3686 Conserved hypothetical exported protein X X - - * 
B2FRX3 Smlt1121 Conserved hypothetical exported protein X X - - * 
B2FRX4 Smlt1122 Conserved hypothetical exported protein X X - - * 
B2FRX9 Smlt1127 Conserved hypothetical exported protein X X - - * 
B2FRZ2 Smlt1140 Conserved hypothetical exported protein X X 655.2 958.01 1.46 
B2FRZ3 Smlt1141 Conserved hypothetical exported protein  X - - ** 
B2FSE9 Smlt3796 Conserved hypothetical exported protein X X 12900 7153.63 1.8 
B2FTB2 Smlt1256 Conserved hypothetical exported protein X X 3182.75 1394.42 2.28 
B2FUT1 Smlt4049 Conserved hypothetical exported protein  X - - ** 
B2FN59 Smlt3358 Conserved hypothetical repetitive protein X X - - * 
B2FT86 Smlt0008 Conserved hypothetical TPR repeat family protein X X 16200 34100 2.11 
B2FLD3 odhL Smlt3199 Dihydrolipoyl dehydrogenase (EC 1.8.1.4) X  - - ** 
B2FQK8 
 
rpoA Smlt0931 
 
DNA-directed RNA polymerase subunit alpha (RNAP 
subunit alpha) (EC 2.7.7.6) (RNA polymerase subunit 
alpha) (Transcriptase subunit alpha) 
X 
  
- 
 
- 
 
** 
 
B2FQ38 
 
rpoB Smlt0898 
 
DNA-directed RNA polymerase subunit beta (RNAP 
subunit beta) (EC 2.7.7.6) (RNA polymerase subunit 
beta) (Transcriptase subunit beta) 
X 
  
- 
 
- 
 
** 
 
B2FQ39 
 
rpoC Smlt0899 
 
DNA-directed RNA polymerase subunit beta' (RNAP 
subunit beta') (EC 2.7.7.6) (RNA polymerase subunit 
beta') (Transcriptase subunit beta') 
X 
  
- 
 
- 
 
** 
 
B2FQ42 fusA Smlt0903 Elongation factor G (EF-G) X X 3462.36 1785.86 1.94 
B2FIA8 tsf Smlt1506 Elongation factor Ts (EF-Ts) X X - - * 
B2FQ31 
 
tufB tuf tuf Smlt0890 
Smlt0904 
Elongation factor Tu (EF-Tu) 
 
X 
 
X 
 
11200 
 
18600 
 
1.66 
 
B2FK88 
 
eno Smlt1715 
 
Enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-
lyase) (2-phosphoglycerate dehydratase) 
X 
 
X 
 
97.41 
 
0 
 
Infinity 
 
B2FJU0 bfr Smlt4297 Ferroxidase (EC 1.16.3.1) X X - - * 
B2FQU5 fliC Smlt2304 Flagellin X X 9892.63 33600 3.39 
B2FQU6 flaA Smlt2305 Flagellin X X - - * 
B2FQU7 Smlt2306 Flagellin X X 837.22 3129.84 3.74 
B2FU50 opgD Smlt0091 Glucans biosynthesis protein D X X 1138.53 2400.54 2.11 
B2FRW6 lptA Smlt1114 Lipopolysaccharide export system protein LptA X X 331.68 522.98 1.58 
B2FQR4 
 
lon Smlt0991 
 
Lon protease (EC 3.4.21.53) (ATP-dependent protease 
La) 
X 
  
- 
 
- 
 
** 
 
B2FPR6 lptE Smlt3484 LPS-assembly lipoprotein LptE X X 3802.32 6374.01 1.68 
B2FPG8 lptD ostA Smlt0821 LPS-assembly protein LptD X  - - ** 
B2FNJ0 
 
smf-1 Smlt0706 
 
Major fimbrial subunit SMF-1 (S. maltophilia fimbriae 1) 
(SMF-1) 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FQL8 mdh Smlt0944 Malate dehydrogenase (EC 1.1.1.37) X X 1040.73 726.02 1.43 
B2FNQ5 
 
ndk Smlt2054 
 
Nucleoside diphosphate kinase (NDK) (NDP kinase) (EC 
2.7.4.6) (Nucleoside-2-P kinase) 
X 
  
- 
 
- 
 
** 
 
B2FIA0 bamA Smlt1498 Outer membrane protein assembly factor BamA X X 12000 15900 1.33 
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B2FNR0 bamB Smlt2059 Outer membrane protein assembly factor BamB X X 13200 24000 1.82 
B2FRR9 comL bamD Smlt3748 Outer membrane protein assembly factor BamD X X 4428.57 2111.78 2.1 
B2FMX8 bamE Smlt1985 Outer membrane protein assembly factor BamE X X - - * 
B2FQY6 lolA Smlt2346 Outer-membrane lipoprotein carrier protein X X - - * 
B2FQ17 lolB Smlt0873 Outer-membrane lipoprotein LolB X X 2395.89 5059.7 2.11 
B2FR43 
 
mrcB Smlt3681 
 
Penicillin-binding protein 1B (PBP-1b) (PBP1b) (Murein 
polymerase) 
X 
 
X 
 
7857.59 
 
3111.21 
 
2.53 
 
B2FLB8 Smlt3182 Peptidyl-prolyl cis-trans isomerase X X - - * 
B2FIF8 Smlt1559 Peptidyl-prolyl cis-trans isomerase (EC 5.2.1.8) X X 2684.47 7155.85 2.67 
B2FR55 Smlt0993 Peptidylprolyl isomerase (EC 5.2.1.8) X  - - ** 
B2FN86 
 
pnp Smlt3385 
 
Polyribonucleotide nucleotidyltransferase (EC 2.7.7.8) 
(Polynucleotide phosphorylase) (PNPase) 
X 
  
- 
 
- 
 
** 
 
B2FSQ8 
 
mqo Smlt1234 
 
Probable malate:quinone oxidoreductase (EC 1.1.5.4) 
(MQO) (Malate dehydrogenase [quinone]) 
X 
  
- 
 
- 
 
** 
 
B2FTS5 tolC Smlt3928 Protein CyaE X X 3975.49 2523.22 1.58 
B2FMY4 grpE Smlt1991 Protein GrpE (HSP-70 cofactor) X X - - * 
B2FRM9 tolB Smlt3704 Protein TolB X X 32600 67300 2.06 
B2FPB2 secA Smlt0764 Protein translocase subunit SecA X X 740.72 289.03 2.56 
B2FHD7 secB Smlt0171 Protein-export protein SecB X  - - ** 
B2FKN2 
 
Smlt4330 
 
Putative 4-hydroxyphenylpyruvate dioxygenase (EC 
1.13.11.27) 
X 
  
- 
 
- 
 
** 
 
B2FP85 
 
Smlt4673 
 
Putative ABC transporter toluene tolerance exported 
protein 
X 
 
X 
 
1887.04 
 
3815.37 
 
2.02 
 
B2FT31 Smlt3869 Putative ACR family protein X X 1140.82 2871.11 2.52 
B2FP33 Smlt3463 Putative alkaline phosphatase X X 5020.76 11300 2.24 
B2FPY7 
 
ahpC Smlt0841 
 
Putative alkyl hydroperoxide reductase subunit c (EC 
1.11.1.15) 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FJX9 Smlt0418 Putative aminopeptidase X  - - ** 
B2FL11 Smlt0541 Putative aminopeptidase X X - - * 
B2FSD8 Smlt3783 Putative aminopeptidase  X - - ** 
B2FQE3 
 
Smlt3574 
 
Putative angiotensin-converting enzyme like peptidyl 
dipeptidase protein 
X 
  
- 
 
- 
 
** 
 
B2FR62 Smlt1001 Putative autotransporter X  - - ** 
B2FPV5 sphB Smlt3524 Putative autotransporter subtilisin-like protease X X - - * 
B2FT88 exbB1 Smlt0010 Putative biopolymer transport exbB protein X X - - * 
B2FT89 exbD1 Smlt0011 Putative biopolymer transport ExbD1 protein X  - - ** 
B2FPM6 Smlt2170 Putative calcineurin phosphoesterase X X - - * 
B2FJY2 
 
ctpA Smlt0421 
 
Putative carboxy-terminal processing protease (EC 
3.4.21.102) 
X 
 
X 
 
4242.05 
 
8272.46 
 
1.95 
 
B2FII6 Smlt2904 Putative decarboxylase  X - - ** 
B2FK12 Smlt0451 Putative dehydrogenase X X 127.74 38.99 3.28 
B2FUE8 
 
dat Smlt1415 
 
Putative diaminobutyrate--2-oxoglutarate 
aminotransferase (EC 2.6.1.76) 
X 
 
X 
 
533.53 
 
125.1 
 
4.26 
 
B2FP98 Smlt4686 Putative dipeptidase  X - - ** 
B2FSF8 Smlt3806 Putative endonuclease P1 (EC 3.1.30.1) X X - - * 
B2FP18 pepO Smlt3447 Putative endopeptidase O (EC 3.4.24.-) X  - - ** 
B2FMI6 Smlt4503 Putative exported dipeptidyl peptidase IV X X 5220.39 2101.49 2.48 
B2FP20 Smlt3450 Putative exported endopeptidase X X - - * 
B2FI03 Smlt4126 Putative exported lipoprotein X  - - ** 
B2FNA4 Smlt4560 Putative exported lipoprotein  X - - ** 
B2FKH7 Smlt3128 Putative exported oligopeptidase  X - - ** 
B2FHW1 Smlt4084 Putative exported oligoPEPTIDASE (EC 3.4.-.-)  X - - ** 
B2FTA3 Smlt1246 Putative exported peptidase (EC 3.4.14.-) X X 5114 10200 2 
B2FUT3 rlpA Smlt4051 Putative exported rare lipoprotein A X X 2113.46 1023.15 2.07 
B2FUS7 Smlt4045 Putative exported tail-specific protease (EC 3.4.21.102) X X - - * 
B2FJY4 Smlt0423 Putative fatty acid transport system, membrane protein X X - - * 
B2FR50 Smlt3688 Putative ferritin DPS-family DNA binding protein X X 4502.44 619.55 7.27 
B2FNJ3 Smlt0709 Putative fimbria adhesin protein X X 8706.82 16200 1.86 
B2FNQ7 Smlt2056 Putative fimbrial biogenesis protein X X - - * 
B2FIR8 Smlt4182 Putative fimbrial protein (Pilin) X  - - ** 
B2FST5 Smlt2569 Putative glucan 1,4-beta-glucosidase X X - - * 
B2FP87 Smlt4675 Putative intercellular spreading VacJ lipoprotein X X - - * 
B2FRZ9 Smlt1148 Putative iron transport receptor protein X X - - * 
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B2FHT9 Smlt2858 Putative iron transporter X  - - ** 
B2FJR8 icd Smlt4273 Putative isocitrate dehydrogenase [NADP] (EC 1.1.1.42) X  - - ** 
B2FQQ5 Smlt0982 Putative isocitrate/isopropylmalate dehydrogenase X X - - * 
B2FP30 Smlt3460 Putative lipoprotein X X 796.29 234.89 3.39 
B2FRR0 Smlt3739 Putative lipoprotein  X - - ** 
B2FUS6 Smlt4044 Putative lipoprotein X  - - ** 
B2FU57 hel Smlt0098 Putative lipoprotein E (Outer membrane protein p4) X  - - ** 
B2FNM5 Smlt0742 Putative LppC family lipoprotein X X - - * 
B2FP06 
 
mltD Smlt3434 
 
Putative membrane-bound lytic murein 
transglycosylase d (EC 3.2.1.-) 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FTM1 
 
Smlt2667 
 
Putative metallo-beta-lactamase l1 (Beta-lactamase 
type ii) (Ec 3.5.2.6) (Penicillinase) (EC 3.5.2.6) 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FRQ3 Smlt3731 Putative MltA scaffolding protein X X - - * 
B2FH96 Smlt0129 Putative modulator of DNA gyrase X X 689.48 1511.75 2.19 
B2FUT4 mltB Smlt4052 Putative murein hydrolase (EC 3.2.1.-) X X - - * 
B2FHC0 Smlt0154 Putative N-acetylmuramoyl-L-alanine amidase X X - - * 
B2FN37 
 
Smlt3330 
 
Putative N-acetylmuramoyl-L-alanine amidase (EC 
3.5.1.28)  
X 
 
- 
 
- 
 
** 
 
B2FJB1 Smlt1619 Putative oar family adhesion protein X X - - * 
B2FLE9 Smlt3215 Putative outer membrane antigen lipoprotein X X - - * 
B2FLE4 Smlt3210 Putative outer membrane antigen protein X X 6869.42 4204.4 1.63 
B2FLY6 smeX Smlt1833 Putative outer membrane efflux protein X X - - * 
B2FSC8 Smlt3773 Putative outer membrane esterase X X - - * 
B2FLX9 Smlt1826 Putative outer membrane lipoprotein X X 20700 35300 1.71 
B2FPV8 Smlt3527 Putative outer membrane lipoprotein X X 847.02 2569.56 3.03 
B2FR78 Smlt1018 Putative outer membrane lipoprotein X X - - * 
B2FI00 Smlt4123 Putative outer membrane Omp family protein X X - - * 
B2FSF7 Smlt3805 Putative outer membrane Omp family protein X X - - * 
B2FHW3 Smlt4086 Putative outer membrane protein  X - - ** 
B2FLU3 Smlt0613 Putative outer membrane protein X X 156.25 569.24 3.64 
B2FLU4 Smlt0614 Putative outer membrane protein X X - - * 
B2FQM8 Smlt0955 Putative outer membrane protein X X - - * 
B2FSS7 
 
rpfN Smlt2559 
 
Putative outer membrane regulator of pathogenicity 
factors protein 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FNJ2 mrkC Smlt0708 Putative outer membrane usher protein mrkc X X - - * 
B2FU40 Smlt0080 Putative patatin-like phospholipase X X - - * 
B2FUT2 dacC Smlt4050 Putative penicillin-binding protein (EC 3.4.16.4) X X - - * 
B2FHG8 Smlt0203 Putative peptidase X  - - ** 
B2FJ20 Smlt0348 Putative peptidase X X 5842.03 12000 2.05 
B2FT85 Smlt0007 Putative peptidase X X 3769.87 5556.8 1.47 
B2FUU5 Smlt4064 Putative PEPTIDASE X X 1765.56 578.87 3.05 
B2FH98 Smlt0131 Putative peptidase/modulator of DNA gyrase  X - - ** 
B2FRM8 Smlt3703 Putative peptidoglycan-associated lipoprotein X X - - * 
B2FLG2 Smlt3229 Putative peptidyl dipeptidase/oligopeptidase X X 5726.61 12100 2.11 
B2FI43 
 
dcp Smlt0223 
 
Putative peptidyl-dipeptidase Dcp (Dipeptidyl 
carboxypeptidase) (EC 3.4.15.5) 
X 
 
X 
 
7953.54 
 
2939.36 
 
2.71 
 
B2FHM5 Smlt1483 Putative peptidyl-prolyl cis-trans isomerase  X - - ** 
B2FTU3 Smlt3950 Putative phosphate selective porin X X 1357.55 2424.36 1.79 
B2FHJ5 
 
Smlt1449 
 
Putative phosphodiesterase-nucleotide 
pyrophosphatase 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FNJ1 Smlt0707 Putative pili chaperone protein X X - - * 
B2FTT7 oprP Smlt3943 Putative porin P (Outer membrane protein d1) X X 12600 25000 1.98 
B2FJ52 Smlt0381 Putative protease X X 12700 24200 1.91 
B2FUA1 qoxB Smlt1361 Putative quinol oxidase subunit 1 X  - - ** 
B2FUU0 mreB Smlt4059 Putative rod shape-determining protein X  - - ** 
B2FRW3 Smlt1111 Putative sigma(54) modulation protein X X - - * 
B2FK97 Smlt1724 Putative subfamily M23B unassigned peptidase X X - - * 
B2FQC5 Smlt3553 Putative subfamily S1C unassigned peptidase X X 23800 57400 2.41 
B2FIM6 dsbG Smlt2946 Putative thiol:disulfide interchange protein  X - - ** 
B2FTY8 Smlt3994 Putative thiol:disulfide interchange protein X X - - * 
B2FPV6 Smlt3525 Putative thiolase  X - - ** 
B2FQ11 Smlt0866 Putative thioredoxin electron transport related protein X X - - * 
B2FPR9 Smlt3487 Putative thioredoxin protein  X - - ** 
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B2FRN0 tolA Smlt3705 Putative TolA transmembrane protein X  - - ** 
B2FRN2 tolQ Smlt3707 Putative TolQ transport transmembrane protein X  - - ** 
B2FRN1 tolR Smlt3706 Putative TolR-related protein X X 2415.3 1479.65 1.63 
B2FLT5 Smlt0602 Putative TonB dependent receptor  X - - ** 
B2FN47 Smlt3340 Putative TonB dependent receptor X X - - * 
B2FP16 Smlt3444 Putative TonB dependent receptor X X - - * 
B2FR08 Smlt3645 Putative TonB dependent receptor X X 10700 21900 2.05 
B2FRP8 Smlt3725 Putative TonB dependent receptor X X - - * 
B2FRR1 Smlt3740 Putative TonB dependent receptor X X 2037.95 5091.01 2.5 
B2FST2 Smlt2566 Putative TonB dependent receptor X X 4419.08 8846.28 2 
B2FT66 Smlt3905 Putative TonB dependent receptor X X - - * 
B2FJ30 Smlt0359 Putative TonB dependent receptor protein X X 24900 11400 2.18 
B2FKT0 Smlt4387 Putative TonB dependent receptor protein X  - - ** 
B2FM99 Smlt3254 Putative TonB dependent receptor protein X X - - * 
B2FP17 Smlt3446 Putative TonB dependent receptor protein X X - - * 
B2FU42 Smlt0083 Putative TonB dependent receptor protein X X 15400 23700 1.54 
B2FHH2 Smlt1426 Putative TonB dependent siderophore receptor X  - - ** 
B2FKE5 Smlt3093 Putative TonB domain protein X X 97.21 1.43 68.11 
B2FHR9 Smlt2835 Putative TonB-dependent outer membrane protein  X - - ** 
B2FPN5 
 
Smlt2179 
 
Putative TonB-dependent outer membrane receptor 
protein 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FUR1 
 
Smlt4026 
 
Putative TonB-dependent outer membrane receptor 
protein 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FRC4 Smlt1067 Putative TonB-dependent receptor X X 583.18 1196.18 2.05 
B2FRM7 Smlt3702 Putative TPR repeat exported protein X X 7715.31 15900 2.06 
B2FNV9 Smlt2112 Putative transcriptional regulator-TetR family  X - - ** 
B2FUP4 Smlt4007 Putative transglycosylase X X - - * 
B2FP62 Smlt4650 Putative transglycosylase protein X X - - * 
B2FL08 Smlt0538 Putative transmembrane anchor protein X X - - * 
B2FHD1 
 
Smlt0165 
 
Putative transmembrane HemY porphyrin biosynthesis 
protein 
X 
  
- 
 
- 
 
** 
 
B2FHE8 Smlt0182 Putative transmembrane protein X X - - * 
B2FN01 Smlt2010 Putative transmembrane protein X X - - * 
B2FQ16 Smlt0872 Putative transmembrane protein X X 2554.26 4920.61 1.93 
B2FIV3 
 
Smlt4218 
 
Putative transmembrane Thiol:disulfide Interchange 
Protein 
X 
  
- 
 
- 
 
** 
 
B2FI94 
 
Smlt0278 
 
Putative two component regulator sensor histidine 
kinase transmembrane transcriptional regulatory 
protein 
X 
  
- 
 
- 
 
** 
 
B2FLR8 Smlt0585 Putative vitamin B12 receptor protein X X - - * 
B2FQZ2 Smlt3629 Putative YciI family periplasmic protein  X - - ** 
B2FJ75 potF Smlt1581 Putrescine-binding periplasmic protein X X 1270.62 526.71 2.41 
B2FM92 rnE rne Smlt3247 Ribonuclease E (RNase E) (EC 3.1.26.12) X  - - ** 
B2FPY1 lepB Smlt3551 Signal peptidase I (EC 3.4.21.89) X  - - ** 
B2FTA7 minD Smlt1251 Site-determining protein X X - - * 
B2FRS2 
 
sucD Smlt3752 
 
Succinyl-CoA ligase [ADP-forming] subunit alpha (EC 
6.2.1.5) 
X 
 
X 
 
- 
 
- 
 
* 
 
B2FLH1 sodA Smlt3238 Superoxide dismutase (EC 1.15.1.1)  X - - ** 
B2FHC6 sodC1 Smlt0160 Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) X X - - * 
B2FHC7 sodC2 Smlt0161 Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) X  - - ** 
B2FTY7 dsbA Smlt3993 Thiol:disulfide interchange protein X X 171.74 30.82 5.57 
B2FQ33 
 
nusG Smlt0892 
 
Transcription termination/antitermination protein 
NusG 
X 
  
- 
 
- 
 
** 
 
B2FQR1 tig Smlt0988 Trigger factor (TF) (EC 5.2.1.8) (PPIase) X  - - ** 
B2FHB5 Smlt0149 Uncharacterized protein X X 8722.45 5246.92 1.66 
B2FHE7 Smlt0181 Uncharacterized protein X X 1739.79 2790.15 1.6 
B2FHF0 Smlt0184 Uncharacterized protein X X - - * 
B2FHG9 Smlt0204 Uncharacterized protein X X 7445.79 14000 1.88 
B2FHL9 Smlt1474 Uncharacterized protein X  - - ** 
B2FHN9 Smlt2799 Uncharacterized protein X  - - ** 
B2FHZ6 Smlt4119 Uncharacterized protein X X - - * 
B2FII7 Smlt2905 Uncharacterized protein X X - - * 
B2FIM5 Smlt2944 Uncharacterized protein X X - - * 
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B2FJR9 Smlt4275 Uncharacterized protein X  - - ** 
B2FJV0 Smlt0387 Uncharacterized protein X X - - * 
B2FJV9 Smlt0397 Uncharacterized protein X  - - ** 
B2FL09 Smlt0539 Uncharacterized protein X X 1622.76 707.26 2.29 
B2FLG5 Smlt3232 Uncharacterized protein X X 87.66 0.34 258.54 
B2FME4 Smlt3304 Uncharacterized protein X X 734.91 2366.12 3.22 
B2FND4 Smlt4590 Uncharacterized protein X X 123.11 551.26 4.48 
B2FND7 Smlt4593 Uncharacterized protein X X - - * 
B2FNK1 Smlt0717 Uncharacterized protein X  - - ** 
B2FNK9 Smlt0725 Uncharacterized protein X X 637.96 3960.14 6.21 
B2FPC4 Smlt0777 Uncharacterized protein  X - - ** 
B2FPU4 Smlt3512 Uncharacterized protein  X - - ** 
B2FQ57 Smlt2204 Uncharacterized protein X X - - * 
B2FQN1 Smlt0958 Uncharacterized protein X X 1436.51 4755.13 3.31 
B2FQN3 Smlt0960 Uncharacterized protein X X - - * 
B2FQN5 Smlt0962 Uncharacterized protein X X 9007.29 24900 2.76 
B2FT51 Smlt3889 Uncharacterized protein  X - - ** 
B2FTS4 pcm Smlt3927 Uncharacterized protein X  - - ** 
B2FUD6 Smlt1403 Uncharacterized protein X X - - * 
B2FUU4 Smlt4063 Uncharacterized protein X  - - ** 
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A7. Nitrocefin assay on intact OMVs 
 
UV-VIS spectroscopy detection of hydrolyzed nitrocefin at OD490 during incubation with intact penicillin G induced 
OMVs, with and without the addition of 50 mM EDTA (2 biological replicate analysis) 
 
  Bio 1   Bio 2   Average   STD   
min -EDTA +EDTA -EDTA +EDTA -EDTA +EDTA -EDTA +EDTA 
5 0.201 0.096 0.175 0.080 0.188 0.088 0.018 0.011 
10 0.334 0.154 0.291 0.123 0.313 0.139 0.030 0.022 
15 0.431 0.212 0.383 0.165 0.407 0.189 0.034 0.033 
20 0.481 0.250 0.438 0.203 0.460 0.227 0.030 0.033 
25 0.514 0.291 0.483 0.230 0.499 0.261 0.022 0.043 
30 0.537 0.331 0.514 0.265 0.526 0.298 0.016 0.047 
35 0.544 0.354 0.526 0.286 0.535 0.320 0.013 0.048 
40 0.549 0.379 0.534 0.311 0.542 0.345 0.011 0.048 
45 0.553 0.404 0.542 0.331 0.548 0.368 0.008 0.052 
50 0.552 0.423 0.545 0.352 0.549 0.388 0.005 0.050 
55 0.554 0.441 0.549 0.371 0.552 0.406 0.004 0.049 
60 0.558 0.455 0.548 0.387 0.553 0.421 0.007 0.048 
 
Rate of hydrolysis derived from linear part of the curve 
 
 
 
  ΔOD(t15-t5) c = A (ΔOD)/ε (M) c (µmol/ml) c (µg/ml) rate (µg/ml.min) 
-EDTA 0.219 1.068E-05 0.011 5.710 0.571 
+EDTA 0.101 4.902E-06 0.005 2.620 0.262 
      
 ε (hydrolyzed nitrocefin) (M-1.cm-1) 20500  
 MW (hydrolyzed nitrocefin) (µg/µmol) 534.5  
y = 0.1095x + 0.0835
R² = 0.9938
y = 0.0503x + 0.0378
R² = 1
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A8. RP-HPLC linear dynamic range of imipenem, amoxicillin and ticarcillin 
 
 
  Imipenem   Amoxicillin   Ticarcillin  
Concentration 
(ng/µl) 
Retention time 
(min) 
Intensity 
(mAU) 
Retention time 
(min) 
Intensity 
(mAU) 
Retention time 
(min) 
Intensity 
(mAU) 
5 2.42 4.49 3.42 10.35 3.66 3.74 
10 2.41 8.50 3.40 21.43 3.65 6.95 
50 2.40 43.32 3.39 76.57 3.65 34.45 
100 2.40 88.75 3.42 129.58 3.64 68.47 
500 2.43 421.12 3.41 384.27 3.62 295.13 
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A9. OMV concentration and size determination 
 
Raw data from OMV concentration and size determination by light scattering based single particle tracking 
(NanoSight LM10-HS) 
 
- ‘ctrl 1’   >   control sample, biological replicate 1 
- ‘ctrl 3’   >   control sample, biological replicate 2 
- ‘imi 1’   >   imipenem sample, biological replicate 1 
- ‘imi 3’   >   imipenem sample, biological replicate 2 
- ‘cip 1’   >   ciprofloxacin sample, biological replicate 1 
- ‘cip 3’   >   ciprofloxacin sample, biological replicate 2 
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A10. Qualitative comparison of the penicillin G- and imipenem-induced OMV proteome 
 
Protein identification list of the 2D-LCMS OMV proteome analysis (identified in minimum 2/3 biological replicate 
runs) (X: identified in that condition) 
 
Entry Protein names Gene names IMI CIP 
B2FIV0 
 
10 kDa chaperonin (GroES protein) (Protein Cpn10) 
 
groS groES 
Smlt4215 
X 
  
B2FNP5 30S ribosomal protein S1 rpsA Smlt2043  X 
B2FQK6 30S ribosomal protein S11 rpsK Smlt0929  X 
B2FQK5 30S ribosomal protein S13 rpsM Smlt0928  X 
B2FIA9 30S ribosomal protein S2 rpsB Smlt1507  X 
B2FQ51 30S ribosomal protein S3 rpsC Smlt0912 X X 
B2FQK7 30S ribosomal protein S4 rpsD Smlt0930  X 
B2FQK1 30S ribosomal protein S5 rpsE Smlt0923  X 
B2FQ41 30S ribosomal protein S7 rpsG Smlt0902  X 
B2FQ35 50S ribosomal protein L1 rplA Smlt0895  X 
B2FQ36 50S ribosomal protein L10 rplJ Smlt0896  X 
B2FQ34 50S ribosomal protein L11 rplK Smlt0894  X 
B2FJU4 50S ribosomal protein L13 rplM Smlt4302  X 
B2FQJ4 50S ribosomal protein L14 rplN Smlt0916  X 
B2FQK3 50S ribosomal protein L15 rplO Smlt0925  X 
B2FQ52 50S ribosomal protein L16 rplP Smlt0913  X 
B2FQK9 50S ribosomal protein L17 rplQ Smlt0933  X 
B2FQK0 50S ribosomal protein L18 rplR Smlt0922  X 
B2FUB6 50S ribosomal protein L19 rplS Smlt1377   X 
B2FQ48 50S ribosomal protein L2 rplB Smlt0909 X X 
B2FQ47 50S ribosomal protein L23 rplW Smlt0908  X 
B2FQ20 50S ribosomal protein L25 (General stress protein CTC) rplY ctc Smlt0876  X 
B2FTD2 50S ribosomal protein L27 rpmA Smlt1279  X 
B2FQ45 50S ribosomal protein L3 rplC Smlt0906  X 
B2FQ46 50S ribosomal protein L4 rplD Smlt0907  X 
B2FQJ6 50S ribosomal protein L5 rplE Smlt0918  X 
B2FQJ9 50S ribosomal protein L6 rplF Smlt0921  X 
B2FQ37 50S ribosomal protein L7/L12 rplL Smlt0897 X X 
B2FKJ7 50S ribosomal protein L9 rplI Smlt3148  X 
B2FIU9 
 
60 kDa chaperonin (GroEL protein) (Protein Cpn60) 
 
groL groEL 
Smlt4214 
X 
 
X 
 
B2FHZ8 Acetyltransferase component of pyruvate dehydrogenase complex (EC 2.3.1.12) pdhB Smlt4121  X 
B2FU43 Acid phosphatase (EC 3.1.3.2) Smlt0084 X  
B2FT48 
 
Adenylate kinase (AK) (EC 2.7.4.3) (ATP-AMP transphosphorylase) (ATP:AMP 
phosphotransferase) (Adenylate monophosphate kinase) 
adk Smlt3886 
 
X 
  
B2FHY7 
 
ATP synthase epsilon chain (ATP synthase F1 sector epsilon subunit) (F-ATPase epsilon 
subunit) 
atpC Smlt4110 
  
X 
 
B2FHY9 
 
ATP synthase gamma chain (ATP synthase F1 sector gamma subunit) (F-ATPase gamma 
subunit) 
atpG Smlt4112 
  
X 
 
B2FHZ0 
 
ATP synthase subunit alpha (EC 3.6.3.14) (ATP synthase F1 sector subunit alpha) (F-
ATPase subunit alpha) 
atpA Smlt4113 
  
X 
 
B2FHZ2 
 
ATP synthase subunit b (ATP synthase F(0) sector subunit b) (ATPase subunit I) (F-type 
ATPase subunit b) (F-ATPase subunit b) 
atpF Smlt4115 
  
X 
 
B2FHY8 
 
ATP synthase subunit beta (EC 3.6.3.14) (ATP synthase F1 sector subunit beta) (F-
ATPase subunit beta) 
atpD Smlt4111 
 
X 
 
X 
 
B2FRP5 Beta-lactamase (EC 3.5.2.6) Smlt3722 X  
B2FNP1 Cell division protein ftsA ftsA Smlt0759 X  
B2FMY5 Chaperone protein DnaK (HSP70) (Heat shock 70 kDa protein) (Heat shock protein 70) dnaK Smlt1992 X X 
B2FLW2 Chaperone protein HtpG (Heat shock protein HtpG) (High temperature protein G) htpG Smlt1809 X  
B2FPG7 Chaperone SurA (Peptidyl-prolyl cis-trans isomerase SurA) (Rotamase SurA) surA Smlt0820 X X 
B2FSI7 Citrate synthase (EC 2.3.3.16) gltA Smlt3835 X  
B2FI05 Conserved hypothetical exported protein Smlt4128 X X 
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B2FJC6 Conserved hypothetical exported protein Smlt1634 X  
B2FKV7 Conserved hypothetical exported protein Smlt0483 X X 
B2FL62 Conserved hypothetical exported protein Smlt1774 X X 
B2FLW5 Conserved hypothetical exported protein Smlt1812 X X 
B2FMI3 Conserved hypothetical exported protein Smlt4500 X  
B2FN54 Conserved hypothetical exported protein Smlt3351 X X 
B2FP55 Conserved hypothetical exported protein Smlt4642 X X 
B2FP89 Conserved hypothetical exported protein Smlt4677  X 
B2FQX4 Conserved hypothetical exported protein Smlt2334 X X 
B2FQY5 Conserved hypothetical exported protein Smlt2345 X  
B2FR42 Conserved hypothetical exported protein Smlt3680 X  
B2FR48 Conserved hypothetical exported protein Smlt3686 X  
B2FRX3 Conserved hypothetical exported protein Smlt1121 X  
B2FRX4 Conserved hypothetical exported protein Smlt1122 X  
B2FRX9 Conserved hypothetical exported protein Smlt1127 X X 
B2FRZ2 Conserved hypothetical exported protein Smlt1140 X  
B2FSE9 Conserved hypothetical exported protein Smlt3796 X X 
B2FTB2 Conserved hypothetical exported protein Smlt1256 X X 
B2FN59 Conserved hypothetical repetitive protein Smlt3358 X  
B2FT86 Conserved hypothetical TPR repeat family protein Smlt0008 X X 
B2FHZ7 Dihydrolipoyl dehydrogenase (EC 1.8.1.4) lpdA Smlt4120  X 
B2FLD3 Dihydrolipoyl dehydrogenase (EC 1.8.1.4) odhL Smlt3199  X 
B2FLD2 
 
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex (EC 2.3.1.61) (2-oxoglutarate dehydrogenase complex 
component E2) 
sucB Smlt3198 
  
X 
 
B2FT83 DNA gyrase subunit B (EC 5.99.1.3) gyrB Smlt0005  X 
B2FQK8 
 
DNA-directed RNA polymerase subunit alpha (RNAP subunit alpha) (EC 2.7.7.6) (RNA 
polymerase subunit alpha) (Transcriptase subunit alpha) 
rpoA Smlt0931 
  
X 
 
B2FQ39 
 
DNA-directed RNA polymerase subunit beta' (RNAP subunit beta') (EC 2.7.7.6) (RNA 
polymerase subunit beta') (Transcriptase subunit beta') 
rpoC Smlt0899 
  
X 
 
B2FQ38 
 
DNA-directed RNA polymerase subunit beta (RNAP subunit beta) (EC 2.7.7.6) (RNA 
polymerase subunit beta) (Transcriptase subunit beta) 
rpoB Smlt0898 
  
X 
 
B2FQ42 Elongation factor G (EF-G) fusA Smlt0903 X X 
B2FIA8 Elongation factor Ts (EF-Ts) tsf Smlt1506 X  
B2FQ31 
 
Elongation factor Tu (EF-Tu) 
 
tufB tuf Smlt0890 
Smlt0904 
X 
 
X 
 
B2FK88 
 
Enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (2-phosphoglycerate 
dehydratase) 
eno Smlt1715 
 
X 
  
B2FIC4 Ferroxidase (EC 1.16.3.1) bfrA Smlt1524 X X 
B2FJU0 Ferroxidase (EC 1.16.3.1) bfr Smlt4297 X X 
B2FQU4 Flagellar hook-associated protein 2 (HAP2) (Flagellar cap protein) fliD Smlt2303  X 
B2FQU5 Flagellin fliC Smlt2304 X X 
B2FQU6 Flagellin flaA Smlt2305 X X 
B2FQU7 Flagellin Smlt2306 X X 
B2FU50 Glucans biosynthesis protein D opgD Smlt0091 X X 
B2FQR4 Lon protease (EC 3.4.21.53) (ATP-dependent protease La) lon Smlt0991  X 
B2FPR6 LPS-assembly lipoprotein LptE lptE Smlt3484 X  
B2FNJ0 Major fimbrial subunit SMF-1 (S. maltophilia fimbriae 1) (SMF-1) smf-1 Smlt0706 X X 
B2FQL8 Malate dehydrogenase (EC 1.1.1.37) mdh Smlt0944 X X 
B2FNX8 
 
NADH-quinone oxidoreductase subunit B (EC 1.6.5.11) (NADH dehydrogenase I subunit 
B) (NDH-1 subunit B) 
nuoB Smlt3404 
  
X 
 
B2FNX7 
 
NADH-quinone oxidoreductase subunit C (EC 1.6.5.11) (NADH dehydrogenase I subunit 
C) (NDH-1 subunit C) 
nuoC Smlt3403 
  
X 
 
B2FNX6 
 
NADH-quinone oxidoreductase subunit D (EC 1.6.5.11) (NADH dehydrogenase I subunit 
D) (NDH-1 subunit D) 
nuoD Smlt3402 
  
X 
 
B2FIA0 Outer membrane protein assembly factor BamA bamA Smlt1498 X X 
B2FNR0 Outer membrane protein assembly factor BamB bamB Smlt2059 X X 
B2FRR9 
 
Outer membrane protein assembly factor BamD 
 
comL bamD 
Smlt3748 
X 
 
X 
 
B2FMX8 Outer membrane protein assembly factor BamE bamE Smlt1985 X  
B2FQY6 Outer-membrane lipoprotein carrier protein lolA Smlt2346 X  
B2FQ17 Outer-membrane lipoprotein LolB lolB Smlt0873 X  
B2FR43 Penicillin-binding protein 1B (PBP-1b) (PBP1b) (Murein polymerase) mrcB Smlt3681 X  
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B2FLB8 Peptidyl-prolyl cis-trans isomerase Smlt3182 X X 
B2FIF8 Peptidyl-prolyl cis-trans isomerase (EC 5.2.1.8) Smlt1559 X X 
B2FR55 Peptidylprolyl isomerase (EC 5.2.1.8) Smlt0993  X 
B2FTS5 Protein CyaE tolC Smlt3928 X  
B2FL31 Protein RecA (Recombinase A) recA Smlt1741  X 
B2FRM9 Protein TolB tolB Smlt3704 X X 
B2FPB2 Protein translocase subunit SecA secA Smlt0764 X X 
B2FHD7 Protein-export protein SecB secB Smlt0171 X  
B2FLD1 Putative 2-oxoglutarate dehydrogenase E1 component (EC 1.2.4.2) sucA Smlt3197  X 
B2FHD0 Putative 3-ketoacyl-CoA thiolase (EC 2.3.1.16) fadI Smlt0164  X 
B2FNK0 Putative ABC transporter component protein Smlt0716  X 
B2FP85 Putative ABC transporter toluene tolerance exported protein Smlt4673 X X 
B2FLC2 Putative ABC transporter, ATP-binding protein Smlt3186 X  
B2FT31 Putative ACR family protein Smlt3869 X  
B2FP33 Putative alkaline phosphatase Smlt3463 X X 
B2FPY7 Putative alkyl hydroperoxide reductase subunit c (EC 1.11.1.15) ahpC Smlt0841 X X 
B2FL11 Putative aminopeptidase Smlt0541 X  
B2FR62 Putative autotransporter Smlt1001 X  
B2FPV5 Putative autotransporter subtilisin-like protease sphB Smlt3524 X X 
B2FRA4 Putative bacteriophage major tail sheath protein Smlt1045  X 
B2FT88 Putative biopolymer transport exbB protein exbB1 Smlt0010 X X 
B2FT89 Putative biopolymer transport ExbD1 protein exbD1 Smlt0011  X 
B2FT90 Putative biopolymer transport ExbD2 protein exbD2 Smlt0012  X 
B2FPM6 Putative calcineurin phosphoesterase Smlt2170 X  
B2FJY2 Putative carboxy-terminal processing protease (EC 3.4.21.102) ctpA Smlt0421 X  
B2FQN9 Putative colicin V production protein Smlt0966  X  
B2FP98 Putative dipeptidase Smlt4686 X  
B2FSF8 Putative endonuclease P1 (EC 3.1.30.1) Smlt3806 X  
B2FP18 Putative endopeptidase O (EC 3.4.24.-) pepO Smlt3447 X  
B2FMI6 Putative exported dipeptidyl peptidase IV Smlt4503 X X 
B2FP20 Putative exported endopeptidase Smlt3450 X X 
B2FI03 Putative exported lipoprotein Smlt4126 X  
B2FNA4 Putative exported lipoprotein Smlt4560 X  
B2FHW1 Putative exported oligoPEPTIDASE (EC 3.4.-.-) Smlt4084 X  
B2FTA3 Putative exported peptidase (EC 3.4.14.-) Smlt1246 X  
B2FUT3 Putative exported rare lipoprotein A rlpA Smlt4051 X  
B2FUS7 Putative exported tail-specific protease (EC 3.4.21.102) Smlt4045 X  
B2FJY4 Putative fatty acid transport system, membrane protein Smlt0423 X X 
B2FR50 Putative ferritin DPS-family DNA binding protein Smlt3688  X 
B2FNJ3 Putative fimbria adhesin protein Smlt0709 X X 
B2FQV5 Putative flagellar hook protein Smlt2314 X X 
B2FST5 Putative glucan 1,4-beta-glucosidase Smlt2569 X X 
B2FP87 Putative intercellular spreading VacJ lipoprotein Smlt4675 X X 
B2FRZ9 Putative iron transport receptor protein Smlt1148 X X 
B2FHT9 Putative iron transporter Smlt2858 X  
B2FQQ5 Putative isocitrate/isopropylmalate dehydrogenase Smlt0982 X   
B2FUS6 Putative lipoprotein Smlt4044 X  
B2FU57 Putative lipoprotein E (Outer membrane protein p4) hel Smlt0098 X  
B2FNM5 Putative LppC family lipoprotein Smlt0742 X X 
B2FRA3 Putative major tail tube protein Smlt1044  X 
B2FP06 Putative membrane-bound lytic murein transglycosylase d (EC 3.2.1.-) mltD Smlt3434 X X 
B2FTM1 
 
Putative metallo-beta-lactamase l1 (Beta-lactamase type ii) (Ec 3.5.2.6) (Penicillinase) 
OS=Stenotrophomonas maltophilia (strain K279a) GN=Smlt2667 PE=4 SV=1 
Smlt2667 
 
 X 
  
B2FRQ3 Putative MltA scaffolding protein Smlt3731 X X 
B2FUT4 Putative murein hydrolase (EC 3.2.1.-) mltB Smlt4052 X X 
B2FHC0 Putative N-acetylmuramoyl-L-alanine amidase Smlt0154 X  
B2FN37 Putative N-acetylmuramoyl-L-alanine amidase (EC 3.5.1.28) Smlt3330 X  
B2FJB1 Putative oar family adhesion protein Smlt1619 X X 
B2FIM3 Putative orn/arg/lys decarboxylase Smlt2942  X 
B2FLE9 Putative outer membrane antigen lipoprotein Smlt3215 X X 
B2FLE4 Putative outer membrane antigen protein Smlt3210 X X 
B2FSC8 Putative outer membrane esterase Smlt3773 X X 
B2FLX9 Putative outer membrane lipoprotein Smlt1826 X X 
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B2FPV8 Putative outer membrane lipoprotein Smlt3527  X 
B2FR78 Putative outer membrane lipoprotein Smlt1018 X X 
B2FI00 Putative outer membrane Omp family protein Smlt4123 X X 
B2FSF7 Putative outer membrane Omp family protein Smlt3805 X X 
B2FLU4 Putative outer membrane protein Smlt0614 X X 
B2FQM8 Putative outer membrane protein Smlt0955 X X 
B2FSS7 Putative outer membrane regulator of pathogenicity factors protein rpfN Smlt2559 X  
B2FNJ2 Putative outer membrane usher protein mrkc mrkC Smlt0708 X X 
B2FU40 Putative patatin-like phospholipase Smlt0080 X  
B2FUT2 Putative penicillin-binding protein (EC 3.4.16.4) dacC Smlt4050 X X 
B2FHG8 Putative peptidase Smlt0203  X 
B2FJ20 Putative peptidase Smlt0348 X X 
B2FT85 Putative peptidase Smlt0007 X X 
B2FUU5 Putative PEPTIDASE Smlt4064 X X 
B2FRM8 Putative peptidoglycan-associated lipoprotein Smlt3703 X X 
B2FLG2 Putative peptidyl dipeptidase/oligopeptidase Smlt3229 X X 
B2FI43 Putative peptidyl-dipeptidase Dcp (Dipeptidyl carboxypeptidase) (EC 3.4.15.5) dcp Smlt0223 X  
B2FHM5 Putative peptidyl-prolyl cis-trans isomerase Smlt1483 X  
B2FRA8 Putative phage baseplate assembly protein Smlt1049  X 
B2FRA6 Putative phage tail protein Smlt1047  X 
B2FRB7 Putative phage-related protein Smlt1058  X 
B2FTU3 Putative phosphate selective porin Smlt3950 X  
B2FHJ5 Putative phosphodiesterase-nucleotide pyrophosphatase Smlt1449 X  
B2FNJ1 Putative pili chaperone protein Smlt0707 X X 
B2FN33 Putative poly-hydroxy-butyrate synthesis protein Smlt3326  X 
B2FTT7 Putative porin P (Outer membrane protein d1) oprP Smlt3943 X X 
B2FJ52 Putative protease Smlt0381 X X 
B2FP90 Putative RmuC family protein Smlt4678  X 
B2FUU0 Putative rod shape-determining protein mreB Smlt4059  X 
B2FK97 Putative subfamily M23B unassigned peptidase Smlt1724 X X 
B2FQC5 Putative subfamily S1C unassigned peptidase Smlt3553 X X 
B2FIM6 Putative thiol:disulfide interchange protein dsbG Smlt2946 X  
B2FTY8 Putative thiol:disulfide interchange protein Smlt3994 X  
B2FQ11 Putative thioredoxin electron transport related protein Smlt0866 X  
B2FRN0 Putative TolA transmembrane protein tolA Smlt3705 X  
B2FRN1 Putative TolR-related protein tolR Smlt3706 X  
B2FLT5 Putative TonB dependent receptor Smlt0602 X  
B2FN47 Putative TonB dependent receptor Smlt3340 X X 
B2FP16 Putative TonB dependent receptor Smlt3444 X X 
B2FR08 Putative TonB dependent receptor Smlt3645 X X 
B2FRP8 Putative TonB dependent receptor Smlt3725 X  
B2FRR1 Putative TonB dependent receptor Smlt3740 X  
B2FST2 Putative TonB dependent receptor Smlt2566 X X 
B2FT66 Putative TonB dependent receptor Smlt3905 X X 
B2FJ30 Putative TonB dependent receptor protein Smlt0359 X X 
B2FM99 Putative TonB dependent receptor protein Smlt3254 X X 
B2FP17 Putative TonB dependent receptor protein Smlt3446 X X 
B2FU42 Putative TonB dependent receptor protein Smlt0083 X X 
B2FHH2 Putative TonB dependent siderophore receptor Smlt1426 X  
B2FKE5 Putative TonB domain protein Smlt3093 X  
B2FHR9 Putative TonB-dependent outer membrane protein Smlt2835 X  
B2FPN5 Putative TonB-dependent outer membrane receptor protein Smlt2179 X X 
B2FUR1 Putative TonB-dependent outer membrane receptor protein Smlt4026 X  
B2FUN9 
 
Putative TonB-dependent receptor for Fe(III)-coprogen, Fe(III)-ferrioxamine B and 
Fe(III)-rhodotrulic acid 
fhuE Smlt3999 
 
X 
  
B2FRM7 Putative TPR repeat exported protein Smlt3702 X X 
B2FUP4 Putative transglycosylase Smlt4007 X  
B2FP62 Putative transglycosylase protein Smlt4650 X  
B2FL08 Putative transmembrane anchor protein Smlt0538 X X 
B2FHD1 Putative transmembrane HemY porphyrin biosynthesis protein Smlt0165 X  
B2FHE8 Putative transmembrane protein Smlt0182  X 
B2FNQ9 Putative transmembrane protein Smlt2058  X 
B2FQ16 Putative transmembrane protein Smlt0872 X  
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B2FIV3 Putative transmembrane Thiol:disulfide Interchange Protein Smlt4218 X  
B2FND5 Putative universal stress protein Smlt4591  X 
B2FLR8 Putative vitamin B12 receptor protein Smlt0585 X X 
B2FJ75 Putrescine-binding periplasmic protein potF Smlt1581 X X 
B2FI64 Ribonucleoside-diphosphate reductase (EC 1.17.4.1) RRM1 Smlt0247  X 
B2FPY1 Signal peptidase I (EC 3.4.21.89) lepB Smlt3551 X  
B2FTA7 Site-determining protein minD Smlt1251 X X 
B2FL86 Succinate dehydrogenase flavoprotein subunit (EC 1.3.5.1) sdhA Smlt1798  X 
B2FRS2 Succinyl-CoA ligase [ADP-forming] subunit alpha (EC 6.2.1.5) sucD Smlt3752  X 
B2FLH1 Superoxide dismutase (EC 1.15.1.1) sodA Smlt3238 X X 
B2FHC6 Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) sodC1 Smlt0160 X X 
B2FHC7 Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) sodC2 Smlt0161 X  
B2FPY3 Transaldolase (EC 2.2.1.2) talB Smlt0837 X  
B2FQ33 Transcription termination/antitermination protein NusG nusG Smlt0892 X  
B2FHB5 Uncharacterized protein Smlt0149 X X 
B2FHE7 Uncharacterized protein Smlt0181 X X 
B2FHF0 Uncharacterized protein Smlt0184 X X 
B2FHG9 Uncharacterized protein Smlt0204 X X 
B2FHZ6 Uncharacterized protein Smlt4119 X  
B2FII7 Uncharacterized protein Smlt2905 X X 
B2FIM5 Uncharacterized protein Smlt2944 X  
B2FJV0 Uncharacterized protein Smlt0387 X X 
B2FLG5 Uncharacterized protein Smlt3232 X  
B2FME4 Uncharacterized protein Smlt3304 X  
B2FND7 Uncharacterized protein Smlt4593 X X 
B2FNK9 Uncharacterized protein Smlt0725 X X 
B2FPY0 Uncharacterized protein Smlt3550 X  
B2FQN1 Uncharacterized protein Smlt0958 X  
B2FQN3 Uncharacterized protein Smlt0960 X X 
B2FQN5 Uncharacterized protein Smlt0962 X X 
B2FTS4 Uncharacterized protein pcm Smlt3927 X X 
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Gent, Belgium 
- RIC Life Sciences Seminar, 24 January 2013, Kortrijk, Belgium 
- IUAP meeting, integrative protein science (iPROS), 26 February 2013, Université de Liège, 
Belgium 
o Poster presentation: ‘Study of the signaling cascades during antibiotic resistance 
induction in Stenotrophomonas maltophilia’ 
- IUAP meeting, integrative protein science (iPROS), 3 October 2013, Université de Liège, 
Begium 
o Presentation: ‘Targeted proteomics – Selection Reaction Monitoring’ 
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- IUAP meeting, integrative protein science (iPROS), 4 April 2014, Universiteit Gent, Begium 
o Presentation: ‘The secretion of outer membrane vesicles contribute to the 
Stenotrophomonas maltophilia resistance response’ 
- Masstastic Voyage Europe (AB Sciex), 14 May 2014, Fujirobio Europe N.V., Belgium 
o Presentation: The promiscuous response of Stenotrophomonas maltophilia to 
antibiotics: a targeted proteomics study 
- IUAP meeting, integrative protein science (iPROS), 28 November 2014, Université de 
Liège, Belgium 
o Presentation: ‘The effect of imipenem and diffusible signalling factors on the 
secretion of outer membranes vesicles and associated Ax21 proteins in 
Stenotrophomonas maltophilia’ 
- Belgian Proteomics Association (BePA), 18-19 December 2014, ULB, Belgium 
o Presentation: ‘The effect of imipenem and diffusible signalling factors on the 
secretion of outer membranes vesicles and associated Ax21 proteins in 
Stenotrophomonas maltophilia’ 
- IUAP meeting, integrative protein science (iPROS), 8 June 2015, Université de Liège, 
Belgium 
o Presentation: ‘The effect of antibiotics on the secretion of outer membrane 
vesicles and their role in resistance’ 
- 4th International Conference on Analytical Proteomics (ICAP), 7-9 September 2015, 
Caparica, Portugal 
o Presentation: ‘The effect of imipenem and diffusible signalling factors on the 
secretion of outer membranes vesicles and associated Ax21 proteins in 
Stenotrophomonas maltophilia’ 
 
Publications 
 
Devos, S., S. Stremersch, K. Raemdonck, K. Braeckmans, B. Devreese (2016). Intra- and inter-
species effect of outer membrane vesicles from Stenotrophomonas maltophilia on β-
lactam resistance. Antimicrob Agents and Chemother - Accepted 
Devos, S., L. Van Oudenhove, S. Stremersch, W. Van Putte, R. De Rycke, G. Van Driessche, J. Vitse, 
K. Raemdonck, B. Devreese (2015). The effect of imipenem and diffusible signaling factors 
on the secretion of outer membrane vesicles and associated Ax21 proteins in 
Stenotrophomonas maltophilia. Front Microbiol 6:298. 
Meuris, L., F. Santens, G. Elson, N. Festjens, M. Boone, A. Dos Santos, S. Devos, F. Rousseau, E. 
Plets, E. Houthuys, P. Malinge, G. Magistrelli, L. Cons, L. Chatel, B. Devreese, N. Callewaert 
(2014). GlycoDelete engineering of mammalian cells simplifies N-glycosylation of 
recombinant proteins. Nat Biotechnol. 32(5):485-9.  
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Education support 
 
- Supervision of Jarne Pauwels, Masterproject, Ghent University (2012): ‘Aanrijkings- en 
scheidingsmethoden voor de analyse van gefosforyleerde peptiden’ 
- Supervision of Sofie Depluverez, Master II dissertation (2012-2013): ‘Optimalisatie van 
analysemethoden voor de studie van antibioticaresistentie in Stenotrophomonas 
maltophilia’ 
- Supervision of Berten Jacobs, Master II dissertation (2013-2014): ‘Tijdsafhankelijke 
targeted proteomics analyse van de imipenem respons van Stenotrophomonas 
maltophilia’ 
- Supervision of Jolien Vitse, Master II dissertation (2014-2015): ‘Onderzoek naar de 
vorming en rol van buitenste membraan vesikels in Stenotrophomonas maltophilia’ 
- Assistant at the practical course ‘General Biochemistry’ for the 2th bachelor Biochemistry-
Biotechnology, Ghent University (2012-2013) 
- Assistant at the practical course ‘Biochemical Analytical Methods’ for the 3th bachelor 
Biochemistry-Biotechnology, Ghent University (2012-2014) 
- Introduction lecture and assistant at the exercise session ‘MS spectrum interpretation in 
proteomics’ (2014-2015) 
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